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Abstract
Epithelial cells are connected to each other via intercellular junctions, which are
established, remodelled and maintained by a complex molecular machinery. Aberrant
regulation of cell-cell junctions leads to loss of tissue organisation and is a hallmark
of cancer formation. Although many kinases that regulate the phosphorylation of
junctional proteins have been described, much less is known about the reversal of
phosphorylation by phosphatases.
This thesis investigates the role of Drosophila ASPP, a scaffold protein that is
localised at adherens junctions, as a regulatory subunit for PP1s. In vitro, ASPP can
bind to PP1 using its RVXF motif and SH3 domain. In vivo, ASPP co-localises with
the PP1α96A and PP1β9C isoforms at cell-cell junctions in the pupal retina and ASPP
function is at least partially dependent on its ability to bind to PP1. Furthermore,
ASPP can recruit two additional coiled coil containing scaffold proteins, RASSF8
and Ccdc85, to form trimeric complexes with PP1α96A. ccdc85 mutants that were
generated in this work have a rough eye, similar to ASPP mutants, suggesting a
similar function in vivo.
Two potential substrates for the ASPP/PP1 complex were tested: (1) Yki a tran-
scriptional co-activator that is part of the Hippo pathway and (2) Baz, a scaffold
protein that is required for cell polarity. Although no evidence for dephosphorylation
of Yki was found, Baz can be dephosphorylated in vitro. The well-described aPKC
phosphorylation site (S980) and five additional serine/threonine residues are strongly
dephosphorylated by ASPP/PP1.
My work also identified three potential regulators/scaffolds of ASPP/PP1. The
Hippo pathway kinase Wts can phosphorylate RASSF8, the E3 ubiquitin ligase Sina
can ubiquitylate and degrade ASPP and the junctional protein Magi can associate
with RASSF8 at adherens junctions. Finally, novel potential regulators, scaffolds or
substrates of the ASPP/PP1 complex were identified through AP-MS experiments
and tested for their ability to modulate the ASPP depletion phenotype in vivo.
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Chapter 1.
Introduction
In this PhD thesis I used the model organism Drosophila melanogaster to study the
cellular function of a phosphatase complex. This introduction covers three main topics
to provide the background of the thesis and introduce the challenges that I tried to
address. Firstly, I will briefly outline the benefits of the model organism and describe
the development of the Drosophila eye, the tissue I most frequently used. Secondly, I
will cover the protein families that make up the phosphatase complex: the PP1 family
that consists of catalytic phosphatase subunits, and the ASPP (Apoptosis stimulating
protein of p53) and N-terminal RASSF (Ras Association Domain Family) families
that are potential regulatory subunits. Lastly, I will portray the molecular context
of two potential substrates of the complex: Hippo signalling for Yki/YAP/TAZ and
apical-basal cell polarity for Baz/PAR3.
1.1. Drosophila as a model organism
Drosophila melanogaster, also known as the common fruit fly, has many advantages
that make it a suitable model organism to study biological principles. Especially for
genetic experiments, it has become a model of choice due to its short generation time
and ease of maintenance. In this subchapter I will briefly describe the history and
benefits of using Drosophila and provide more details on the development of the fly
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eye. The aim of this subchapter is to motivate my choice of Drosophila as a model
in general and the developing eye in particular.
1.1.1. Drosophila can be used to study principles of biology and
human disease
A century ago, Thomas H. Morgan was studying spontaneous mutations in his Dro-
sophila colonies and traced the inheritance of these mutations. Through this work, he
discovered general principles of heredity, such as genetic linkage and sex-linked inher-
itance. His laboratory became known as the Fly Room (From Nobel Lectures 1965).
Starting with his lab’s early experiments, Drosophila was used to investigate basic
principles of biology. Numerous mutants have been isolated that were first obtained
from random events and later deliberately induced. These studies did not only pro-
vide insights into biology, but also supplied practical techniques for experimental
handling and genetic manipulation of fruit flies. A notable example is the discovery
that chromosomal inversions can suppress crossing over during meiosis (Dobzhansky
1931). Thus, it became possible to stably keep lethal mutations as heterozygotes
through the use of “balancer chromosomes” with multiple inversions. Today, Dro-
sophila geneticists can draw on an ever-expanding collection of tools to generate
targeted mutant and transgenic flies (see Materials and Methods).
Additional to understanding fundamental principles of biology, the vast array of
tools of Drosophila research can also be used to study human disease more directly.
This can be done in two ways. Firstly, the function of genes that are conserved
between humans and flies can be studied in Drosophila. With the complete sequencing
of the Drosophila genome (Adams et al. 2000, Myers et al. 2000) it became apparent
that about 60 % of all human genes that are disease associated are conserved in
Drosophila (Chien et al. 2002). Function and genetic interactions with other genes
can be uncovered in flies that are likely to be transferable to the human orthologues.
However, the use of flies in medical research goes even beyond the study of orthologous
genes. Although not immediately relevant for this thesis, Drosophila can be used to
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directly test compounds in phenotype-based screening (Gasque et al. 2013) and for
drug profiling (Dar et al. 2012).
Another benefit of Drosophila is its simpler genome. As an invertebrate, it often
has fewer copies per gene, while vertebrates usually possess multiple copies due to two
rounds of genome duplication events in early vertebrate evolution (Dehal and Boore
2005). For instance, in the case of ASPP and ccdc85, two genes I investigated in this
thesis, I could study null mutant phenotypes in single mutants, instead of having to
generate double or triple mutants in mice.
1.1.2. The Drosophila eye develops from an epithelial layer
To study the effect of mutants and transgenes, I have mostly used the developing
pupal retina as a model tissue. The compound eye of Drosophila consists of about 750
hexagonally shaped individual subunits called ommatidia. The highly stereotypical
arrangement of the adult eye is generated during larval and pupal development in
waves of proliferation, differentiation and apoptosis (Wolff and Ready 1993). The
adult eye is especially suited to the investigation of defects in proliferation, apoptosis
and cell-cell contacts, as even minor defects can be easily detected as eye roughness
when multiplied through the repeated ommatidial units. Thus, the adult eye has
been extensively used to conduct large-scale genetic screens for perturbation in these
processes.
Each of the light-sensing ommatidia consists of eight photoreceptor cells and sup-
porting cells (Fig. 1.1 and 1.2C). Four lens-secreting cone cells sit immediately atop
of the photoreceptor cells, which are surrounded by two primary pigment cells, six
secondary pigment cells and three tertiary pigment cells. The pigment cells optically
insulate neighbouring clusters of photoreceptor cells from stray light. In addition
to the above-mentioned cells, three mechanosensitive bristle complexes can be found
around each ommatidium. The secondary pigment cells are shared with one neigh-
bouring ommatidium, while tertiary pigment cells and bristles are shared with two
neighbouring ommatidia. The secondary and tertiary pigment cells are collectively
referred to as interommatidial cells (IOCs).
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Figure 1.1.: Cross-section of an ommatidium during pupal development
Lens-secreting cone cells (c) sit atop of photoreceptor cells (p). Primary pigment
cells (1) surround them. Further distal are secondary pigment cells (not visible in this
view), tertiary pigment cells (3) and the bristle complex (b). Compare to Fig. 1.2C for
X-Y section at the same developmental stage. Adapted with permission from Carthew
2007, copyright of original held by Elsevier.
During embryonic development, a cluster of around 20 cells are specified as an eye
primordium under the control of the eye specification cascade (Kumar 2010), a com-
plex gene regulatory network involving eyeless and twin-of-eyeless, which encode two
paired domain/homeodomain transcription factors similar to vertebrate PAX6. This
embryonic primordium invaginates to give rise to the larval eye-antennal imaginal
disc, a bi-layered epithelial tissue composed of closely apposed layers: the pseudo-
stratified disc proper and the squamous peripodial membrane. The eye-antennal disc
produces the retina itself, as well as the antenna and head capsule. Cells within the eye
disc proper (hereafter referred to as “eye disc”) epithelium proliferate asynchronously
during the first and second larval stages (or instars). During the third larval instar,
cells begin to commit to specific fates. Differentiation starts from the posterior part of
the imaginal disc in a physical indentation known as the morphogenetic furrow (MF),
which sweeps anteriorly across the disc during the third instar (Treisman 2012). The
MF is driven by the secreted morphogen Hedgehog, which promotes the localised ex-
pression of the Bone Morphogenetic Protein family member Decapentaplegic (Dpp).
Hh and Dpp combine to initiate the expression of the pro-neural factor Atonal, which
resolves to regularly spaced individual cells under the influence of Notch signalling,
giving rise to the first photoreceptor R8 at regular intervals in the MF. Posterior
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Figure 1.2.: During the pupal stage, supernumerary cells are eliminated by
apoptosis
The illustrations depict the development of the pupal retina and are based on confocal
images.
(A) At 18 h APF, the clusters that were already formed in the third instar larval stage
have each recruited two primary pigment cells (purple). Bristle cells (orange) have been
specified at this stage. In apical X-Y confocal sections, only the cone cells (blue) are
visible, while all photoreceptor cells are basal of the cone cells and thus invisible.
(B) At 24 h APF, the undifferentiated cells (pale) that will become secondary and
tertiary pigment cells have arranged into single layers between the pairs of primary
pigment cells. Supernumerary IOCs are eliminated from the tissue by apoptosis in the
following eight hours.
(C) At 40 h APF, the final pattern has formed. The different cell types are indicated:
cone cells (c), bristles (b), primary pigment cells (1), secondary pigment cells (2o and 2h)
and tertiary pigment cells (3). Secondary pigment cells can have a horizontal position
(2h, contacting four primary pigment cells) or an oblique position (2o, contacting two
primary pigment cells).
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to the MF, pre-clusters of cells form by sequential recruitment of undifferentiated
cells that will give rise to the other photoreceptors. A subset of cells not initially re-
cruited to the pre-clusters undergo one last round of divisions (second mitotic wave)
in the wake of the MF. At the end of the third larval instar, the cell clusters con-
tain all photoreceptor cells and the four cone cells. By this time the photoreceptor
cell bodies have descended basally, thus in confocal sections of the apical IOCs, the
photoreceptors cannot be seen.
By 18 h after puparium formation (APF), the clusters have recruited two cells
that will become primary pigment cells (Monserrate and Brachmann 2007). At the
same time, bristles are specified (Fig. 1.2A). The bristles, like other invertebrate
sensory organs, are comprised of a group of four cells (Cagan and Ready 1989).
The four cells arise in three consecutive rounds of cell divisions. Out of those four
cells, only the neuron and its glial cell survive in the adult animal (Perry 1968).
Between 18 and 24 h APF, the remaining undifferentiated cells arrange themselves
into a single layer between the pairs of primary pigment cells (Fig. 1.2B and Larson
et al. 2008, Monserrate and Brachmann 2007). As the number of the undifferentiated
cells still exceeds the number of cells required in the adult eye, cells begin to be
eliminated by apoptosis. By 32 h APF, the final number of cells has been reached
and secondary/tertiary pigment cells have attained their final positions (Monserrate
and Brachmann 2007). Most often, the final arrangement is visualised at 40 h APF
using cell membrane markers (Fig. 1.2C). 40 h is chosen, as the rearrangement has
finished, but IOCs are still easily visualised. From this time point onwards, IOCs
constrict their apical surface so that it becomes impossible to count them properly.
1.1.3. The compound eye can be used as a read-out for defects
in cell-cell adhesion and apoptosis
The first type of defects that can affect the patterning of IOCs is the disruption of
cell-cell contacts. This is due to the requirement for cell-adhesion molecules during
remodelling of the tissue to form a single IOC layer. Between 18–24 h APF, Notch sig-
nalling (Bao 2014) and the immunoglobulin superfamily adhesion molecules Roughest
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(Rst or Irregular Chiasm), Kirre (Kin of Irre), Hibris and Sns (Sticks’n’stone) (Bao
and Cagan 2005, Bao et al. 2010) are important. Delta (Dl), the Notch ligand, is
expressed in cone cells at 18 h APF, leading to higher Notch levels in primary pig-
ment cells (Bao 2014). In these cells, Notch enhances the expression of Hibris and
Sns, while decreasing the expression of Rst and Kirre. Thus, primary pigment cells
express Hibris/Sns, while IOCs express Rst/Kirre (Bao and Cagan 2005, Bao et al.
2010) due to an unknown mechanism. Rst and Kirre preferentially bind in trans to
Hibris and Sns, forming trans-heterodimers (Bao and Cagan 2005, Bao et al. 2010).
This leads to the preferred formation of cell-cell contacts between primary pigment
cells and IOCs. Furthermore, while the contact surface between primary pigment
cells and IOCs are maximised, the inter-IOC contacts are minimised. As a result, a
single layer of IOCs forms between primary pigment cells (Bao and Cagan 2005).
Particularly striking is the minimisation of inter-IOC contacts when the single layer
is initially formed. For a brief period of time, IOCs have elliptically shaped apical
profiles. Inter-IOC contacts shrink to points (Bao and Cagan 2005). This is also the
stage where cell contacts and junctions are very dynamic, as small perturbations can
cause gaps in adherens junctions (Langton et al. 2009). At the same time, adherens
junctions and particularly E-Cadherin (Grzeschik and Knust 2005) are required for
the correct localisation of Rst/Kirre/Hibris/Sns. Any disruption to the adherens
junctions (Grzeschik and Knust 2005), or to any of the four adhesion molecules leads
to the failure of forming a single layer of IOCs (Bao and Cagan 2005, Bao et al. 2010).
In the case of disrupting Rst, Kirre, Hibris or Sns, superfluous IOCs do not undergo
apoptosis (Bao et al. 2010). However, it is not entirely clear why apoptosis fails. One
possibility is that intact junctions are required for the transmission of a death signal.
The second type of defect that can interrupt the patterning of the fly eye is by
directly modifying the propensity of IOCs to undergo apoptosis. Based on cell-
ablation experiments, it has been proposed that primary pigment cells secrete Spitz,
an EGFR (Epidermal Growth Factor Receptor) ligand that promotes the survival of
IOCs through the inhibition of the pro-apototic Hid protein (Miller and Cagan 1998,
Monserrate and Brachmann 2007). Direct mutation of hid (Bao et al. 2010) as well as
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genes of the Hippo pathway (see 1.4) that promote apoptosis such as kibra (Genevet
et al. 2010, Yu et al. 2010) also lead to the survival of IOCs, resulting in supernu-
merary cells at 40 h APF. The molecular nature of the signal that determines which
IOCs undergo apoptosis is unclear. However, being adjacent to bristle cells and in
a horizontal position (for definition see Fig 1.2C) increases the chance of an IOC
undergoing apoptosis (Monserrate and Brachmann 2007).
1.2. Protein dephosphorylation
Proteins can undergo various post-translational modifications (e.g., phosphorylation,
ubiquitylation and acetylation) which can modulate their function, stability or sub-
cellular localisation. Phosphorylation, or the transfer of γ-phosphate from ATP, is
one of the best studied and is involved in regulatory steps of all key cellular functions,
Protein phosphorylation is highly dynamic due to its reversibility, leading to a balance
between phosphorylation, which is catalysed by protein kinases and dephosphoryla-
tion, which is catalysed by phosphoprotein phosphatases. In this subchapter, I will
give a broad overview of different families of protein phosphatases and a more de-
tailed description of the PP1 family with an emphasis on the importance of regulatory
subunits in PP1 complexes.
1.2.1. Protein phosphorylation regulates many cellular processes
Most commonly, serine, threonine and tyrosine residues are phosphorylated to form
phosphomonoesters. Among these three residues, in humans, 86 % are phosphoser-
ines, followed by 12 % phosphothreonines and 3 % phosphotyrosines (Olsen et al.
2006). Although this thesis is only concerned with serine and threonine phosphory-
lation, further residues can phosphorylated. In bacteria, histidine and aspartate are
phosphorylated, as part of two-component signal transduction (Stock et al. 2000) and
at least theoretically, phosphorylation of cysteine, arginine, lysine and glutamate are
possible.
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Phosphorylation as a reversible modification to adjust enzyme activity was first
studied by Fischer and Krebs (Fischer and Krebs 1955). They discovered that a
kinase, the enzyme that catalyzes the transfer of the γ-phosphate, is required to
activate phosphorylase. To reverse the activation, the phosphate on phosphorylase
can be hydrolyzed (dephosphorylation) with the help of a phosphatase (Cori and Cori
1945).
Today, many more functions of protein phosphorylation are known. The following
three examples that involve proteins mentioned in this thesis only scrape at the sur-
face of the diverse spectrum of functionality. (i) In addition to activating enzymes as
in the case of phosphorylase, phosphorylation can also inhibit enzymatic activity, for
example when the kinase Src is phosphorylated (Okada et al. 1991) by C-terminal
Src kinase (Csk). (ii) Furthermore, phosphorylation can generate new protein binding
surfaces, as it adds negative charges and bulk. For instance, 14-3-3 adaptor proteins
specifically bind to phosphorylated proteins (Muslin et al. 1996). (iii) Phosphory-
lation can also influence the cellular localisation of proteins. For example Bazooka
(Baz), a polarity determinant, can be excluded from the baso-lateral membrane of
epithelial cells, when it is phosphorylated by Par1 (Benton and St Johnston 2003).
From this incomplete list of functions it already becomes clear that both proteins
phosphorylation and dephosphorylation must be carefully calibrated.
1.2.2. Serine/threonine phosphatases form protein complexes
with regulatory subunits
The number of kinases and phosphatases within the human genome provides an
interesting view on the balance between phosphorylation and dephosphorylation. For
tyrosine phosphorylation, the scoreboard is even. There are 90 kinases (Manning
et al. 2002) and 107 phosphatases (Alonso et al. 2004) in humans. Assuming a
roughly commensurate specificity and number of substrates, this would equalise the
action of kinases and phosphatases. However for serine/threonine phosphorylation,
the numbers are not comparable. While there are 428 kinases (Manning et al. 2002),
only about 40 phosphatases exist (Bollen et al. 2010). This apparent conundrum
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Figure 1.3.: PP1s non-covalently associate with regulatory subunits
During evolution, protein tyrosine phosphatases (PTPs) acquired regulatory modules
that are fused to the catalytic domain. Thus, with novel substrates and regulatory
requirements, more copies of PTPs were kept in the genome. The family of PP1 ser-
ine/threonine phosphatases in contrast binds to regulatory subunits non-covalently.
Thus, only few PP1s, but many more PP1 regulatory proteins can be found in genomes.
Adapted with permission from Moorhead et al. 2009, copyright of original held by Port-
land Press.
in numbers is solved when taking into account the different domain architectures.
While tyrosine phosphatases have evolved as fusion proteins of regulatory domains
attached to catalytic domains, many serine/threonine phosphatases just consist of
the catalytic domain (Moorhead et al. 2009). The specificity of serine/threonine
phosphatases is maintained by separate regulatory subunits that bind to the catalytic
subunit non-covalently (Fig. 1.3). Thus, taking the regulatory subunits into account,
there are probably several hundred serine/threonine phosphatase complexes (Heroes
et al. 2013) to counterbalance the 428 kinases.
1.2.3. The PPP family shares the same catalytic core residues,
but differs in holoenyzme composition
The group of serine/threonine phosphatases can be divided into three families that
have arisen separately during evolution: phosphoprotein phosphatases (PPPs), metal-
dependent protein phosphatases (PPMs) and FCP/SCP (TFIIF-associating compo-
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nent of RNA polymerase II C-terminal domain CTD phosphatase/small CTD phos-
phatase) family phosphatases (Shi 2009). While PPPs and PPMs use divalent metal
cations to activate a water nucleophile for hydrolysis of the phosphate, FCP/SCP
family phosphatases rely on a conserved aspartate as the initial nucleophile.
The main interest of this thesis is PP1, a highly conserved group of phosphatases
belonging to the PPP family. PP1 is only one out of the seven groups that comprise
the PPP family. Other groups are: PP2A, PP2B/Calcineurin, PP4, PP5, PP6 and
PP7 (Shi 2009). All groups share the same catalytic core residues. Within each
group, conservation between species is very high, so that for example human PP1
can replace its yeast orthologue (Gibbons et al. 2007). This suggests that evolution is
acting on the regulatory subunits to change or extend the range of substrates, rather
than on the catalytic subunits (Moorhead et al. 2009).
The best-studied groups among the seven are PP1, PP2A and PP2B/Calcineurin.
The main difference between these groups is that while PP1 has nearly 200 potential
regulatory subunits that share little similarity with each other (Heroes et al. 2013),
PP2A and PP2B/Calcineurin holoenzymes (referring to the ensemble of catalytic
subunit, regulatory subunit and other scaffolds) have a very stereotypical complex
composition.
The PP2A complex is a heterotrimer that consists of the catalytic or C subunit,
a scaffold (A subunit) and a regulatory or B subunit (Shi 2009). There are four
families of B subunits; each is comprised of several isoforms. PP2B/Calcineurin
is also a heterotrimer (Shi 2009). The core enzyme consists of a catalytic subunit
(Calcineurin A) and a regulatory subunit (Calcineurin B). Several different isoforms
of the catalytic and regulatory subunits exist. Additionally, for full activity, binding
to a Ca2+-bound Calmodulin scaffold is required.
1.2.4. The PP1 catalytic subunit associates with different
regulatory proteins to increase substrate specificity
From the disproportionately low number of serine/threonine phosphatases in compar-
ison to kinases, it is clear that the catalytic subunit alone cannot provide sufficient
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specificity. This is indeed the case for PP1 (Bollen et al. 2010, Peti et al. 2013). Unlike
kinases with defined substrate consensus sites, PP1 does not recognize any sequence
specific pattern. Moreover, small peptides derived from bona fide substrates are not
efficiently dephosphorylated by PP1, suggesting that other features of the full-length
substrates must be important (Bollen et al. 2010).
Specificity for PP1 is provided by regulatory subunits that directly bind to the
catalytic subunit. They promote activity either by localising PP1 in proximity to its
substrate and/or by directly modifying the substrate binding surface of PP1 (Bollen
et al. 2010). There are two known mechanism of how substrate specifying sub-
units work. (i) Neurabin/Spinophilin (Dancheck et al. 2011, Ragusa et al. 2010)
and PNUTS (Choy et al. 2014) achieve selectivity by sterically hindering non-specific
substrates from accessing the active site of PP1. (ii) In contrast, MYPT1 (Terrak
et al. 2004) and NIPP1 (O’Connell et al. 2012) extend the substrate binding site
of PP1 and modify its electrostatic properties. None of these interactors have any
influence on the conformation of PP1. They only change substrate specificity by
increasing or decreasing PP1/substrate binding surfaces.
While the above mentioned regulators do not block the active site, like most other
PP1 regulators (Hendrickx et al. 2009), they are able to reduce the activity of PP1
towards non-specific substrates, such as phosphorylase, without any detrimental effect
on their bona fide substrates. However, there is a small group of regulators that are
also termed inhibitors, which can block the activity of PP1 completely. At least some
of them, namely I-2 (Hurley et al. 2007) and CPI-17 (Eto et al. 2007) achieve this by
blocking the active site of PP1, thus barring substrates from accessing the catalytic
core.
1.2.5. Binding to PP1 is facilitated by different binding motifs
With the discovery of the first few PP1 interactors, it became apparent that they
shared little sequence similarity. However, small regions that confer binding to PP1
could be identified (Johnson et al. 1996). One of those regions corresponds to the
RVXF motif, a binding motif that can be found in most of the known PP1 interactors.
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The definition of the RVXF motif has undergone several rounds of refinements (Hen-
drickx et al. 2009, Meiselbach et al. 2006, Wakula et al. 2003). Based on biochemical
binding assays for PP1 interactors, a good compromise between specificity and sen-
sitivity is the five residue [KR][KR][VI]{FIMYDP}[FW] definition (Hendrickx et al.
2009)—in curly brackets are the residues that are disallowed. Basic residues are of-
ten found N-terminally and acidic residues C-terminally of the motif (Egloff 1997,
Hendrickx et al. 2009).
Other motifs that have been described are far less common. Only few PP1 interac-
tors share the SILK motif (Hendrickx et al. 2009, Huang et al. 1999), the MyPhoNE
motif (Hendrickx et al. 2009, Terrak et al. 2004) or the ΦΦ/ΦΦ-R motif (Choy et al.
2014). The SILK motif, defined as [GS]IL[KR], is found in I-2 (Huang et al. 1999) and
six other PP1 interactors, N-terminally of the RVXF motif (Hendrickx et al. 2009).
MyPhoNE, or myosin phosphatase N-terminal element, is found in MYPT1 (Terrak
et al. 2004) and six additional PP1 interactors (Hendrickx et al. 2009). As with the
SILK motif, the MyPhoNE motif is only found N-terminally of the RVXF motif (Ter-
rak et al. 2004). The ΦΦ motif (O’Connell et al. 2012) or its extended version,
ΦΦ-R (Choy et al. 2014), which includes an additional arginine residue, is found
C-terminally of the RVXF motif in four PP1 interactors.
1.2.6. Multiple motifs can increase binding affinity to PP1
All motifs described are binding to distinct surfaces of PP1 that are remote of the
catalytic site (Choy et al. 2014, Hurley et al. 2007, Terrak et al. 2004). Thus, they
serve as anchors for binding without changing the conformation of PP1, or inhibiting
its catalytic activity (Peti et al. 2013). The stability of the PP1 conformation seems
to be a more general feature, as binding to small molecule inhibitors that attach to
the catalytic core also does not change the PP1 conformation (Kelker et al. 2009,
Kita et al. 2002, Maynes et al. 2001 2006, Ragusa et al. 2010).
Due to the distinct binding sites of the motifs, a combination of different motifs can
be used to engage a single PP1 subunit. This fact can also aid in identifying novel
PP1 interactors. As each motif is too short to be specific enough for genome wide
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searches for PP1 interactors, several motifs combined could increase the sensitivity
and specificity of the search (Heroes et al. 2013). Discovering further PP1-binding
motifs will make database searches more specific. Having more than one binding
motif can also increase the affinity between PP1 and its interactors (Hendrickx et al.
2009).
1.2.7. Substrate targeting subunit and inhibitor can bind to PP1
simultaneously
An added layer of complexity is that substrate targeting subunit and inhibitor can
bind to PP1 at the same time. The formation of this type of trimeric complex has been
shown for GADD34/I-1/PP1 (Connor et al. 2001), Neurabin/I-2/PP1(Terry-Lorenzo
et al. 2002) and Sds22/I-3/PP1 (Lesage et al. 2007). Initially, these complexes were
not thought to be possible, as most regulatory subunits rely on their RVXF motif
to bind to PP1 that can only engage with one RVXF motif at a time. However,
it has been structurally shown that at least in the case of Neurabin/I-2/PP1, I-2
uses it SILK motif instead of its RVXF motif for binding to PP1 when Neurabin is
present (Dancheck et al. 2011). The trimeric Neurabin/I-2/PP1 complex is normally
inactive, as I-2 inhibits PP1. Only upon phosphorylation of I-2 (Hemmings et al.
1982), it is released from the catalytic core of PP1 and PP1 activity is restored.
Thus, the complex can be switched on and off quickly depending on other signalling
events.
The flexibility of I-2 to switch between its canonical binding mode via its RVXF
motif and the SILK-only binding mode within the trimeric Neurabin/I-2/PP1 com-
plex is facilitated by the intrinsically disordered nature of I-2 (Dancheck et al. 2011).
I-2 belongs to the group of intrinsically disordered proteins (IDPs) that do not have
a defined tertiary structure and only become folded when bound to interacting pro-
teins (Tompa 2005). As some estimates assign 70 % of all PP1 interactors as partially
disordered (Bollen et al. 2010), it is possible that this sort of trimeric complex between
substrate specifying subunit, inhibitor and PP1 is widespread.
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Figure 1.4.: PP1s can be grouped into PP1αs and PP1βs
Distance tree based on alignment between human and Drosophila PP1s. There are
two large groups of PP1s, PP1αs and PP1βs. The distance tree was generated using
BioNJ (Gascuel 1997) and was based on an alignment created by ClustalW (Larkin et al.
2007). The length of the branches corresponds to the distance between the sequences.
1.2.8. Humans and Drosophila have several PP1 isoforms that
are highly conserved
In humans, there are four PP1 isoforms, PP1α, PP1β, PP1γ1 and PP1γ2 (Bollen
et al. 2010). The difference between the isoforms is very small. Only few residues are
different, mostly at the N- and C-termini. Most regulatory subunits do not distinguish
between the isoforms and bind to all with similar affinities. A notable exception is
MYPT1, the myosin phosphatase targeting subunit, which preferentially binds to
PP1β (Hurley et al. 2007, Scotto-Lavino et al. 2010, Terrak et al. 2004).
In Drosophila, there are four PP1 isoforms, PP1α13C, PP1α87B, PP1α96A and
PP1β9C (Dombrádi et al. 1990 1993). The three Drosophila PP1αs are orthologous
to the human PP1α and PP1γ1/2 isoforms, while PP1β9C is more similar to human
PP1β (Fig. 1.4). Unusually, Drosophila PP1α13C and PP1α87B have short C-termini
not found in other organisms (Fig. 3.1D). In Drosophila, two regulatory subunits
are known to bind to a subset of catalytic isoforms. MYPT-75D, the ortholog of
human MYPT1, preferentially binds to PP1β9C (Vereshchagina et al. 2004) and Uri,
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a chaperone, binds to all three PP1α isoforms, but not to PP1β9C (Kirchner et al.
2008).
1.2.9. Current challenges and outlook
The biggest challenge in the field of PPPs is the identification of bona fide sub-
strate/phosphatase pairs (Brautigan 2013). Especially for PP1 substrates, the iden-
tification of the regulatory subunit is the crucial step, as the catalytic subunit displays
no specificity. A complete description of substrate/phosphatase pairs additionally re-
quires to include scaffolds that localise the PP1 holoenzyme, inhibitors and further
regulatory mechanisms that modify phosphatase activity.
Two obstacles complicate the identification of novel PP1 holoenzymes and their
biological substrates. (1) Firstly, in contrast to protein tyrosine phosphatases (PTPs),
no substrate trapping mutants (Blanchetot et al. 2005) can be generated for PP1s.
In PTP substrate trapping mutants, the enzymatic activity is lost, but substrate-
binding capability is preserved. Thus, affinity purification of these mutants readily
co-purify substrates. The reason why PTP trapping mutants can be generated is that
the first nucleophile is a cysteine residue. When mutated to serine, catalytic function
is eliminated, while the overall tertiary structure is preserved. However, PPPs in
contrast rely on divalent metal cations as first nucleophiles. Thus, mutations that
affect the binding of the metals will always have consequences for the structural
integrity of the protein. (2) Secondly, as with other enzymes that remove post-
translational modifications, such as deubiquitinating enzymes, it is helpful if a reliable
source of a modified (phosphorylated) substrate is established first. Optimally, a
kinase for specific phosphorylation sites should be known. In most cases, neither
condition is fulfilled.
Ultimately, identifying novel PP1 regulatory subunits means that small molecule
drugs could be developed that target specific PP1 holoenzymes. This could prove to
be superior to inhibiting or activating (Reither et al. 2013) the PP1 catalytic sub-
unit, which obviously can lead to unspecific side-effects. As a proof-of-principle, PP1
regulatory subunits have been successfully targeted by small molecules in phenotype-
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based screens (Boyce et al. 2005, Tsaytler et al. 2011). With increased knowledge
of PP1 holoenzymes, target-based approaches with specific PP1 substrates in mind
might be used in the development of novel PP1 inhibitors and activators.
1.3. ASPP and N-terminal RASSF family proteins
ASPP (Apoptosis-stimulating protein of p53) family proteins are primarily known
for their regulation of p53-dependent transcription, while N-terminal RASSF family
proteins have been described as potential tumour suppressors or oncoproteins, but are
not well studied. Previous work from our lab showed a connection between these two
protein families. Drosophila ASPP and RASSF8 form a complex at cell-cell junctions
to maintain junctional integrity. In this subchapter, I will describe what is known
about these two protein families, as they are potential regulatory subunits of a PP1
complex.
1.3.1. The ASPP family of proteins is characterised by ankyrin
repeats and an SH3 domain
ASPP family proteins are characterised by two conserved regions (Fig. 1.5). The N-
terminal region contains coiled coils and the C-terminal region contains four ankyrin
repeats and an SH3 domain. There are three members of this family in humans,
ASPP1/2 (Samuels-Lev et al. 2001) and iASPP (inhibitor of ASPP) (Bergamaschi
et al. 2003), while Drosophila has only one orthologue, ASPP (Langton et al. 2007).
ASPP1 and ASPP2 have an additional globular domain at their N-terminus that
structurally resembles the Ras-association (RA) domain of human RASSF8 (Tidow
et al. 2007). RA domains belong to the ubiquitin-fold family and some RA domains
bind to the small GTPases of the Ras family (Wohlgemuth et al. 2005). To predict if
RA domains are able to bind to Ras family proteins, modelling based on structures
containing RA domain/Ras complexes can be used (Chan et al. 2013, Kiel et al. 2007).
However, although modelling suggested that the RA-like domain of ASPP1/2 could
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Figure 1.5.: The N- and C-termini are conserved between human ASPP1/2 and
Drosophila ASPP
Domain structure of ASPP family proteins in Drosophila and humans. The Drosophila
ASPP N-terminus is conserved in ASPP1/2, while its C-terminus is conserved in all
three human ASPP family members. Coiled coil regions were predicted by jpred3 (Cole
et al. 2008). Although the predicted coiled coil regions are of different length, they share
high sequence similarity, suggesting a similar tertiary structure. The RA-like domain of
ASPP1/2 annotation is based on the ASPP2 N-terminus structure (Tidow et al. 2007).
Four ankyrin repeats and SH3 domain annotation based on ASPP2 structure (Gorina
and Pavletich 1996).
not bind to Ras (Tidow et al. 2007), two recent studies have shown the opposite (Wang
et al. 2013a, Wang et al. 2013b).
1.3.2. ASPP family proteins regulate p53 dependent transcription
The ASPP family is primarily known for their regulation of p53 dependent transcrip-
tion of pro-apoptotic genes (Bergamaschi et al. 2003, Samuels-Lev et al. 2001). The
binding between ASPP family proteins and p53 was first described for p53BP2, a
truncated form of ASPP2 (Iwabuchi et al. 1994). This binding requires the ankyrin
repeats and the SH3 domain of p53BP2. This was confirmed by a co-crystal structure
of p53BP2 and p53 (Gorina and Pavletich 1996).
Later, ASPP1 (Samuels-Lev et al. 2001) and iASPP (Bergamaschi et al. 2003)
were described as additional p53 interacting partners. While ASPP1/2 promote the
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transcription of p53 targets that are pro-apoptotic, such as BAX and PIG3, they do
not alter the transcription level of cell cycle arrest genes such as p21WAF1 (Samuels-
Lev et al. 2001). iASPP, as its name suggests, works antagonistically to ASPP1/2,
by competing with ASPP1/2 for binding to p53 (Bergamaschi et al. 2003, Slee et al.
2004). Once bound to p53, iASPP inhibits the transcription of pro-apoptotic p53
target genes (Bergamaschi et al. 2003). The ASPP family proteins not only bind and
regulate p53, but also other p53 family proteins, namely p63 and p73 (Bergamaschi
et al. 2003, Canning et al. 2012).
It is interesting to note that ASPP1 and ASPP2 have different functions in vivo
(see below). However, in most experiments in vitro, they are treated as equal and
show perfect interchangeability in many cell culture experiments (e.g., Samuels-Lev
et al. 2001, Wang et al. 2013b).
1.3.3. iASPP and p63 are important for the homeostasis of the
epidermis
In contrast to the other ASPP family members, iASPP does not share a conserved N-
terminal region (Fig. 1.5). Thus, Drosophila ASPP is more likely to be a functional
equivalent of ASPP1/2. However, iASPP is more ancient than the split between
vertebrates and invertebrates, as Caenorhabditis elegans has an iASPP orthologue
(Ce-iASPP), but no obvious ASPP1/2 orthologue (Bergamaschi et al. 2003). Since
ASPP1/2 are more closely related to Drosophila ASPP, I will primarily describe
ASPP1/2 in this introduction and only briefly mention what is known about iASPP
in this subsection.
Originally, iASPP was described to bind to the transcription factor RelA/p65 (Yang
et al. 1999). Although, this was confirmed independently (Herron et al. 2005), it is
not clear whether this interaction is important in vivo (Notari et al. 2011). Instead,
an important function of iASPP seems to be the regulation of p63 in stratified ep-
ithelia (Chikh et al. 2011, Notari et al. 2011). iASPP is co-expressed with p63 in the
proliferating basal layer of the epidermis and loss of iASPP leads to the premature
differentiation of keratinocytes (Chikh et al. 2011, Notari et al. 2011). Spontaneous
38
Chapter 1. Introduction
mutations in iASPP that were found in mice and cattle lead to defects of the skin,
heart and hair, supporting the idea that iASPP is important for the homeostasis of
the epidermis (Herron et al. 2005, Simpson et al. 2009, Toonen et al. 2012). It is
interesting to note that ASPP2 in contrast is required in differentiated keratinocytes
of the apical layers of the epidermis. ASPP2 prevent the formation of squamous cell
carcinomas by blocking the expression of p63 in differentiated keratinocytes (Tordella
et al. 2013). Thus, in the epidermis at least, although ASPP2 and iASPP have an-
tagonistic functions, they do not act within the same cell to regulate p53 family
dependent transcription.
1.3.4. ASPP1/2 have p53 independent functions in vivo
ASPP family proteins have p53 family independent functions as well. This is most
apparent in ASPP1 mutant mice (Hirashima et al. 2008). If ASPP1/2 were key acti-
vators of p53, loss of ASPP1/2 would be expected to cause some phenotypic similarity
compared to p53 mutant mice. p53 deficient mice are highly tumour prone (Done-
hower et al. 1992) and show various developmental defects (Armstrong et al. 1995,
Rotter et al. 1993, Sah et al. 1995). In contrast, ASPP1 mutant mice do not de-
velop tumours and only show defects during the establishment of the lymphatic sys-
tem (Hirashima et al. 2008), a phenotype that is not observed in p53 deficient mice.
Furthermore, p53 deficiency in ASPP1 null mutant mice does not worsen the lym-
phatic phenotype (Hirashima et al. 2008), suggesting that in vivo, ASPP1 has p53
independent functions.
ASPP2 heterozygous mutant mice are more tumour prone (Kampa et al. 2009,
Vives et al. 2006), suggesting that this might be due to misregulation of p53. However,
the two different mutants that were generated differ in their propensity to genetically
interact with p53. While in the case of the deletion of exon 3, p53 heterozygosity
increased tumour susceptibility (Vives et al. 2006), in the other case (deletion of exon
10–17), it did not (Kampa et al. 2009). Additionally, targeting of exon 3 was only
semi-lethal and a small number of homozygous mutants were born (Vives et al. 2006),
while the bigger deletion proved to be lethal in early embryogenesis (Kampa et al.
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2009). Although these results support a tumour-suppressing role of ASPP2, they also
suggest that ASPP2 has p53-independent functions.
1.3.5. ASPP1/2 have many binding partners other than p53
The array of different binding partners that have been found for ASPP1/2 suggest
what these p53-independent functions might be (Kampa et al. 2009). In this subsec-
tion, I will focus on four aspects: (i) Regulation of oncogenic Ras-induced senescence,
(ii) regulation of the Hippo pathway, (iii) regulation of cell-cell junctions and (iv) the
association with PP1.
Oncogenic Ras-induced senescence depends on ASPP2
Oncogenic Ras can induce senescence, a state of irreversible growth arrest, in non-
transformed cells (Campisi and d’Adda di Fagagna 2007). This is dependent on
ASPP2, but independent of p53 (Wang et al. 2011d). The N-terminus of ASPP2
plays an important role as it contains the RA-like domain that can directly bind to
oncogenic Ras (Wang et al. 2013a, Wang et al. 2013b). The requirement of the RA-like
domain is also observed in a mouse tumour model, where ASPP2 mutant fibroblasts
that expressed oncogenic Ras were injected into the flanks of nude mice. The RA-like
domain of ASPP2 alone inhibits Ras-induced tumour growth as effectively as full
length ASPP2 (Wang et al. 2012).
Although ASPP2 activates the Ras/Raf/ERK pathway (Wang et al. 2013a, Wang
et al. 2013b) the main effector for oncogenic Ras, several observations suggest a
more complicated model than a linear ERK activation by ASPP2 leading to senes-
cence. Firstly, there is feedback regulation: ASPP1/2 and p53-dependent transcrip-
tion is enhanced by oncogenic Ras (Wang et al. 2013a), which might be partially
due to the activating phosphorylation of ASPP2 by ERK (Godin-Heymann et al.
2013). Secondly, the N-terminus of ASPP2 can also bind to ATG5/ATG12 (Au-
tophagy5/Autophagy12), thereby preventing Ras-induced autophagy and promoting
Ras-induced senescence (Wang et al. 2012). However, the relationship between au-
tophagy and senescence are not entirely clear (Gewirtz 2013).
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Although the mechanistic details require further work, there is at least a consensus
that ASPP2 is required for oncogene-induced senescence and thus acts as a tumour
suppressor in this context. In the next subsection, I will introduce the interaction
of ASPP1/2 with members of the Hippo pathway. In this case, it is not yet clear
whether ASPP1/2 act as tumour suppressors or oncoproteins.
ASPP1 interacts with core components of the Hippo pathway
YAP (Yes-activated protein), a transcriptional co-activator and core member of the
Hippo pathway (see 1.4.2) has been described to directly bind to p53BP2, the ASPP2
fragment (Espanel and Sudol 2001). An interaction between YAP and ASPP2 was
also found in several recent proteomics experiments (Couzens et al. 2013, Hauri et al.
2013, Kohli et al. 2014, Wang et al. 2014). The YAP paralogue TAZ (transcriptional
co-activator with PDZ-binding motif) (see 1.4.2) can also bind to ASPP2 (Liu et al.
2011). Additionally, it was shown that the Hippo pathway downstream kinases LATS1
and LATS2 could bind to and phosphorylate ASPP1 (Aylon et al. 2010, Vigneron et al.
2010).
Despite this mounting evidence of binding between ASPP family proteins and mem-
bers of the Hippo pathway, there is no overarching model for the biological function
of these interactions. On the one hand it was proposed that ASPP1 might have a
pro-apoptotic role (Aylon et al. 2010). ASPP1 is phosphorylated by LATS2, in the
presence of oncogenic Ras and translocates to the nucleus to drive the expression of
p53 dependent pro-apoptotic genes.
On the other hand ASPP family proteins might also have an anti-apoptotic role (Liu
et al. 2011, Vigneron et al. 2010). ASPP1 can decrease the S127 phosphoryla-
tion of YAP, leading to nuclear YAP accumulation (see 1.4.2) and an increase in
YAP-dependent (anti-apoptotic) transcription (Vigneron et al. 2010). Although Vi-
gneron et al. suggest that ASPP1 acts through competing with LATS2 to decrease
YAP S127 phosphorylation (Vigneron et al. 2010), an alternative model could also
explain this observation: ASPP1 could dephosphorylate YAP S127 directly as part
of a phosphatase complex. This alternative model was proposed for the ASPP2/PP1
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complex, which can dephosphorylate TAZ on S89, the equivalent site to YAP S127
(Liu et al. 2011 and see 1.4.3). However, this pro-growth function in antagonising
the LATS1/2 tumour suppressor is not consistent with the idea that ASPP2 acts as
a tumour suppressor in vivo (Kampa et al. 2009, Vives et al. 2006).
ASPP2 interacts with the polarity determinant PAR3 and is required for the
de novo formation of tight junctions
Another layer of complexity in ASPP function was added when ASPP2 and Droso-
phila ASPP were found at tight junctions (Cong et al. 2010, Sottocornola et al. 2010)
and adherens junctions (Langton et al. 2009) respectively. In Drosophila, ASPP is
required for proper adherens junction formation during retinal morphogenesis (see
1.3.9). Similarly, mammalian tight junction formation requires ASPP2, which binds
to and recruits PAR3 to nascent cell-cell contacts (Cong et al. 2010, Sottocornola
et al. 2010). Upon ASPP2 depletion, cells in culture cannot form a proper imperme-
able epithelial monolayer, similar to loss of PAR3 (Cong et al. 2010). Loss of ASPP2
in vivo, also causes defects in apical-basal polarity in the retina and neuroepithe-
lium (Sottocornola et al. 2010).
ASPP family proteins directly bind to PP1 via their RVXF motifs
All members of the human ASPP family can also bind to PP1 (Helps et al. 1995, Liu
et al. 2011, Llanos et al. 2011, Skene-Arnold et al. 2013). ASPP1 and ASPP2 bind to
PP1 via a canonical RVXF motif (Egloff 1997, Llanos et al. 2011, Skene-Arnold et al.
2013). In contrast, iASPP does not have an RVXF motif. Whether the degenerate
motif in iASPP that aligns to the RVXF motif of ASPP1/2 could bind to PP1 in a
similar manner as the canonical motif is unclear (Llanos et al. 2011, Skene-Arnold
et al. 2013).
As interactors of PP1s, ASPP family proteins could act as regulatory subunits
for the catalytic PP1 subunit. In this case, any protein that binds to ASPP family
proteins might form a trimeric complex with ASPP and PP1 and undergo dephos-
phorylation. This has been proposed for p53 (Helps et al. 1995). However, PP1 and
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p53 both bind to the C-terminal anykrin repeats and SH3 domain of p53BP2 (the
ASPP2 fragment). A trimeric complex could not be observed (Helps et al. 1995). For
TAZ, the Hippo pathway transcriptional co-activator, it has been shown that ASPP2
might indeed act as regulatory scaffold for PP1 (Liu et al. 2011 and see 1.4.3). For
other ASPP binding partners, this hypothesis has not been tested.
1.3.6. ASPP family proteins can shuttle between the nucleus and
the cytoplasm
A model that could explain the multitude of functions of ASPPs is based on the
idea that the cellular localisation of ASPP would define its function (Vigneron et al.
2010). This model is very attractive, as the reported localisation of ASPP family
proteins is highly context-dependent. Initially, ASPP family proteins were thought
to be predominantly cytoplasmic (Samuels-Lev et al. 2001). However, to directly
influence p53-dependent transcription, ASPP family proteins would have to be able
to translocate to the nucleus. This is possible, as the C-terminal ankyrin repeats of
ASPP family proteins are sufficient for nuclear accumulation (Sachdev et al. 1998, Slee
et al. 2004). More recently, Drosophila ASPP (Langton et al. 2009) and ASPP2 (Cong
et al. 2010, Sottocornola et al. 2010) have also been found at cell-cell junctions and
at the plasma membrane (Wang et al. 2013a, Wang et al. 2013b).
In a simple model, one could assume that in the cytoplasm, ASPP1/2 would in-
hibit LATS1/2 function, thus be anti-apoptotic (Vigneron et al. 2010), while nuclear
ASPP1/2 would enhance p53 activity and be pro-apoptotic (Aylon et al. 2010) and
junctional ASPP2 would only be required in certain cells such as epithelial cells.
However, the reality is possibly more complicated. Nuclear accumulation is only a
snapshot of what is likely to be a dynamic process, where nuclear import only needs
to be slightly more efficient than nuclear export. Furthermore, the cellular distri-
bution of ASPP is not static. For example, phosphorylation can tilt the balance.
ASPP1 can be phosphorylated by LATS2, which leads to nuclear translocation in
the presence of oncogenic Ras (Aylon et al. 2010). ASPP2 can also be phosphoryla-
ted by ERK, detaching it from the plasma membrane and inducing cytoplasmic and
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Figure 1.6.: Drosophila RASSF8 has conserved N- and C-termini
Domain structure of RASSF8 in Drosophila and RASSF7/8 in humans. The Drosophila
RASSF8 has a conserved RA domain and a conserved C-terminus that contains coiled
coil regions. The C-terminus of Drosophila RASSF8 is more similar to human RASSF8
than RASSF7. Coiled coil regions were predicted by jpred3 (Cole et al. 2008). The
RA domain annotation is based on the human RASSF8 RA domain structure (PDB:
2CS4).
nuclear localisation (Godin-Heymann et al. 2013). Lastly, iASPP can be phosphory-
lated during the G2/M transition, which prevents its dimerisation and causes nuclear
accumulation (Lu et al. 2013).
The recent description of a Ran-GDP-dependent nuclear import for specific ankyrin
repeats (Lu et al. 2014) is another step towards understanding the control of ASPP
localisation. If specific residues in two consecutive ankyrin repeats are hydrophobic,
this enables binding to the GDP-bound form of the nuclear transport factor Ran.
Binding allows the ankyrin repeat-containing protein to piggyback with Ran-GDP
into the nucleus, when it is imported with NTF2, a nuclear transport factor (Lu
et al. 2014). Identifying the signals and contexts that affect ASPP localisation will
be necessary to understand how the different interaction partners contribute to the
overall function of ASPP family proteins.
1.3.7. N-terminal RASSF family proteins are putative tumour
suppressors and oncoproteins
N-terminal RASSF family proteins are characterised by an RA domain at their N-
termini and coiled coil regions at their C-termini (Fig. 1.6). In Drosophila, there are
three members of this family: RASSF8, CG13875 and CG32150 (Sherwood et al.
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2009). Humans have four orthologues: RASSF7, 8, 9 and 10. Drosophila RASSF8 is
the only orthologue of human RASSF7 and RASSF8, while CG13875 and CG32150
resemble human RASSF9 and RASSF10 more closely.
Although their name might suggest a close relationship with the classical RASSF
family proteins (RASSF1–6 in humans and RASSF in Drosophila), there is no evi-
dence that these two families are more closely related than other proteins containing
RA domains (Sherwood et al. 2009). The RA domain of human RASSF7 (Chan et al.
2013, Takahashi et al. 2011) and RASSF9 (Rodriguez-Viciana et al. 2004) can bind to
oncogenic Ras, but human RASSF8 and 10 cannot (Chan et al. 2013). Furthermore,
Drosophila RASSF8 could not bind Rab11, another small GTPase (Eunice Chan—
unpublished observations) and human RASSF8 could not bind to RalA, CDC42 and
RAB11 (Gail Doughton—unpublished observation). So far, the functional signifi-
cance of binding of the N-terminal RASSFs to small GTPases remains little explored.
1.3.8. Human N-terminal RASSF family members are putative
tumour suppressors and oncoproteins
In contrast to ASPP family proteins, N-terminal RASSF family members are less well
studied. There are no obvious unifying themes, except the for notion that N-terminal
RASSF family can either be tumour suppressors or oncoproteins. In this subsection,
I will present what is known about the human orthologues before introducing Dro-
sophila RASSF8 in the next subsection. CG13875 and CG32150 are currently being
studied in our lab and will be the subject of another PhD thesis.
RASSF7 is the only member of the N-terminal RASSF family that was suggested
to function as an oncoprotein. In many types of cancer, RASSF7 levels are in-
creased (Underhill-Day et al. 2011). RASSF7 expression is upregulated under hy-
poxic conditions (Recino et al. 2010), which are found in the centre of large solid
tumours. Two potential mechanisms explaining how RASSF7 might be required for
tissue growth have been proposed. Firstly, in Xenopus embryos (Sherwood et al.
2008) and human cell lines (Recino et al. 2010), RASSF7 is required for mitosis.
RASSF7 is localised at centrosomes and is required to activate Aurora B, a mitotic
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kinase, perhaps due to a role controlling in microtubule dynamics (Recino et al. 2010).
Another mechanism for the pro-growth function of RASSF7, is its ability to inhibit
pro-apoptotic JNK signalling (Takahashi et al. 2011). RASSF7 can bind to N-Ras
via its RA-domain and also to MKK7, a MAP kinase kinase. These interactions allow
RASSF7 to inhibit the activation of JNK by MKK7 (Takahashi et al. 2011).
RASSF8 is a putative tumour suppressor. Expressing RASSF8 in a lung cancer cell
line can decrease its propensity to grow in soft agar (Falvella et al. 2006). Conversely,
stable transfection with shRNAs targeting RASSF8 in carcinoma cells, increases their
ability to form tumours, when injected into immune-deficient mice (Lock et al. 2010).
Similarly to Drosophila RASSF8 (see below), human RASSF8 is found to stabilise
cell-cell junctions (Lock et al. 2010).
The function of RASSF9 and RASSF10 are less well studied. It has been suggested
that RASSF9, which is also known as P-CIP1 (PAM C-terminal interactor protein-
1), could aid vesicular trafficking of the enzyme Peptidyl-glycine alpha-amidating
monooxygenase or PAM (Chen et al. 1998). More recently, RASSF9 gene function
was described to be necessary for mouse skin development. RASSF9 mutants showed
excess proliferation of cells within the epidermis and the dermis and aberrant differ-
entiation (Lee et al. 2011). Whether this is connected to its reported function on
PAM is unknown.
Similar to RASSF8, RASSF10 expression inhibits colony formation in soft agar (Hill
et al. 2011). RASSF10 localises to the perinuclear region, but seems to be restricted
to the nucleus when the cell undergoes mitosis (Hill et al. 2011). It is not known how
RASSF10 functions molecularly to inhibit proliferation. However, the RASSF10 gene
is epigenetically silenced by promoter methylation in some types of cancer (Volodko
et al. 2014).
1.3.9. Drosophila RASSF8 and ASPP form a complex to regulate
junctional integrity, at least in part through Csk
Our lab has studied Drosophila ASPP and RASSF8 for several years (Langton et al.
2007 2009). Initially, we became interested in RASSF8 as it was identified in a
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yeast two-hybrid screen as a putative interaction partner of the kinase Warts (Giot
et al. 2003), a core component of the Hippo pathway (see 1.4.1). The same screen
also suggested that ASPP was a binding partner of RASSF8. Drosophila ASPP is
the only orthologue of the human ASPP family and Drosophila RASSF8 is the only
orthologue of human RASSF7 and RASSF8 (Fig. 1.5 and 1.6).
In contrast to human ASPP family proteins, Drosophila ASPP does not seem to
bind to Drosophila p53 (Langton et al. 2007), as many of the key residues that are
found at the interaction surface between ASPP2 and p53 (Gorina and Pavletich 1996)
are not conserved (Langton et al. 2007). Furthermore, ASPP has never been observed
in the nucleus, but was rather found at adherens junctions (Langton et al. 2009). This
does not exclude a context-dependent nuclear function for ASPP, as the residues that
are part of the Ran-GDP dependent nuclear import signal (see 1.3.5) are conserved.
Despite the difference in p53 binding, ASPP appears to limit growth in Drosophila as
well, since ASPP null mutant flies are bigger overall and have overgrown wings and
eyes (Langton et al. 2007).
Similar to ASPP and mammalian RASSF8, Drosophila RASSF8 is localised at
cell-cell junctions in epithelial cells; it co-localises with E-cadherin at adherens junc-
tions (Langton et al. 2009). RASSF8 and ASPP form a complex and are mutually de-
pendent for their junctional localisation. Together they regulate junctional integrity.
In particular during the remodelling phase of retinal development at around 26 h APF
(see 1.1.3), when supernumerary cells are eliminated by apoptosis and cell-cell junc-
tions are dynamically rearranged, lack of RASSF8 or ASPP leads to gaps in adherens
junctions in IOCs. This is at least in part due to the activation of Csk, an inhibitor
of the tyrosine kinase Src, by ASPP (Langton et al. 2009). ASPP and RASSF8 are
thought to form a complex that causes the local activation of Csk at adherens junc-
tions. This is proposed to inhibit Src by phosphorylation of a C-terminal residue
that promotes Src auto-inhibition, thereby preventing it from dissolving adherens
junctions (Langton et al. 2009).
The phenotypes of RASSF8 null mutant flies resemble those of ASPP null mutant
flies (Langton et al. 2007 2009). Both mutants are slightly overgrown, have larger
47
Chapter 1. Introduction
wings and rough eyes. However, there are also subtle differences. RASSF8 null
mutant flies have rounder wings than ASPP null mutant flies and the eye roughness
appears to be more severe. Thus, although the function of RASSF8 and ASPP are
coupled, they might have independent functions as well.
1.4. The Hippo signalling pathway
How to stop growing when the appropriate size has been reached is a key question for
any developing multicellular organism. The Hippo pathway is a conserved signalling
network that regulates developmental and homeostatic growth, as well as a number of
cell fate choices. It was initially discovered using genetic screens for growth suppres-
sors in Drosophila. Over the last few years many inputs have been described that feed
into the Hippo pathway. In this subchapter I will describe the core components of
the Hippo pathway with a particular focus on the transcriptional co-activator Yorkie
(Yki), a potential substrate of the ASPP/PP1 complex.
1.4.1. The conserved Hippo pathway consists of a core kinase
cascade that inhibits proliferation and promotes apoptosis
Five proteins can be considered as the core of the Hippo pathway: two kinases and
their two scaffolding partners, as well as a transcriptional co-activator (Fig. 1.7A
and Yu et al. 2013). The kinase Warts (Wts) was the first member of the Hippo
pathway described to cause overgrowth when mutated in mitotic clones (Justice et al.
1995, Xu et al. 1995). Wts acts together with its binding partner Mats (Mob1 as tu-
mour suppressor) (Lai et al. 2005) to phosphorylate and inactivate the transcriptional
co-activator Yki (Huang et al. 2005). Wts is itself activated by the upstream Ste20-
like kinase Hippo (Hpo) (Harvey et al. 2003, Jia et al. 2003, Pantalacci et al. 2003,
Udan et al. 2003, Wu et al. 2003), which functions in concert with its scaffold binding
partner Salvador (Sav) (Kango-Singh et al. 2002, Tapon et al. 2002).
All five proteins are conserved in humans. Hpo has two orthologues, MST1/2
(Mammalian Sterile 20-like) that can both phosphorylate and activate LATS1/2
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Figure 1.7.: The conserved Hippo pathway regulates proliferation and apoptosis
(A) Different stimuli can regulate the Hippo pathway. The regulation can act on dif-
ferent core members. When the core kinase Hpo is activated, it can phosphorylate and
activate Wts, the downstream kinase, which in turn phosphorylates and inactivates the
transcriptional co-activator Yki.
(B) Wts can phosphorylate three serines on Yki. Unphosphorylated Yki can shuttle
between the cytoplasm and the nucleus, where it acts together with the transcription
factor Sd.
(B’) Phosphorylation of S168 creates a 14-3-3 binding site. 14-3-3 is able to retain Yki
in the cytoplasm.
(Large tumour suppressor), the orthologues of Wts (Chan et al. 2005). Mats and
Sav have orthologues in humans as well, MOB1A/B and SAV1 respectively. Impor-
tantly, the signalling cascade is conserved, and activation of MST1/2 leads to the
subsequent phosphorylation and inactivation of YAP (Dong et al. 2007, Zhao et al.
2007) and TAZ (Lei et al. 2008), the Yki orthologues.
Together with the transcription factor Scalloped (Sd) (Goulev et al. 2008, Wu
et al. 2008, Zhang et al. 2008), or TEAD1–4 in humans (Zhao et al. 2008), Yki drives
the transcription of proliferation and anti-apoptotic genes such as diap1 (Drosophila
Inhibitor of Apoptosis Protein 1), cyclinE (Huang et al. 2005) and bantam (Nolo
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et al. 2006, Thompson and Cohen 2006). Some of the Yki transcriptional targets,
such as expanded (ex), merlin (mer) or four-jointed (fj), are upstream activators
of the pathway (Cho et al. 2006, Hamaratoglu et al. 2006 and see below). Thus a
negative feedback loop is thought to limit signalling activity.
1.4.2. Yki and its orthologues YAP/TAZ are transcriptional
co-activators that are retained in the cytoplasm upon
phosphorylation
Yki is phosphorylated by Wts on three serine residues, S111, S168 and S250 (Dong
et al. 2007, Oh and Irvine 2008 2009) that fit the H-x-[HKR]-x-x-[ST] Wts consen-
sus sequence derived from peptide phosphorylation experiments using LATS1 (Hao
et al. 2008). Phosphorylation of S168 generates a binding site for the adaptor protein
14-3-3 (Dong et al. 2007, Oh and Irvine 2008). Upon binding to 14-3-3, Yki is prefer-
entially retained in the cytoplasm and thus inactivated (Fig. 1.7B). Phosphorylation
of S111 and S250 also inhibit Yki function (Oh and Irvine 2009). However, the exact
mechanism how these two phosphorylated sites regulate Yki is unclear. Similarly,
YAP (Hao et al. 2008, Zhao et al. 2007) and TAZ (Lei et al. 2008) can be phospho-
rylated by LATS1/2 on four and five serines, respectively. All three serines that are
phosphorylated in Yki are also found in YAP and TAZ. As in Yki, phosphorylation
of S127 in YAP and S89 in TAZ, the corresponding residues to S168 in Yki, inhibits
transcription by promoting 14-3-3 binding and retention in the cytoplasm (Lei et al.
2008, Zhao et al. 2007).
Additionally, the levels of YAP and TAZ can be regulated by proteasomal degra-
dation. A similar mechanism has not been found for Yki. S397 of YAP (Zhao et al.
2010) and S311 of TAZ (Liu et al. 2010), two residues that have no obvious equivalents
in Yki, are initially phosphorylated by LATS1/2. In a secondary step, casein kinase 1
phosphorylates nearby residues, promoting binding of the E3 ubiquitin ligase complex
SCFβTRcP, which ubiquitylates and degrades YAP/TAZ (Liu et al. 2010, Zhao et al.
2010). TAZ can also be phosphorylated by GSK3, a kinase that is inhibited by the
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PI3K pathway. Phosphorylation on two N-terminally located serines, S58 and S62
by GSK3 also promotes degradation via SCFβTRcP (Huang et al. 2012).
In many studies, YAP and TAZ are treated as functionally interchangeable or
they are not differentially analysed. However, YAP is slightly larger than TAZ and
contains an N-terminal proline-rich region, one more WW domain and an SH3-binding
domain (Varelas 2014). Thus, it is likely that some of the binding partners and
therefore functionality differ between YAP and TAZ. In vivo, Yap knock-out mice
die at embryonic day 8.5 (Morin-Kensicki et al. 2006), while Taz knock-out mice
mostly reach adulthood (Hossain et al. 2007). This suggests that YAP and TAZ have
different roles during development. Yet a certain degree of redundancy must exist,
as Yap and Taz are both required during early embryonic development and Yap; Taz
double mutant mice do not even reach the 16-cell stage (Nishioka et al. 2009).
1.4.3. TAZ can be dephosphorylated by an ASPP2/PP1 complex
As phosphorylation is central to the activation of Hippo signalling, reversing the
phosphorylation is equally important. The scaffold protein RASSF, the only member
of the classical RASSF family in Drosophila, (Polesello and Tapon 2007) is part of
a PP2A complex that inhibits Hippo signalling by dephosphorylating Hpo (Ribeiro
et al. 2010). Whether this is conserved is unclear, as in humans, there are six classical
RASSF family proteins, some of which are activating while others are inhibitory with
respect to Hippo signalling (Ikeda et al. 2009, Praskova et al. 2004).
YAP and TAZ can also be dephosphorylated. S127 of YAP (Wang et al. 2011b)
and S89 of TAZ (Byun et al. 2014, Liu et al. 2010) can be dephosphorylated by
PP1. Additionally, YAP appears also to be dephosphorylated by PP2A (Schlegelmilch
et al. 2011). The difficulty in interpreting three of these studies (Byun et al. 2014,
Schlegelmilch et al. 2011, Wang et al. 2011b) is that all experiments that investigate
YAP/TAZ regulation only involve the catalytic phosphatase subunit. Regulatory sub-
units are not mentioned or considered. As noted (see 1.2.3 and 1.2.4), the catalytic
subunits of PP1 and PP2A have little specificity by themselves. Thus, it is uncer-
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tain if the observed dephosphorylation reactions would also occur under physiological
conditions in vivo.
In contrast, Liu et al. identified ASPP2 as the regulatory subunit of a PP1 complex
that dephosphorylates TAZ, but not YAP (Liu et al. 2010). They provide several cru-
cial pieces of evidence that ASPP2/PP1 can dephosphorylate TAZ. They demonstrate
binding between TAZ and ASPP2, as well as an increase in TAZ S89 phosphorylation
upon ASPP2 knockdown. However, most importantly, Liu et al. show that, in con-
trast to wild type ASPP2, a PP1-binding deficient ASPP2 (RVXF mutant) neither
promotes TAZ S89 dephosphorylation in 293T cells, nor inhibits 14-3-3 binding to
TAZ. These two experiments show that an ASPP2/PP1 complex can promote TAZ
dephosphorylation.
1.4.4. Different cues modulate Hippo signalling
The known upstream regulation of the Hippo pathway can be roughly subdivided into
five groups: (i) The Expanded (Ex), Kibra (Kib), Merlin (Mer) complex, (ii) apical-
basal polarity determinants (iii) Fat (Ft) and Dachsous (Ds) dependent planar cell
polarity (PCP), (iv) G-protein coupled receptors (GPCRs) and (v) mechanical forces
sensed through the actin cytoskeleton.
The Expanded, Kibra, Merlin complex regulates Hippo signalling
A recurring theme in Hippo pathway regulation is the influence of regulators that
are membrane bound and localised either at apical junctions, or baso-laterally (Gen-
evet and Tapon 2011). One group of apically localised proteins that affects Hippo
signalling is the Ex, Kib and Mer complex (Baumgartner et al. 2010, Genevet et al.
2010, McCartney et al. 2000, Yu et al. 2010). All three proteins are scaffold proteins.
Mutations in either ex (Boedigheimer and Laughon 1993), kib or mer (LaJeunesse
et al. 1998) causes tissue overgrowth.
Furthermore, ex, kib and mer genetically interact. Double mutants of ex and mer
show enhanced overproliferation when compared to the single mutants (Hamaratoglu
et al. 2006, McCartney et al. 2000). Similarly, kib loss-of-function also enhances the
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overproliferation of ex and mer mutants (Baumgartner et al. 2010, Genevet et al.
2010, McCartney et al. 2000, Yu et al. 2010). This is especially noticeable in the
developing eye. Firstly, double mutant combinations of ex, kib and mer strongly
increase the number of extra IOCs. While single mutants have few extra IOCs, any
double mutant combination causes massive overproliferation that is reminiscent of
hpo, wts or sav mutants (Hamaratoglu et al. 2006, Yu et al. 2010). Secondly, Hippo
pathway targets are substantially upregulated in double mutant clones, while single
mutant clones show no detectable change (Baumgartner et al. 2010, Yu et al. 2010).
Although early studies suggested that the regulation of Hippo pathway target genes
by Ex was through activating the kinase cascade (Hamaratoglu et al. 2006), later it
was reported that Ex can directly bind to and inactivate Yki independently of the
core kinases (Badouel et al. 2009, Oh et al. 2009). Yki localises to the sub-apical
membrane when Ex is overexpressed (Badouel et al. 2009). However, this does not
exclude the possibility that Ex, Kib and Mer could also activate the core kinases in
parallel of sequestering Yki, especially since Sav can directly bind to Kib and Mer,
while Hpo can directly bind to Ex (Yu et al. 2010). Indeed, recent work suggests
that Mer directly binds to Wts and recruits it to the apical membrane, where it is
activated by the Hpo/Sav complex (Yin et al. 2013).
Kib and Mer have orthologues in humans, KIBRA and NF2. KIBRA and NF2
are also functionally equivalent of Kib and Mer, as they bind to each other and
promote YAP phosphorylation by LATS1/2 (Zhang et al. 2010). Ex does not have a
direct orthologue in mammals (Bossuyt et al. 2014). AMOT (Angiomotin), a tight
junction-associated protein seems to be the functional equivalent of Ex. AMOT can
bind to YAP/TAZ directly to recruit them to the tight junctions, leading to reduced
nuclear YAP/TAZ activity (Chan et al. 2011, Wang et al. 2011c, Zhao et al. 2011).
Furthermore, AMOT interacts with NF2 and is required for NF2 function (Yi et al.
2011).
Additional to the Ex, Kib and Mer complex, core components of the pathway have
also been shown to localise sub-apically. A certain fraction of Hpo is found at the
apical membrane in larval eye imaginal discs (Grzeschik et al. 2010) and Mats is
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mostly found apically (Ho et al. 2010). In cultured S2 cells, Hpo is associated with
the membrane fraction (Yu et al. 2010). This has led to the idea that the apical
membrane is a key site for the activation of the Hippo core kinase cascade.
Apical-basal determinants influence Yki activity
Apical-basal determinants (see 1.5) can also influence Yki activity. Crumbs (Crb),
a sub-apically localised transmembrane protein is required for the localisation of
Ex (Chen et al. 2010, Ling et al. 2010, Robinson et al. 2010). Loss of crb leads
to overgrowth phenotypes and the activation of Yki target genes, similar to loss of
ex. Although Crb stabilises Ex at the sub-apical membrane, it also targets Ex for
degradation via the proteasome (Ribeiro et al. 2014). Thus, not only loss of crb, but
also overexpression of Crb leads to an upregulation of Yki targets through loss of
Ex function (Grzeschik et al. 2010). The role of Crb in regulating Hippo signalling
is conserved in humans. Knock-down of CRB3 leads to the upregulation of YAP
target genes (Varelas et al. 2010). Similar to Crb, the sub-apically localised kinase
aPKC (atypical Protein Kinase C) can induce an upregulation of Yki targets when
overexpressed (Grzeschik et al. 2010, Sun and Irvine 2011).
Crb and aPKC overexpression can lead to a spreading of the apical domain at the
expense of the basal domain (see 1.5.7). Thus, the loss of baso-lateral determinants,
which also causes spreading of the apical domain (see 1.5.7), would be expected to
result in a similar upregulation of Yki target genes. Indeed, this is observed when
scribble (scrib) or lethal giant larvae (lgl) are lost in mitotic clones of larval imaginal
discs (Grzeschik et al. 2010). In combination with oncogenic Ras, the loss of scrib
or lgl causes hyperproliferation and invasive growth (Brumby and Richardson 2003,
Pagliarini and Xu 2003). In breast cancer cells, human SCRIB has been directly
implicated in YAP inhibition by scaffolding the core kinase cassette and promoting
YAP phosphorylation (Cordenonsi et al. 2011).
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Fat/Ds dependent planar cell polarity, GPCRs and mechanical stress also
regulate Yki activity
Another group of upstream regulators include the two atypical cadherins Ft (Fat)
and Ds (Dachsous), which can form hetero-dimers through their extracellular do-
mains (Clark et al. 1995). The interaction between Ft and Ds is modulated by the
Golgi kinase Four-jointed (Fj) (Ishikawa et al. 2008). Fj can phosphorylate both Ft
and Ds while they transit through the Golgi apparatus. While the phosphorylation
of Ft increases its affinity towards Ds, the phosphorylation of Ds decreases its affinity
towards Ft (Brittle et al. 2010, Simon et al. 2010). Loss of ft leads to the upregulation
of Yki targets (Bennett et al. 2006, Cho et al. 2006, Feng and Irvine 2007, Silva et al.
2006, Tyler and Baker 2007, Willecke et al. 2006). The exact mechanism through
which Ft/Ds influence Hippo signalling is debated. Initially, it was proposed that Ft
might act entirely through regulating Ex levels (Bennett et al. 2006, Silva et al. 2006,
Willecke et al. 2006). However, subsequently, it was shown that in some tissues ex; ft
double mutants have a stronger overgrowth phenotype as either single mutant (Feng
and Irvine 2007, Tyler and Baker 2007), suggesting that Ft and Ex have separate
functions. Ft/Ds might regulate the Hippo pathway, through the inhibition of the
atypical myosin Dachs by Ft (Cho et al. 2006). Dachs can in turn promote Wts
degradation (Cho et al. 2006, Rauskolb et al. 2011).
Ft and Ds are also known to regulate PCP, a form of polarity that allows cells to
orient themselves in the plane of an epithelium. Two distinct systems control PCP:
the Ft/Ds and the Frizzled/Flamingo systems (Simons and Mlodzik 2008). Loss of
any component leads to loss of planar tissue organisation, for example misoriented
hair in the wing blade, as cells lose the ability to align along the correct axis. (Simons
and Mlodzik 2008). In many tissues, Fj and Ds are expressed in opposing gradients
along the proximo-distal axis, while Ft expression is unpatterned (Yang et al. 2002).
The tissue-wide gradient is responsible for the localisation of Ft and Ds to the two
opposing sides of a cell (Brittle et al. 2012). In this way each cell know its orientation
along the axis of the gradient.
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GPCRs have recently been identified as regulators of YAP/TAZ activity (Miller
et al. 2012, Mo et al. 2012, Yu et al. 2012). Small extracellular ligands can bind and
activate GPCRs (Miller et al. 2012, Yu et al. 2012), or GPCRs can be activated by
proteolytic cleavage (Mo et al. 2012). Downstream signalling is mediated by Rho
GTPases in the former instance (Miller et al. 2012, Yu et al. 2012), but seems to be
Rho-independent in the latter (Mo et al. 2012). As Rho GTPases can regulate actin
dynamics (Ridley 2006), F-actin might also be involved in the transduction of the
signal to YAP/TAZ.
Perturbation of the F-actin cytoskeleton was initially shown in Drosophila to mod-
ulate Yki activity (Fernández et al. 2011, Sansores-Garcia et al. 2011). An increase in
F-actin, achieved for example by mutating actin filament capping proteins, leads to
an increased Yki activity (Fernández et al. 2011, Sansores-Garcia et al. 2011). This
actin-sensing function is conserved in mammalian tissue culture cells (Aragona et al.
2013, Dupont et al. 2011, Wada et al. 2011). The actin cytoskeleton is known to me-
diate many of the cellular effects of physical tension, and Yki/YAP/TAZ have been
proposed to connect cell proliferation and cell fate choice to the cell’s physical envi-
ronment by responding to cytoskeletal tension (Halder et al. 2012). Indeed, plating
tissue culture cells on a stiff extracellular matrix activated YAP/TAZ, while soft con-
ditions lead to YAP/TAZ inhibition. However, the dependence of this Yki/YAP/TAZ
regulatory mechanism on the core kinase cascade remains debated.
1.5. Baz/PAR3 and epithelial cell polarity
Cell polarity is required for any asymmetric cellular function. Some cells are tran-
siently polarised for example when they move in a specific direction. Other cells,
such as neurons or epithelial cells, stably maintain their polarised architecture. In
this subchapter I will describe the organisation of epithelial cells along their apical-
basal axis in Drosophila and compare it to mammalian epithelial cells. I will focus
on the polarity determinant Bazooka (Baz), as it is a further potential substrate of
the ASPP/PP1 complex.
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1.5.1. Epithelial cells are subdivided into distinct regions along
the apical-basal axis
Epithelial tissues are one of the basic building blocks in animals. In epithelia, one or
more layers of cells form a sheet-like structure. The two sides of the epithelial sheet are
physically separated and can adopt different properties. Three characteristics define
epithelial cells (McCaffrey and Macara 2011): (1) Epithelial cells have intercellular
contacts. These contacts maintain cell cohesion, allow the epithelium to withstand
mechanical forces and enable neighbouring cells to communicate with each other. (2)
During expansion of the epithelium, oriented cell divisions parallel to the axis of the
epithelial sheet ensure that both daughter cells remain within the sheet. Thus, the
architecture of the epithelium is maintained when it is growing. (3) Each cell has a
different molecular composition along the two opposing sides of the epithelial sheet.
This apical-basal polarity allows the epithelium to distinguish between the two sides.
Along the apical-basal axis of epithelial cells, several distinct domains of the plasma
membrane can be distinguished (Fig. 1.8) that fulfil different functional roles (St John-
ston and Ahringer 2010). On the apical side, the membrane that faces the luminal
space or the external milieu is often highly extended. Especially in absorbtive tissues,
small protrusions known as microvilli decorate this side to maximise the contact sur-
face. On the lateral side, the most apical structures are adherens junctions, which
provide a mechanical link between neighbouring cells and hold epithelial tissues to-
gether. Basal to the adherens junctions are septate junctions, which serve as physical
barriers and limit diffusion through the intercellular space (occluding junctions). The
basal side is in contact with the basement membrane, which links the epithelium to
the underlying connective tissue.
In each domain, characteristic protein complexes associate with the plasma mem-
brane. These protein complexes are not only found in epithelial cells, but are a feature
that is shared between different polarised cells. Many of the proteins described below
were first discovered in C. elegans embryos (Hoege and Hyman 2013). In Drosophila
these polarity proteins are also important in the non-epithelial neuroblasts and in
oocytes.
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Figure 1.8.: Epithelial cells have distinct membrane domains along the apical-
basal axis
The general layout of epithelial cells in Drosophila (A) and mammals (B) is similar.
Most notably, the occluding junctions that restrict para-cellular diffusion in Drosophila
(septate junctions) are basal to the adherens junctions, while in mammals the occluding
junctions (tight junctions) are apical to the adherens junctions.
1.5.2. The Crb and Par complexes define the sub-apical region
In epithelial cells, the most apical region of the lateral membrane is referred to as the
sub-apical region or marginal zone. In this region, the Crb and the Par (Partitioning
defective) complexes are localised. The Crb complex consists of the transmembrane
protein Crb, the MAGUK (membrane associated guanylate kinase) protein Sdt (Star-
dust) and the PDZ domain containing protein Patj (Bulgakova and Knust 2009). Sdt
serves as scaffold for the other proteins. It binds to Crb (Bachmann et al. 2001, Hong
et al. 2001) and to Patj (Bachmann et al. 2004) via different domains. Addition-
ally, the Crb complex can associate with the Four point one, Ezrin, Radixin, Moesin
(FERM) domain containing proteins Moesin (Moe), Yurt (Yrt) and Ex (Chen et al.
2010, Laprise et al. 2006, Ling et al. 2010, Médina et al. 2002, Robinson et al. 2010).
The other protein complex in the sub-apical region, the Par complex, consists of the
PDZ domain containing Par6 and aPKC. Par6 can directly bind to aPKC (Hutterer
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et al. 2004). Additionally, a small GTPase, Cdc42, can bind to Par6 in its GTP-bound
form (Hutterer et al. 2004). Cdc42 relieves the inhibition of the catalytic activity
of aPKC by Par6 (Atwood et al. 2007). The Par complex and the Crb complex
are connected by direct binding between Sdt and Par6 (only shown for mammalian
orthologues Wang et al. 2004), Crb and Par6 (Kempkens et al. 2006), as well as by
phosphorylation of Crb through aPKC (Sotillos et al. 2004).
1.5.3. Baz can associate with the Par complex, but is localised at
adherens junctions in epithelia
In some systems, the PDZ domain containing protein Baz (known as PAR3 in verte-
brates) is considered as a core component of the Par complex. This stems from obser-
vations in non-epithelial systems such as C. elegans embryos, Drosophila oocytes and
Drosophila neuroblasts, where Baz (par-3 in C. elegans) is found in the same mem-
brane domain as Par6 and aPKC (St Johnston and Ahringer 2010). Furthermore, Baz
can directly bind to aPKC (Wodarz et al. 2000) and Par6 (Petronczki and Knoblich
2001). However, in many epithelial systems such as Drosophila embryos (Harris and
Peifer 2005) or photoreceptors (Nam and Choi 2003), Baz co-localises with adherens
junction markers, basal to the Crb and Par complexes. Similarly, mammalian PAR3
is also often found basal of the Par complex (Afonso and Henrique 2006, Martin-
Belmonte et al. 2007, Satohisa et al. 2005).
Two independent mechanisms are required to separate Baz from the Par complex
(Fig. 1.9). Firstly, Baz/PAR3 can be phosphorylated by aPKC on a conserved serine
(S980 in Baz), which leads to the dissociation of Baz/PAR3 from aPKC (Nagai-Tamai
et al. 2002, Morais-de Sá et al. 2010). Secondly, Crb can compete with Baz to bind to
Par6 (Morais-de Sá et al. 2010). In several epithelia in Drosophila, both mechanisms
are required to exclude Baz from the sub-apical region. (Morais-de Sá et al. 2010,
Walther and Pichaud 2010). To prevent Baz from spreading into the baso-lateral
membrane (Fig. 1.9B), Par1, a baso-laterally localised kinase, phosphorylates Baz on
S151 and S1085 (Benton and St Johnston 2003). Phosphorylation allows the adaptor
protein 14-3-3 to bind, which is thought to dissociate Baz from the plasma membrane.
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Figure 1.9.: Baz localization to adherens junctions is regulated by phosphory-
lation
(A) Baz can directly bind to Par6 and aPKC. (A’) Phosphorylation of Baz by aPKC
on S980 and competition for Par6 binding by Crb leads to the apical exclusion of Baz.
(B) Baz is thought to be able to diffuse along the plasma membrane. In the baso-
lateral region, Par1 phosphorylates Baz on S151 and S1085. (B’) Both sites are
phosphorylation-dependent 14-3-3 binding sites. 14-3-3 binding leads to the dissoci-
ation of Baz from the membrane.
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Furthermore, phosphorylation of S151 prevents Baz multimerisation, while the phos-
phorylation of S1085 reduces aPKC binding (Benton and St Johnston 2003). The
Par1 phosphorylation sites are conserved in mammals (Hurd et al. 2003, Izaki et al.
2005). However, aPKC binding is not inhibited by 14-3-3 binding to PAR3 (Izaki
et al. 2005). The phosphorylation of Baz/PAR3 can be reversed by phosphatases.
S1085 is dephosphorylated by a PP2A phosphatase complex in Drosophila (Krahn
et al. 2009). How the other sites of Baz are dephosphorylated is unknown. In PAR3,
the equivalent residues to Baz S151 and S980 can be dephosphorylated by the cat-
alytic PP1 subunit alone (Traweger et al. 2008). However, as PP1 normally acts as
a multimeric holoenzyme that requires regulatory subunits (see 1.2.4), it is not clear
if PP1 could dephosphorylate PAR3 in vivo.
Baz (Krahn et al. 2010) and PAR3 (Horikoshi et al. 2011) can directly associate
with the plasma membrane by binding to phosphoinositide lipids in a conserved region
close to the C-terminus. It had been suggested that the second PDZ domain of PAR3
may also bind to phosphoinositides (Wu et al. 2007a), but the binding appears to
be much weaker than binding through the conserved C-terminal region (Horikoshi
et al. 2011). Rho-kinase can phosphorylate Baz on unidentified residues within the
conserved C-terminus and thereby inhibits phosphoinositide binding (Matos Simões
et al. 2010). It is not clear if this mechanism is conserved in mammalian PAR3, as
Rho-kinase has instead been reported to disrupt the binding between PAR3 and the
Par complex (Nakayama et al. 2008).
In addition to being actively excluded form the sub-apical and baso-lateral regions,
Baz has also been reported to bind several adherens junction components. Echinoid
(Ed), a Nectin-like cell adhesion molecule, as well as Armadillo (Arm, orthologue of
β-catenin), have PDZ binding motifs that mediate their binding to Baz (Wei et al.
2005). Mammalian Nectin-1 and Nectin-3 can also bind to PAR3 (Takekuni et al.
2003). By interacting with these proteins, Baz has been proposed to promote adherens
junction assembly. Indeed, Baz initiates accumulation of new adherens junction ma-
terial in cellularising embryos and photoreceptors (McGill et al. 2009, McKinley et al.
2012, Walther and Pichaud 2010).
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1.5.4. Adherens junctions are required to connect neighbouring
cells
Adherens junctions have two core complexes that are required for their function as me-
chanical links between neighbouring cells (Harris and Tepass 2010). The first complex
consists of the adhesion molecule E-Cadherin, the transcription factor/scaffold protein
Arm (β-catenin in mammals) and the actin-binding protein α-catenin. E-Cadherin
has extracellular cadherin repeats that mediate homophilic trans-interactions (Harris
and Tepass 2010). Intracellularly, E-Cadherin directly binds Arm (Oda et al. 1994,
Tepass et al. 1996). Via Arm, E-cadherin is connected to α-catenin, which can di-
rectly bind to the actin cytoskeleton (Rimm et al. 1995). However, some biochemical
studies suggest that a simple quaternary complex of E-Cadherin, Arm, α-catenin and
F-actin may not form (Drees et al. 2005, Yamada et al. 2005), though recent in vivo
work disputes this view (Desai et al. 2013).
The second complex consists of the Nectin-like Ed and Canoe (Cno), an Afadin
orthologue (Harris and Tepass 2010). Similar to E-Cadherin, Ed can also mediate
interactions between neighbouring cells. It binds in-trans to other Ed molecules (Islam
et al. 2003) and intracellularly associates with Cno (Wei et al. 2005). Through Cno,
Ed is connected to the actin cytoskeleton (Sawyer et al. 2009).
1.5.5. Septate junctions seal the intercellular space
Basal of the adherens junctions are septate junctions, which seal the intercellular
space and prohibit free para-cellular diffusion (St Johnston and Ahringer 2010). The
septate junctions mark the apical part of the baso-lateral membrane. Several proteins
with extracellular domains are necessary for the formation and maintenance of sep-
tate junctions. These include three Claudin family members Megatrachea (Behr et al.
2003), Sinuous (Wu et al. 2004) and Kune-Kune (Nelson et al. 2010), the Na+/K+-
ATPase (Paul et al. 2003), Neurexin (Baumgartner et al. 1996), Gliotactin , Neu-
roglian (Genova and Fehon 2003, Schulte et al. 2003), Contactin (Faivre-Sarrailh et al.
2004), Lachesin (Llimargas et al. 2004) and Fasciclin III (Snow et al. 1989). Intracel-
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lularly, the two FERM domain containing proteins Yrt and Coracle (Cora) (Laprise
et al. 2009), as well as the MAGUK protein Varicose (Wu et al. 2007b) are localised
at septate junctions and required for their function. Although most proteins listed
above affect each other’s localisation, it is not entirely clear if they all form a single
physical complex.
1.5.6. The Scrib group of proteins defines the baso-lateral
domain
Another group of proteins that resides on the baso-lateral membrane is the Scrib
group. This group comprises the two PDZ domain-containing proteins Scrib and Discs
large (Dlg), as well as the WD-40 repeat protein Lgl. Sometimes, the three proteins
are referred to as a complex. However, so far only an indirect interaction between
Scrib and Dlg via a third protein, GUK-holder, has been described (Mathew et al.
2002). They are generally grouped together because they partially co-localise and
function together to regulate cell polarity, sharing some mutant phenotypes (Bilder
et al. 2000). Scrib and Dlg co-localise with septate junction proteins in the apical part
of the baso-lateral membrane (Bilder and Perrimon 2000, Woods and Bryant 1991),
while Lgl spreads along the full length of the baso-lateral membrane (Bilder et al.
2000). Despite the co-localisation of the Scrib group with septate junction proteins,
the two groups seem to be distinct entities. In FRAP experiments, Dlg showed a fast
recovery, while septate junction proteins were largely immobile (Oshima and Fehon
2011). Lastly, the kinase Par1, which phosphorylates Baz, is also localised at the
baso-lateral membrane (Benton and St Johnston 2003).
1.5.7. Mutual regulation is required to maintain the molecular
identity of the distinct domains
The molecular complexes described above establish and maintain the distinct iden-
tities of the membrane domains by mutual regulation (Tepass 2012). Although the
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required complexes can vary between contexts, the idea of mutual antagonisms is a
recurring theme.
The best-characterised mutual antagonism is between the apical Par/Crb com-
plexes and the baso-lateral Scrib group. This interaction is conserved between Dro-
sophila and vertebrate systems (Chalmers et al. 2005). The loss of apical determinants
such as aPKC (Chalmers et al. 2005, Wodarz et al. 2000) or Crb (Bilder et al. 2003,
Tanentzapf and Tepass 2003) leads to the spread of baso-lateral determinants. Con-
versely, the loss of the Scrib group leads to the spread of apical determinants (Bilder
et al. 2000). This mutual antagonism is at least partially due to the phosphorylation
of Lgl by aPKC. aPKC can phosphorylate Lgl in order to remove it from the plasma
membrane on the apical side (Betschinger et al. 2003, Hutterer et al. 2004, Plant
et al. 2003, Yamanaka et al. 2003). Conversely, Lgl binds to the Par complex and
inhibits the activity of aPKC (Atwood and Prehoda 2009, Yamanaka et al. 2003)
Another mutually antagonistic interaction is observed between the Yrt/Cora group
and the Crb complex (Laprise et al. 2009). The Yrt/Cora group of septate junction
proteins comprises Yrt, Cora, Neurexin and the Na+/K+-ATPase. During organo-
genesis of the Drosophila embryo (stages 11–13), removing either the Yrt/Cora group
or the Crb complex leads to the spreading of the other along the plasma membrane.
It is unknown if this mutual antagonistic pair is required in any other context to
maintain apical-basal polarity.
It has been proposed on the basis of computational modelling that mutual antago-
nism alone is not sufficient for efficient membrane polarisation (Fletcher et al. 2012).
Additionally, a positive feedback loop driven by Crb cis-homo-multimerisation might
be required.
1.5.8. In mammalian epithelial cells, the adherens junctions are
basal to the tight junctions
The general structure of epithelial cells is similar in Drosophila compared to mam-
mals (Fig. 1.8). The most striking difference is that, in mammalian epithelia, the
occluding junctions (tight junctions) are apical of the baso-laterally localised ad-
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herens junctions (St Johnston and Ahringer 2010). Tight junctions are functional
equivalents of septate junctions, but morphologically and molecularly, they are strik-
ingly different (Furuse and Tsukita 2006). Two groups of adhesion molecules that
are found in mammalian tight junctions (JAMs and Occludins) are not found in the
Drosophila genome.
Despite the shuﬄing of the occluding junctions and the adherens junctions, the
polarity determinants are not affected in their apical-basal order. As in Drosophila,
the PAR and CRB complexes are found in the apical region in mammalian epithelial
cells. PAR3 is associated with the most apical cell-cell junctions (Baz with adherens
junctions and PAR3 with tight junctions). Lastly, the SCRIB group is found at the
baso-lateral membrane.
In contrast to the polarity determinants that are in the same topological order,
the functional components of adherens junctions are not. Thus, E-Cadherin, α- and
β-catenin, as well as Nectin and Afadin (the Ed and Cno orthologues) are baso-lateral
to the tight junctions in mammalian epithelial cells.
1.6. Aims of this thesis
During epithelial tissue development, the establishment and subsequent maintenance
of cell-cell contacts is crucial to the function of the tissue (see 1.5). The aim of
this thesis is to elucidate the molecular details how the scaffold proteins ASPP and
RASSF8 regulate cell-cell junction dynamics in a developmental context. Previously,
our lab had shown that both proteins form a complex and localise at adherens junc-
tions in epithelial tissues, where they are required to maintain junctional integrity
during developmental tissue remodelling (Langton et al. 2007 2009).
At the time I started this work, our lab had already gained some insights into the
regulation of adherens junctions by ASPP through Csk/Src (see 1.3.9). In parallel, our
collaborators in Zurich, led by Matthias Gstaiger, provided an extensive proteomic
analysis of the mammalian ASPP network suggesting a new additional function. In
AP-MS experiments with human ASPP1/2 and RASSF8 as bait, Ser/Thr protein
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Figure 1.10.: Interaction network of ASPP and N-terminal RASSF family pro-
teins from AP-MS experiments
Bait proteins (hexagons) were affinity purified and associated preys identified using
mass spectrometry. Arrows point away from bait proteins towards the retrieved prey
proteins. Previously described interactions are shown as dashed lines. Colouring indi-
cates ASPP and N-terminal RASSF family proteins (purple in the lower right corner),
PP1 catalytic subunits and canonical regulatory subunits (orange), Ccdc85 family pro-
teins (purple in the upper left corner) and potential substrates of ASPP/PP1 complexes
(green). Adapted from (Hauri et al. 2013).
phosphatases of the PP1 family were pulled down (Fig. 1.10). Conversely, ASPP1/2
were also detected in a pull-down of PP1γ. Since ASPP1/2 possesses a conserved,
PP1 binding RVXF motif, this suggested that ASPP and N-terminal RASSF family
proteins could act as PP1 regulatory subunits at cell-cell junctions. This thesis is
primarily focused on testing this hypothesis.
In the following result section (Chapter 3), I will describe the complex that forms
between Drosophila PP1, ASPP and RASSF8. Chapter 4 explores two potential
substrates of this complex: The transcriptional co-activator Yki/YAP and the po-
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larity determinant Baz/PAR3. Chapter 5 outlines the potential regulation of the
ASPP/RASSF8 complex by Hippo signalling. Chapter 6 concludes the results sec-
tion and examines further possible substrates and regulators.
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Materials and Methods
2.1. Molecular biology: DNA
2.1.1. Genomic DNA isolation
Fly genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen). One
male fly was homogenised in 180 μL PBS and processed according to the cultured
cell protocol provided by the manufacturer. The final elution volume was 100 μL. For
PCR reactions (see 2.1.3), 1 μL of the extracted DNA was used.
2.1.2. cDNA isolation for cloning
cDNA was obtained in a two-step process. Firstly, total RNA was obtained from Dro-
sophila S2 cells or tissue using the RNeasy Mini Kit (Qiagen). Secondly, cDNA was
produced from 2 μg of total RNA using the First Strand cDNA Synthesis Kit for RT-
PCR (Roche). Alternatively, if available, cDNA clones from the DGRC (Drosophila
Genomics Resource Center) collection were used as template for PCR.
2.1.3. Polymerase Chain reaction
DNA segments of interest were amplified using the appropriate oligonucleotides (see
2.1.15) in a PTC-200 Peltier thermal cycler (MJ Research). For all molecular cloning,
Pwo Master (Roche) with 3’ to 5’ proofreading activity was used. For genotyping,
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Taq PCR Master Mix Kit (Qiagen) with lower fidelity was used. Typical reactions
were carried out in 50 μL volume with a final concentration of 200 nM of forward and
reverse primer.
The standard PCR program used was as follows:
Hot start: 95 ◦C for 2 min
Denaturation: 95 ◦C for 15 s
Annealing: 50–65 ◦C for 30 s (normally 55◦C, adjusted to primers)
Extension: 72 ◦C for 1 min per kb of product
Final extension: 72 ◦C for 8 min
The denaturation, annealing and extension steps were repeated for 32 cycles.
DNA purification
For cloning, the product was purified after PCR. For restriction enzyme based cloning
(see 2.1.7), the PCR product was purified using the QIAquick PCR Purification Kit
(Qiagen). For generating entry vectors for the Gateway system (see 2.1.6), the PCR
product was separated on 1 % agarose gels stained with ethidium bromide (Sigma-
Aldrich). Gel slices containing the product were purified using the QIAquick Gel
Extraction Kit (Qiagen). This was done to remove primer dimers that would compete
with the PCR product to recombine with the entry vector.
2.1.4. RT-PCR
Total RNA was isolated from ten flies using the RNeasy Mini Kit (Qiagen). Isolated
RNA was treated with DNase (Promega) for 37 ◦C for 30 minutes before adding
DNase Stop Solution (Promega) and another incubation at 65 ◦C for 10 minutes to
inactivate DNase. cDNA was synthesised from 1 μ g of isolated RNA with oligo(dT)
primers using the First Strand cDNA Synthesis Kit for RT-PCR (Roche) according
to the manufacurer’s instructions. Lastly, a standard PCR was carried out using the
synthesised cDNA as template for 30 cycles.
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2.1.5. Agarose gel/DNA visualisation
DNA was separated by size using 1 % agarose gels containing ethidium bromide
(Sigma-Aldrich). The agarose was dissolved in 0.5x TAE buffer. Gels were imaged
using a BioDocIt (UVP) imaging system.
2.1.6. Gateway cloning
All Drosophila S2 cell expression vectors were obtained using Gateway cloning (In-
vitrogen). The system is based on reversible recombination by two enzymes called
LR clonase and BP clonase. The LR clonase recombines DNA flanked by attL1 and
attL2 sequences with DNA flanked by attR1 and attR2 sequences. The recombina-
tion not only exchanges the DNA fragments, but also generates different flanking se-
quences. attL1/2 become attB1/2, while attR1/2 become attP1/2. The new attB1/2
and attP1/2 are recognised by the BP clonase. Thus, BP clonase can reverse the
recombination carried out by LR clonase.
Entry vectors
In the initial cloning step, entry vectors were generated. Target DNA was amplified
by PCR using primers containing attB1 and attB2 sequences, as well as a Kozak
sequence (ACC) in front of an ATG start codon for the forward primer. The PCR
product was recombined with the Gateway pDONR/Zeo Vector (Invitrogen) using
Gateway BP clonase II Enzyme mix (Invitrogen) according to the manufacturer’s
protocol.
Expression vectors
Expression vectors were obtained in the second step by recombining the entry vec-
tor containing the target DNA with an expression vector using Gateway LR clonase
II Enzyme mix (Invitrogen) according to manufacturer’s protocol. Most Drosophila
expression vectors come from the Drosophila Gateway Vector Collection. The nomen-
clature of these vectors indicates the promoter as well as the type and placement of
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the tag. For example, the pAFW vector is a plasmid (p) that contains the actin (A)
promoter and codes for a FLAG-tag (F) upstream of the Gateway cassette (W).
The different tags that were used in this thesis are: FLAG-tag (F), GFP-tag (G),
HA-tag (H), Myc-tag (M) and V5-tag (V).
2.1.7. Restriction-based cloning
For the generation of some Gateway vectors (see 2.1.16 and 2.1.18), Restriction-
based cloning was used. Vectors and the amplified target DNA (insert) were digested
using suitable restrictions enzymes (NEB). The vectors were treated with Alkaline
Phosphatase (NEB) to avoid self-ligation of the vector. Digested DNA was purified
using the QIAquick Gel Extraction Kit (Qiagen). Subsequently, the vector and insert,
in a 1:3 molar ratio, were ligated at 16 ◦C overnight using T4 DNA Ligase (NEB).
2.1.8. Site-directed mutagenesis
Site-directed mutagenesis was performed using a primer pair of 33 nucleotide length
with the altered codon in the middle. The PCR was carried out using PfuTurbo
DNA Polymerase (Stratagene). 50 ng of plasmid DNA was used as template in
a 50 μL reaction. As for standard PCR reactions, primers were added to a final
concentration of 200 nM.
The PCR program used was as follows:
Hot start: 95 ◦C for 2 min
Denaturation: 95 ◦C for 30 s
Annealing: 55 ◦C for 60 s (normally 55◦C, adjusted to primers)
Extension: 68 ◦C for 2 min per kb of plasmid
The denaturation, annealing and extension steps were repeated for 30 cycles.
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2.1.9. N-/C-terminal truncations
For truncations of either end of a target DNA, a PCR was carried out using primers
that only amplify the shorter DNA segment of interest.
2.1.10. Deletions
For deletions, two PCRs were carried out with primers amplifying both ends flanking
the deletion. The primers in the middle were chosen to contain a restriction enzyme
site that did not occur elsewhere within the amplified DNA. Both products were
digested with the appropriate enzyme and ligated. The ligated product served as
template for PCR with attB1 and attB2 sites for the generation of entry vectors (see
2.1.6).
2.1.11. Bacterial transformation
One Shot TOP10 Competent cells (Invitrogen) were incubated with plasmid DNA on
ice for 10 minutes, then heat-shocked at 42 ◦C for 25 seconds and then chilled on ice.
SOC medium (Invitrogen) was added and the mixture was incubated for 37 ◦C for 1 h
and plated on LB agar plates with appropriate antibiotics. The plates were incubated
overnight at 37 ◦C. In the case of cloning expression vectors for the Gateway system
that had no insert, One Shot ccdB Survival Competent cells (Invitrogen) were used
instead of TOP10 cells.
2.1.12. Plasmid purification
For Minipreps, single colonies were isolated from LB agar plates and incubated in
5 mL LB at 37 ◦C over night. For Midipreps, single colonies were isolated and
incubated in 5 mL LB for 8 h at 37 ◦C. The 5 mL culture was added to 100 mL LB
and incubated at 37 ◦C over night. Plasmid DNA was isolated from the over night
cultures using QIAprep Spin Miniprep Kit (Qiagen) and HiSpeed Plasmid Midi Kit
(Qiagen) according to the manufacturer’s protocol.
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2.1.13. Sequencing
DNA was sequenced by the Equipment Park using their specified protocols. PCR
products were purified using the DyeEx Spin kit (Qiagen) according to the manufac-
turer’s protocol.
2.1.14. dsRNA production
To generate dsRNA for RNAi in S2 cells, appropriate DNA templates were amplified
using PCR. The PCR product was gel purified using QIAquick Gel Extraction Kit
(Qiagen). The purified DNA was transcribed in vitro using the MEGAscript T7
Transcription Kit (Ambion) according to the manufacturer’s protocol. The reaction
was run over night at 37 ◦C. The transcribed RNA was precipitated in 0.1 M sodium
acetate containing 70 % Ethanol at -20 ◦C for 10 min. The RNA was washed twice
with 70 % ethanol. Dried RNA was dissolved in water and stored at -80 ◦C.
2.1.15. List of oligonucleotides
Table 2.1.: List of oligonucleotides
Generating pKC26w
mini-white 451 f TACGCCATCAATTAAACACAAAGTG
mini-white r GCCCTGGCACCCGCACCGCGGACTAGTACTAGTTCCAGTG
AAATCCAAGC
pW25 DraIII mut f CACATCGTCGAATACCACCTGCCCCAGTTCGGG
pW25 DraIII mut r CCCGAACTGGGGCAGGTGGTATTCGACGATGTG
Generating pKC26w_W/GW
3’ GW casette TAAGGTTCCTTCACAAAGATCC
5’ GW casette CGGGGTACCACGCGTACAAGTTTGTACAAAAAAGCTGA
5’ GFP GW casette CGGGGTACCCACCATGGTGAGCAAGGGCG
RNAi
Wts RNAi f TAATACGACTCACTATAGGGCACAAAGTGGGACTGCC
Wts RNAi r TAATACGACTCACTATAGGGGCAGGGTTTTCATCGCATAC
lacZ RNAi f TAATACGACTCACTATAGGTTGCCGGGAAGCTAGAGTAA
lacZ RNAi r TAATACGACTCACTATAGGGCCTTCCTGTTTTTGCTCAC
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List of oligonucleotides (continued)
dsRed f CTAATACGACTCACTATAGGGAGCGAGGACGTCATCAAGG
AGT
dsRed r CTAATACGACTCACTATAGGGAGGGTGATGTCCAGCTTGG
AGT
ASPP RNAi f CTAATACGACTCACTATAGGGAGCAGTAGCTCTTGCCGTT
TCC
ASPP RNAi r CTAATACGACTCACTATAGGGAGTTTTGCAACTGCAACAG
AGG
ASPP RNAi #2 f TAATACGACTCACTATAGGGTCCTCAAGTCGCAGGAGGT
ASPP RNAi #2 r TAATACGACTCACTATAGGGCCTTCTCGCTGAACAGTGC
PP1α13C RNAi f TAATACGACTCACTATAGGGATGGCGGAGGTTCTCAATTT
PP1α13C RNAi r TAATACGACTCACTATAGGGGATATCGCCGCAGATCTTGA
PP1α87B RNAi f TAATACGACTCACTATAGGGATGGGCGACGTGATGAATA
PP1α87B RNAi r TAATACGACTCACTATAGGGCCGCAGATCTTCAACGGT
PP1α96A RNAi f TAATACGACTCACTATAGGGTCGGATATCATGAACATCGAC
PP1α96A RNAi r TAATACGACTCACTATAGGGGCCTCCAGCTCCAGGAGTAT
PP1β9C RNAi f TAATACGACTCACTATAGGGATGGGCGACTTCGATCTG
PP1β9C RNAi r TAATACGACTCACTATAGGGAGTCGCCGAGGAACAAGTAG
Genotyping
ccdc85 genotyping f TGCCTCGAATCTGGTGGGGA
ccdc85 genotyping r ATGAAGAGGAGCCCGCGGA
PP1α96A genotyping f GCGGAAATGTTGCTGAAGCA
PP1α96A genotyping r CAATGATCACTTACCCGCGT
RT-PCR
CG3558 RT 1060f TTCCCGTGCTGGGACCTGC
CG3558 RT 1470r CAGTTCACTCACCACAGGCTCG
Ccdc85 RT 900f GCGTGCGCTGAAGGAGCA
Ccdc85 RT 1320r GTTCAGCGTGTGGGCATGAC
RpL32 f GACGCTTCAAGGGACAGTATCTG
RpL32 r GCAGTAAACGCGGTTCTGCATGAG
Site directed mutagenesis
RASSF8 S209A f GAGAAATCGCTGGCCAATCCGCTGGAC
RASSF8 S209A r GTCCAGCGGATTGGCCAGCGATTTCTC
RASSF8 Y297A f CTAGTCCCACCACCAGCTCGTGACCCGCCACCC
RASSF8 Y297A r GGGTGGCGGGTCACGAGCTGGTGGTGGGACTAG
ASPP V812A,F814A f AAGCTGGGTCGAAGGGCCAGCGCTGATCCGCTG
ASPP V812A,F814A r CAGCGGATCAGCGCTGGCCCTTCGACCCAGCTT
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List of oligonucleotides (continued)
ASPP W987K f GATGCCGAGAACGAGAAGTGGTGGGCACGGAAT
ASPP W987K r ATTCCGTGCCCACCACTTCTCGTTCTCGGCATC
Baz S151A f ATGGTGCGTCGCAGCGCTGATCCCAATCTGCTG
Baz S151A r CAGCAGATTGGGATCAGCGCTGCGACGCACCAT
Baz S980A f GCTTTGGGACGACGCGCCATCTCTGAGAAGCAC
Baz S980A r GTGCTTCTCAGAGATGGCGCGTCGTCCCAAAGC
Baz S1085A f ATGAAGAAGTCCTCGGCGTTGGAGTCGCTCCAG
Baz S1085A r CTGGAGCGACTCCAACGCCGAGGACTTCTTCAT
Baz S169D f AGTAACAAACGCTGGGACGCGGCGGCTCCCCAC
Baz S169D r GTGGGGAGCCGCCGCGTCCCAGCGTTTGTTACT
Baz S180D f TACGCTGGCGGGGATGACCCGGAGCGCCTGTTT
Baz S180D r AAACAGGCGCTCCGGGTCATCCCCGCCAGCGTA
Baz S235D f CAGCCGTTTGCCCGAGACGGTCGCCTGTCGATG
Baz S235D r CATCGACAGGCGACCGTCTCGGGCAAACGGCTG
Baz S239D f CGATCCGGTCGCCTGGACATGCAATTTCTTGGC
Baz S239D r GCCAAGAAATTGCATGTCCAGGCGACCGGATCG
Baz T712E f GCCGAGGCCATGGAGGAGCTACGTCGGGCAATG
Baz T712E r CATTGCCCGACGTAGCTCCTCCATGGCCTCGGC
Baz S806D f GGCGGAGGTGGTGGCGACGCTGGCAATGAGATG
Baz S806D r CATCTCATTGCCAGCGTCGCCACCACCTCCGCC
Baz S815D f GAGATGAATAGATGGGACAATCCCGTTTTGGAT
Baz S815D r ATCCAAAACGGGATTGTCCCATCTATTCATCTC
Baz S1126D f CGGGCGGCGGTGGTCGACGAACCGGATGCGAGC
Baz S1126D r GCTCGCATCCGGTTCGTCGACCACCGCCGCCCG
Baz S1131D f GACGAACCGGATGCGGACAAGCCCCGCAAGACC
Baz S1131D r GGTCTTGCGGGGCTTGTCCGCATCCGGTTCGTC
Baz T1136E f GACAAGCCCCGCAAGGAGTGGCTTTTGGAGGAT
Baz T1136E r ATCCTCCAAAAGCCACTCCTTGCGGGGCTTGTC
Baz S1169D,S70D f AAACACGGCTGCAAGGACGACCGGGCCAAGAAG
Baz S1169D,S70D r CTTCTTGGCCCGGTCGTCCTTGCAGCCGTGTTT
Baz S1170D f CACGGCTGCAAGTCGGACCGGGCCAAGAAGCCA
Baz S1170D r TGGCTTCTTGGCCCGGTCCGACTTGCAGCCGTG
Baz S1176D f CGGGCCAAGAAGCCAGACATACTGCGCGGTATC
Baz S1176D r GATACCGCGCAGTATGTCTGGCTTCTTGGCCCG
Baz T1410E f TTTGTGACGCAGGTGGAGATACGGGAGCAGAGC
Baz T1410E r GCTCTGCTCCCGTATCTCCACCTGCGTCACAAA
Magi P323A f TCTCACTGGCTGGATGCGCGGCTCTCCAAGTAC
Magi P323A r GTACTTGGAGAGCCGCGCATCCAGCCAGTGAGA
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List of oligonucleotides (continued)
Magi P370A f ACGCAGTACGAGAACGCAGTGCTGGAGGCCAAG
Magi P370A r CTTGGCCTCCAGCACTGCGTTCTCGTACTGCGT
Sina C87A f CCGCCGATCCTGCAGGCCTCCAGCGGGCACCTG
Sina C87A r CAGGTGCCCGCTGGAGGCCTGCAGGATCGGCGG
Deletions
ASPP 1-234 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAA
GGAGCCGACGAACACTTTG
ASPP 1-234 attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGCTGCTGCTG
CTGCTGATG
ASPP 231-795 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGCA
ACAGCAGCAGCACCA
ASPP 231-795 attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGGCTGGTTGT
CACGGTTGT
ASPP 796-1020 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAA
CATCAAGGAGCGAACG
ASPP 796-1020 attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGGCCGCACTT
CAGCGAT
Baz 1-1096 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAA
GGTCACCGTCTGCTT
Baz 1-1096 attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACAGCTC
CTGCACCATAGTCT
Baz 1097-end attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGCA
GATGTCGGATGAGCCG
Baz 1097-end (stop) attB2 r GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACACCTT
GGAGGCGTG
PP1α96A ΔC attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATCGTCG
CTTGTCGGCGG
PP1β9C ΔC attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACTTCTT
CTCGGATGGTTT
RASSF8 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGA
ACTTAAAGTATGGGTGGA
RASSF8 1-134 r GGGGGGATCCGTTCGACTTTTGCTTTAGCAAAGT
RASSF8 1-181 r GGGGGGATCCCGGTGCTCCCATGGCCGTTT
RASSF8 attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTCATACATAT
ATGCCTTCAGGATTAAAA
RASSF8 214-end f GGGGGGATCCATGACCAGCACGGGTAGCAA
RASSF8 221-end f GGGGGGATCCCCACCCGCACCTACAAATGG
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List of oligonucleotides (continued)
Cloning
PP1α13C attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGC
GGAGGTTCTCAAT
PP1α13C attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTCTACTTCTT
GCGCTTCTCGA
PP1α87B attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGG
CGACGTGATGAATA
PP1α87B attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACTTTTT
ACGCTTGTCGG
PP1α96A attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTC
GGATATCATGAACATCG
PP1α96A attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATTTTTT
CTTGTTTTTATTGTTAGCT
PP1β9C attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGG
CGACTTCGATCTG
PP1β9C attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATTTCTT
CTTGTTGGTCG
Ccdc85 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTC
CGGCAATCAACAG
Ccdc85 attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTTAGAGCGG
CTCCAGGGC
MYPT-75D attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAT
CAAGGGCATTCTGATAC
MYPT-75D attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGCATCAGGAC
GCAACACCT
Sina attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTC
CAATAAAATCAACCCGAAG
Sina attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGGACCAGAGA
TATGGTCACGT
Sqh attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTC
ATCCCGTAAGACCGC
Sqh attB2 stop GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACTGCTC
ATCCTTGTCCT
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2.1.16. Generation of cell culture plasmids
Generation of pAVW and pAWV
N- and C-terminally V5-tag expressing vectors are not part of the Drosophila Gate-
way Vector Collection. In order to express V5-tagged proteins, pAVW and pAWV
vectors were generated from FLAG-tag vectors. The DNA encoding the FLAG-tag
was cut out from pAFW and pAWF using ScaI and AgeI restriction enzymes (NEB).
Synthesized single stranded oligos (Sigma-Aldrich) containing the V5-tag flanked by
ScaI and AgeI restriction sites (see 2.1.15) were annealed by heating to 95 ◦C in a
water bath and slowly cooled to room temperature. The annealed V5-DNA fragment
was cut with ScaI and AgeI and ligated with cut pAFW and pAWF using T4 DNA
Ligase (NEB).
2.1.17. List of cell culture plasmids
All plasmids that were used for cell culture were generated using Gateway cloning.
For the nomenclature of the plasmids that were used see 2.1.6. If the plasmid was
readily available or derived from an available entry clone using an LR reaction, the
originator is given in the source column. cDNA indicates that cDNA from primary
fly tissue served as template, DGRC indicates that the template was obtained from
DGRC and mutagenesis indicates that an available entry vector was used as template
for mutagenesis.
Table 2.2.: List of plasmids for cell culture
Name Backbone Source
14-3-3ε pAWF pAWF N. Tapon/M. Wehr
14-3-3ζ pAWF pAWF N. Tapon/M. Wehr
aPKC pAHW pAHW N. Tapon/P. Ribeiro
ASPP 1-234 pAFW pAFW Mutagenesis
ASPP 231-795 pAFW pAFW Mutagenesis
ASPP 796-1020 pAFW pAFW Mutagenesis
ASPP FA pAFW pAFW Mutagenesis
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List of plasmids for cell culture (continued)
ASPP FA pAHW pAFW Mutagenesis
ASPP FA pAMW pAMW Mutagenesis
ASPP FA/WK pAMW pAMW Mutagenesis
ASPP pAFW pAFW N. Tapon/P. Langton
ASPP pAGW pAGW N. Tapon/P. Langton
ASPP pAHW pAMW N. Tapon/P. Langton
ASPP pAMW pAMW N. Tapon/P. Langton
ASPP WK pAMW pAMW Mutagenesis
Baz pAFW pAFW A. Wodarz
Baz pAMW pAMW A. Wodarz
Baz S1085A pAFW pAFW Mutagenesis
Baz S1126,31D T1136E pAFW pAFW Mutagenesis
Baz S1126D pAFW pAFW Mutagenesis
Baz S1169,70,76D pAFW pAFW Mutagenesis
Baz S1169,70D pAFW pAFW Mutagenesis
Baz S1176D pAFW pAFW Mutagenesis
Baz S151A pAFW pAFW Mutagenesis
Baz S169D pAFW pAFW Mutagenesis
Baz S180D pAFW pAFW Mutagenesis
Baz S235D pAFW pAFW Mutagenesis
Baz S239D pAFW pAFW Mutagenesis
Baz S806D pAFW pAFW Mutagenesis
Baz S815D pAFW pAFW Mutagenesis
Baz S980A pAFW pAFW Mutagenesis
Baz T1410E pAFW pAFW Mutagenesis
Baz T712E pAFW pAFW Mutagenesis
BazC pAGW pAGW Mutagenesis
BazN pAGW pAGW Mutagenesis
Ccdc85 pAFW pAFW DGRC (RE60986)
Ccdc85 pAMW pAMW DGRC (RE60986)
GFP pAFW pAFW N. Tapon
GFP pAMW pAMW N. Tapon
Hpo pAWF pAWF N.Tapon
Hpo pAWH pAWF N. Tapon
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List of plasmids for cell culture (continued)
Hpo pAWM pAWM N. Tapon
Hs RASSF8 isoformA pTO-N-HAStrep A. Chalmers
Magi P323A pAFW pAFW Mutagenesis
Magi P370A pAFW pAFW Mutagenesis
Magi pAFW pAFW N. Tapon/M. Wehr
Magi ΔWW pAFW pAFW A. Djiane
MYPT-75D pAWG pAWG DGRC (LD4660)
PP1α13C pAFW pAFW cDNA
PP1α13C pAHW pAHW cDNA
PP1α87B pAFW pAFW cDNA
PP1α87B pAHW pAHW cDNA
PP1α96A pAFW pAFW cDNA
PP1α96A pAHW pAHW cDNA
PP1α96A pAVW pAVW cDNA
PP1α96A ΔC pAFW pAFW cDNA
PP1β9C pAFW pAFW cDNA
PP1β9C pAHW pAHW cDNA
PP1β9C ΔC pAFW pAFW cDNA
RASSF pAFW pAFW N. Tapon
RASSF8 pAMW pAMW N. Tapon/E. Chan
RASSF8 pAWF pAWF N. Tapon/E. Chan
RASSF8 pAWH pAWH N. Tapon/E. Chan
RASSF8 Y297A pAWF pAWF Mutagenesis
RASSF8-SA pAWF pAWF Mutagenesis
RASSF8-SA pAWH pAWH Mutagenesis
RASSF8-Δ1 pAWH pAWH Mutagenesis
RASSF8-Δ2 pAWH pAWH Mutagenesis
Sec15 pAFW pAFW N. Tapon/E. Chan
Sina C87A pAFW pAWF Mutagenesis
Sina pAFW pAWF DGRC (HL08111)
Sqh pAFW pAFW DGRC (LD14743)
WAVE pAWF pAWF N. Tapon/E. Chan
Yki pAWF pAWF N. Tapon
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2.1.18. Generation of plasmids for injection into Drosophila
embryos
Generation of pKC26w, pKC26w_W, pKC26w_GW and pKC26w_WG
The pKC26 vector that was available in the lab from the Vienna RNAi stocks centre
was not suitable for PhiC31 mediated insertion at most attP sites (see 2.3.3), as
it only contained half of the mini-white gene. Half of the mini-white gene is not
sufficient for the expression of the red eye pigment. When pKC26 is recombined into
a restriction-based attP locus with the other half of the mini-white gene, red pigment
is produced. This is useful to ensure the correct insertion of a transgene. However,
only few attP site carrying flies (e.g., VIE217, see 2.3.2) have the other half of the
mini-white gene. Thus, I decided to restore the whole mini-white gene to allow the
insertion into any attP locus yielding a visible eye marker.
The original pKC26 vector contained an attB site for PhiC31 mediated recombina-
tion, an ubiquitin promoter upstream of a multiple cloning site for restriction-based
cloning and half of the mini-white gene. The missing half of mini-white, flanked by
DraIII and SpeI restriction sites, was cloned from pW25 into pCR-Blunt II-TOPO
(Invitrogen). A DraIII restriction site within the mini-white fragment was silently
mutagenized to allow restriction-based cloning of the fragment into pKC26. The
resulting vector was named pKC26w.
In order to allow Gateway cloning (see 2.1.6), a Gateway cassette was inserted by
restriction-based cloning using primers containing NheI and KpnI sites. Three vectors
were created, pKC26w_W, pKC26w_GW and pKC26w_WG. The first vector only
has a Gateway cassette, while the other two code for N- and C-terminal GFP-tags
as well. The pKC26w_WG vector was generated by Pedro Gaspar. To allow easy
exchange or removal of the ubiquitin promoter, all three vectors have an additional
MluI restriction site inserted upstream of the Gateway cassettes. Thus, a single MluI
digest, followed by self-ligation will generate promoterless vectors.
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Table 2.3.: List of plasmids for injection
Name Backbone Source
UAS-ASPP-FA-HA pUASg-HA Mutagenesis
UAS-ASPP-HA pUASg-HA Mutagenesis
UAS-Ccdc85 pUASg DGRC (RE60986)
Ubi-GFP-ASPP pKC26w GW Mutagenesis
Ubi-GFP-ASPP-FA pKC26w GW Mutagenesis
Ubi-GFP-PP1α87B pKC26 Mutagenesis
Ubi-GFP-PP1α96A pKC26 Mutagenesis
Ubi-RASSF8-GFP pKC26 N. Tapon/E. Chan
Ubi-RASSF8-SA-GFP pKC26 Mutagenesis
2.2. Molecular Biology: Cell culture and protein
2.2.1. Drosophila Cell Culture
Drosophila S2 cells were maintained at 25 ◦C in Schneider’s Drosophila Medium
(Gibco) supplemented with 10 % Fetal Bovine Serum (Sigma-Aldrich) and
100 unit/mL penicillin and 100 μg/mL streptomycin (Gibco) in 75 cm2 cell culture
flasks (Corning).
2.2.2. Transient transfection
For DNA transfections, 30 min prior to transfection, 3x106 S2 cells were seeded per
well of a 6-well plate (Corning) in 2 mL of serum-containing Schneider’s Drosophila
Medium (Gibco). 200-400 ng of DNA per plasmid were transfected per well using
Effectene Transfection Reagent (Qiagen) according to the manufacturer’s protocol.
The amount of Enhancer and Effectene Reagent used per well was 3.2 μL and 10 μL
respectively. Cells were lysed/prepared for immunofluorescence 48 h after transient
transfection.
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2.2.3. RNAi in S2 cells
For RNAi, 1.5x106 S2 cells were seeded per well of a 6-well plate 1 h before. 25 ng of
dsRNA was diluted in 1 mL of serum-free Schneider’s Drosophila Medium (Gibco) per
well. The dsRNA was added for 30 minutes. Subsequently, 2 mL of serum-containing
Schneider’s Drosophila Medium (Gibco) were added. Cells were lysed/prepared for
immunofluorescence 72 h after adding dsRNA. For parallel RNAi and transient trans-
fection, 24 h after adding dsRNA, the transfection was carried out as described above.
2.2.4. Proteasome inhibitor treatment
For proteasome inhibition experiments, S2 cells were treated with 50 μM MG132
(Calbiochem) and 50 μM calpain inhibitor I (Ac-LLnL-CHO or LLnL) (Sigma) for
4 h before cell lysis.
2.2.5. Cell lysis
For immunoprecipitations (IPs), S2 cells were washed once with PBS before lysis.
The lysis was carried out with 200 μL of HEPES lysis buffer supplemented with
protease inhibitor cocktail with EDTA (Roche) for one well of a 6-well plate. The
lysis was left on ice for 10 minutes. For detecting phospho-proteins (e.g., mobility shift
assays, phospho-specific antibody Western blot), additionally, Phosphatase Inhibitor
Cocktail 2 and 3 (Sigma-Aldrich) and 20mM NaF were added to the lysis buffer. The
soluble lysis fraction was obtained through centrifugation (16,000 g, 20 minutes).
2.2.6. Tissue lysis
Fly heads
Fly heads were collected from adult flies. For each sample, 250 heads were lysed in
400 μL HEPES lysis buffer supplemented with Phosphatase Inhibitor Cocktail 2 and
3 (Sigma-Aldrich) and 20mM NaF with the help of a Kontes Pellet Pestle Cordless
Motor (Kimble Chase). The lysate was bound to 80 μL of Anti-HA-Agarose beads
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(Sigma-Aldrich) for 1 h at 4 ◦C. The IPed material was eluted in Sample Loading
buffer.
2.2.7. Co-immunoprecipitation (co-IP)
Half of the soluble S2 cell lysate (100 μL, see above) from the lysis of one well of a
6-well plate was added to 20 μL of ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich) or
15 μL of GFP-Trap agarose (ChromoTek) in 100 μL HEPES lysis buffer. The lysate
and the beads were incubated for 1 h at 4 ◦C. After the binding, the beads were
washed four times with 1 mL of HEPES lysis buffer. The IPed material was eluted
in Sample Loading buffer.
Indirect IP
For co-IPs of overexpressed ASPP and RASSF8 from S2 cells, the vectors were sepa-
rately transfected into different cells to avoid aggregation. Cleared lysates from cells
overexpressing ASPP and RASSF8 were then mixed before adding to beads. Binding,
washing and elution was carried out as for regular co-IPs.
2.2.8. Western Blotting
For protein analysis, either 5 μL of cleared protein lysate from one well of a 6-well plate
or half of the IPed material were denatured in Sample Loading buffer for 5 minutes at
95 ◦C. The denatured samples were loaded into NuPAGE Novex 4-12 % Bis-Tris Mini
gels (Invitrogen) and run for 1 h at 195 V in XCell SureLock Mini-Cells (Invitrogen)
with NuPAGE MOPS SDS Running Buffer (Invitrogen).
Proteins were transferred from the gels onto methanol activated Amersham
Hybond-P PVDF membranes (GE Healthcare) using Mini-PROTEAN Tetra Cells
(Biorad). The blotting procedure was done at 100 V for 1.5 h in Tris-Glycine blot-
ting buffer.
After blotting, the membranes were blocked in PBS with 5 % (w/v) skimmed milk
powder for 30 minutes at room temperature. Primary antibody in the appropriate
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concentrations (see 2.2.10) dissolved in PBS with 5 % (w/v) skimmed milk powder
was used to replace the blocking solution. The membrane was incubated with the
primary antibody overnight at 4 ◦C. Subsequently, the membrane was washed for
four times with PBST to remove unbound primary antibody. After the wash, the
membrane was incubated for 30 minutes at room temperature with horseradish per-
oxidase conjugated secondary antibody in the appropriate concentration (see 2.2.10)
diluted in PBS with 5 % (w/v) skimmed milk powder. Afterwards, unbound sec-
ondary antibody was washed off for five times with PBST. Lastly, proteins on the
membrane were visualised by chemiluminescence using ECL Plus Western Blotting
Substrate (Pierce). Amersham Hyperfilm ECL (GE Healthcare) was used to capture
the chemiluminescence signal.
2.2.9. Generation of antibodies
The pS209 antibody was generated by Eurogentec. In vitro synthesised peptides
of the sequence CHEKSLpSNPLD were injected into rabbits. Purification of the
antibody was also carried out by Eurogentec.
2.2.10. Antibodies used for Western blotting
Table 2.4.: List of antibodies for Western blotting
Primary Antibody Species Concentration Source
Baz pS151 Rabbit 1/500 A. Wodarz
Baz pS980 Rabbit 1/500 D. St Johnston
Baz pS1085 Rabbit 1/500 A. Wodarz
FLAG (M2) Mouse 1/5000 Sigma Aldrich
GFP (3E1) Mouse 1/1000 Cancer Research UK
HA (3F10) Rat 1/2000 Roche
Myc (sc-40) Mouse 1/5000 Santa Cruz
RASSF8 Rabbit 1/1000 N. Tapon/Eurogentec
RASSF8 pS209 Rabbit 1/1000 N. Tapon/Eurogentec
Myosin LC pS19 (#3671) Rabbit 1/1000 Cell Signaling
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List of antibodies for Western blotting (continued)
Tubulin (E7) Mouse 1/5000 DSHB
V5 (R960-25) Mouse 1/5000 Life Technologies
Wts Guniea Pig 1/1000 N. Tapon/Eurogentec
Yki pS168 Rabbit 1/5000 N. Tapon/Eurogentec
Yki (69) Rabbit 1/5000 N. Tapon/Eurogentec
Secondary Antibody Species Concentration Source
HRP anti-rabbit Donkey 1/5000 GE Healthcare
HRP anti-mouse Sheep 1/5000 GE Healthcare
HRP anti-rat Goat 1/5000 GE Healthcare
HRP anti-guinea pig Rabbit 1/5000 Sigma
2.2.11. Mobility shift assays
In order to achieve better separation for mobility shift assays, 8 % hand-cast gels
were used. The separation gel contained 8 % Acrylamide/Bis-acrylamide (Sigma-
Aldrich) in a 29:1 ratio, 390 mM Tris (pH 8.8), 0.1 % (w/v) SDS, 0.1 % (w/v)
ammonium persulfate and 0.04 % TEMED (v/v). The stacking gel contained 5 %
Acrylamide/Bis-acrylamide (Sigma-Aldrich) and 125 mM Tris (pH 6.8). Other in-
gredients were the same as in the separation gel. The gel was run for 100 minutes
at 190 V in a Mini-PROTEAN Tetra Cell with Tris-glycine electrophoresis buffer.
Blotting was performed as with pre-cast gels.
2.2.12. Phosphatase assay
Expression and purification of the phosphatase complex
ASPP and PP1α96A were expressed in S2 cells in one well of a 6-well plate, while
RASSF8 and Ccdc85 were expressed in a separate well. The cells were lysed with
HEPES lysis buffer supplemented with protease inhibitor cocktail (Roche). The
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cleared lysates were mixed and bound to 15 μL of GFP-Trap agarose (ChromoTek)
or ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich) for 1 h at 4 ◦C. Unbound proteins
were washed away for four times with PBST.
Expression and purification of the substrate
The substrate (FLAG-tagged Baz) was expressed in S2 cells in two wells of a 6-well
plate. Before lysis, 50 mM Calyculin A (Sigma-Aldrich) was added to the S2 cell
medium to block PP1 and PP2A family phosphatases for 25 minutes, which lead to
the hyperphosphorylation of Baz. Then, cells were lysed with RIPA lysis buffer sup-
plemented with Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich) and 20 mM
NaF. The cleared lysate was bound to 25 μL of ANTI-FLAG M2 Affinity Gel (Sigma-
Aldrich) for 1 h at 4 ◦C. Unbound proteins were washed away for four times with
PBST. After washing, FLAG-tagged Baz was eluted from the beads using 50 μL
Elution buffer for 20 minutes at 4 ◦C.
Dephosphorylation reaction
The eluted substrate was added to the ASPP/PP1 complex bound to GFP- or FLAG-
beads. The suspension was incubated for the indicated duration at 30 ◦C. The
reaction was stopped by adding Sample Loading buffer.
2.2.13. Buffers and Solutions
TAE
40 mM Tris
20 mM Acetic acid
1 mM EDTA
PBS
137 mM NaCl
2.7 mM KCl
10 mM Na2HPO4
1.8 mM KH2PO4
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PBST
PBS + 0.1 % (v/v) Tween 20
HEPES lysis buffer
150 mM NaCl
50 mM HEPES NaOH pH 7.5 NaCl
0.5 % (v/v) Triton X-100
RIPA buffer
10 mM Tris HCl pH 7.4
150 mM NaCl
1 % (v/v) Triton X-100
0.1 % (w/v) SDS
1 % (w/v) Sodium Deoxycholate
Elution buffer
50 mM Tris HCl pH 7.4
30 mM NaCl
150 ng/μL 5x FLAG-peptide
Sample Loading buffer
NuPAGE LDS Sample Buffer (Invitrogen)
NuPAGE Sample Reducing Agent (Invitrogen)
Tris-Glycine electrophoresis buffer
25 mM Tris
250 mM Glycine
0.1 % (w/v) SDS
Tris-Glycine blotting buffer
25 mM Tris
192 mM Glycine
20 % (v/v) Methanol
PBT
PBS + 0.1 % (v/v) Triton X-100
LB (1 L)
10 g Tryptone
5 g Yeast extract
5 g NaCl
1 mM NaOH
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2.3. Fly genetics
2.3.1. Balancer and stock maintenance
Flies were kept at 25 ◦C. All mutant and transgenic stocks were kept with balancer
chromosomes. The balancer chromosomes that were used all contain multiple inver-
sions or translocations that minimise the frequency of crossing-over. The balancers
also carried recessive lethal mutations and visible markers. The recessive lethal mu-
tations allow mutants or transgenics to be kept stably together with the balancer
chromosome, as all surviving progeny will either have one balancer chromosome and
one chromosome carrying the mutation or transgene, or will be homozygous for the
mutation/transgene (if not recessive lethal).
The balancer chromosomes that were used are: FM7c for the X chromosome (car-
rying B1 as visible marker), CyO for the 2nd chromosome (carrying Cy1 as visible
marker), TM3 Sb for the 3rd chromosome (carrying Sb1 as visible marker), TM3 Ser for
the 3rd chromosome (carrying Ser1 as visible marker) and TM6b Tb for the 3rd chro-
mosome (carrying Tb1 and AntpHu as visible marker).
2.3.2. Recombination of genomic loci
Mutations or transgenes that were located on the same chromosome were combined
using female meiotic recombination. Females carrying the two genetic loci of interest
were crossed to males with double balancer chromosomes. Single male progeny of this
cross were then genotyped (see 2.1.1), selected on G418 (Gibco) antibiotic containing
food, characterised by visible markers or by phenotype.
For recombining FRT chromosomes, single males were kept in vials with 300 μL of
25 μg/mL G418 (Gibco) aqueous solution added to the food one day before. As FRT
chromosomes that were used in this thesis contained a neomycin resistance gene, flies
could be selected based on their viability in vials with G418 containing food.
In the case of recombining UAS-transgenes with GAL4 drivers, male progeny could
be selected based on their visible phenotype. Similarly, ubi-transgenes that carried a
visible eye marker (w+) could be selected based on their eye colour.
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2.3.3. PhiC31 integrase-mediated generation of transgenic flies
To generate flies with targeted insertion of transgenes, the PhiC31 integrase system
was used. In contrast to random insertion, the targeted insertion of transgenes leads
to comparable expression levels, as the genomic context of two different insertions
is the same. When PhiC31 integrase is present, recombination between a plasmid
carrying the attB sequence and genomic DNA that harbours an attP sequence occur,
leading to the integration of the plasmid into the genome. Embryos of flies carrying
an attP site at a defined position within their genome were injected with a plasmid
carrying the transgene and the attB sequence as well as a plasmid coding for PhiC31
integrase (pKC40). The injections were done by the LRI Fly Facility and BestGene.
For this thesis, the following transgenic flies were generated:
Table 2.5.: List of transgenic flies
Plasmid Fly Line Bloomington ID Locus
Ubi-GFP-ASPP PBacy[+]-attP-9AVK00018 9736 2R (53B2)
Ubi-GFP-ASPP FA PBacy[+]-attP-9AVK00018 9736 2R (53B2)
Ubi-GFP-PP1α87B Vie217 N/A 3
Ubi-GFP-PP1α96A Vie217 N/A 3
Ubi-RASSF8-GFP Vie217 N/A 3
Ubi-RASSF8-SA-GFP Vie217 N/A 3
UAS-ASPP-FA-HA PBacy[+]-attP-9AVK00018 9736 2R (53B2)
UAS-ASPP-HA PBacy[+]-attP-9AVK00019 9736 2R (53B2)
UAS-Ccdc85 PBacy[+]-attP-3BVK00002 9723 2L (28E7)
2.3.4. P-element excision
To generate the ccdc85C1.1 mutant, a transposon or more specifically the
P{XP}d06579 P-element was imprecisely excised. This was done by crossing
P{XP}d06579 containing flies to flies expressing the transposase (Δ2-3) that mediates
the mobilisation of P-elements. The progeny of the first cross, where the P-element
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was mobilised, were then crossed to double balancer flies. This second generation of
flies contained male progeny that lost the visible eye colour marker of the P-element
(w+) indicating a successful mobilisation of the P-element. These selected flies were
then genotyped for deletions within the ccdc85 gene using PCR.
2.3.5. GAL4/UAS system
The GAL4/UAS system was used for tissue or pattern specific expression of trans-
genes. The transgenes were either protein coding or RNAi coding, allowing overex-
pression or silencing. The expression of the transgene was achieved by crossing flies
that express the GAL4 transcription factor under the control of tissue or pattern spe-
cific promoters to other flies that carry transgenes fused to UAS promoter regions.
In the progeny, GAL4 transcription factor bound to UAS promoter regions to drive
the expression of the transgene.
2.3.6. Flp/FRT system
The Flp/FRT system was used to generate mosaic mutant tissue. In a first step, flies
with a mutation in the gene of interest were recombined with an FRT site at the
base of the chromosome arm. These flies were then crossed with flies that expressed
flippase (Flp) and carried an FRT site at the base of the same chromosome arm
as the gene of interest additional to a ubiquitously expressed GFP transgene. In all
tissues of the progeny where Flp was expressed, the FRT sites could recombine during
mitosis.
As a result, a mosaic tissue was generated with different genotypes marked by
different intensities of GFP. GFP-negative tissue was homozygous mutant for the
gene of interest, weakly GFP-positive tissue was heterozygous mutant, and strongly
GFP-positive tissue was of wild type.
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2.3.7. MARCM system
The MARCM (Mosaic analysis with a repressible cell marker) system was used to
express a transgene in mutant tissue in a mosaic fashion. The MARCM system com-
bines the Flp/FRT system and the GAL4/UAS system and adds in GAL80, a GAL4
repressor. Instead of having the GFP expressing transgene on an FRT chromosome
as in the regular Flp/FRT system, it has a ubiquitously expressed GAL80 transgene.
In a first step flies that have a mutation in the gene of interest were recombined to an
FRT chromosome, together with a transgene fused to UAS promoter regions. Then,
these flies were crossed to flies that express Flp, carry the FRT GAL80 chromosome,
ubiquitously express GAL4 and have GFP fused to UAS promoter regions. In the
progeny of this cross, all tissue that did not express Flp was heterozygous for the
mutation and neither the transgene, nor GFP was expressed as GAL4 was repressed
by the ubiquitous expression of GAL80. In tissue with Flp expression, FRT sites
could recombine during mitosis, as with the Flp/FRT system.
As a result, a mosaic tissue was generated. GFP-positive tissue was lacking GAL80,
thus was homozygous for the mutation. All other GFP-negative tissue had either one
or two copies of GAL80. In contrast to Flp/FRT mosaics, heterozygous mutant tissue
could not be distinguished from wild type tissue, as both did not express GFP.
2.3.8. Modifier screen
For the modifier screen, genomic deficiency lines were selected that had defined ge-
nomic deletions and were as small as possible. ASPP RNAi was first recombined with
GMR-GAL4. Then, the resulting flies were crossed to the genomic deficiency lines
(see Appendix B) and kept at 29 ◦C. Adult progeny were screened for eye roughness.
2.3.9. Fly tissue preparation
Eye-antennal and wing imaginal disc
Crosses were set-up at 25 ◦C. For the generation of mosaic clones using the Flp/FRT
system, two different promoters for Flp were used. eyFlp expresses Flp only in the
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eye, while hsFlp is ubiquitously expressed under higher temperatures. When hsFlp
(Flp under the control of Hsp70 promoter) was used, larvae were shifted to 37 ◦C
for 1 h, 48 h after egg laying. For isolating eye-antennal and wing imaginal discs,
wandering third instar larvae were collected.
Pupal retina
For 26 h APF (after puparium formation) pupal retina preparations, white pre-pupae
were collected and kept at 25 ◦C for 26 h. For 40 h APF pupal retina preparations,
white pre-pupae were collected, and shifted to 18 ◦C for 16 h over night (which
corresponds to 8 h at 25 ◦C) and back to 25 ◦C until they have been at 25 ◦C for a
total of 32 h.
Adult wings
As animal density and quality of food can influence animal size and weight, all
wing size quantification experiments were done under density-controlled conditions
at 25 ◦C. Crosses with the same number of flies for different genotypes were kept on
apple juice plates with yeast paste for 12 h. The plates were incubated for another
12 h. First instar larvae were collected individually and 50 larvae were placed into
one vial. Adult flies were put into ethanol before imaging.
2.4. Immunohistochemistry
2.4.1. Preparation of fly tissues
Larval imaginal discs and pupal retinas were dissected in PBS. The tissue was fixed
with 4 % formaldehyde in PBS at room temperature for 20 minutes, protected from
light. After fixation, the tissue was washed twice with PBT and then permeabilised
with PBS containing 0.3 % (v/v) Triton X-100 for 30 minutes at room temperature.
After permeabilisation, tissues were blocked with PBT containing 10 % Normal Goat
Serum (NGS) for 30 minutes at room temperature. Primary antibody diluted ap-
93
Chapter 2. Materials and Methods
propriately (see 2.4.3) was added and the tissue was incubated at 4 ◦C over night.
Unbound primary antibody was washed away using PBT for four times before sec-
ondary antibody (see 2.4.3) diluted in PBT with 10 % NGS was added for 1 h at
room temperature, protected from light. Unbound secondary antibody was washed
away with PBT for four times and lastly, the tissue was mounted in Vectashied with
DAPI (Vector) on glass microscopy slides.
2.4.2. Preparation of S2 cells
S2 cells were transfected as normal in one well of a 6-well plate. Two days post trans-
fection, cells were seeded 1:3 (70 μL cell suspension + 130 μL fresh S2 cell medium) on
4-well CultureSlides (BD Falcon). The cells were kept for 1 h at room temperature to
allow for adherence to the slides. Cells were washed once with PBS before they were
fixed with 4 % formaldehyde in PBS for 10 minutes at room temperature, protected
from light. After fixation, cells were washed three times with PBT and blocked with
10 % NGS containing PBT for 15 minutes. Primary antibody was added for 1 h at
room temperature, before unbound antibodies were washed away for three times with
PBT. Secondary antibody in 10 % NGS containing PBT was added for 30 minutes
before unbound antibodies were washed away for four times with PBT. Vectashied
with DAPI (Vector) was added for mounting.
2.4.3. List of antibodies used
Table 2.6.: List of antibodies for IHC
Primary Antibody Species Concentration Source
Arm (N2 7A1) Mouse 1/10 DSHB
ASPP Rat 1/500 N. Tapon/Eurogentec
Baz Rabbit 1/500 F. Pichaud
Beta-gal Mouse 1/500 Promega
Ecad (DCAD2) Rat 1/100 DSHB
Ex Rabbit 1/500 A. Laughon
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List of antibodies for IHC (continued)
RASSF8 (08) Rabbit 1/500 N. Tapon/Eurogentec
Secondary Antibody Species Concentration Source
Rhodamine Red X anti-rabbit Donkey 1/500 Jackson ImmunoResearch
Rhodamine Red X anti-rat Donkey 1/500 Jackson ImmunoResearch
AlexaFluor 647 anti-mouse Goat 1/500 Life Technologies
AlexaFluor 488 anti-rabbit Goat 1/500 Life Technologies
2.4.4. Microscopy techniques and settings
Fluorescence images were acquired on a Zeiss LSM 710 confocal laser-scanning mi-
croscope. For whole eye-antennal and wing imaginal disc images a 20x dry lens was
used. All other images were acquired using a 63x water immersion lens with water
as immersion fluid. The pinhole was set at 1.1 μm for the 63x lens and at 2.0 μm for
the 20x lens.
2.5. Mass spectrometry
2.5.1. Sample preparation
Samples were loaded as for Western blotting in NuPAGE Novex 4-12 % Bis-Tris
Mini gels (Invitrogen). Samples from phosphatase assays were run for 1 h at 195 V,
while samples for proteins identification were only run for 2 cm. The gels were
stained with SimplyBlue SafeStain (Invitrogen). For phosphatase assays the whole
gel was send to the LRI Protein Analysis and Proteomics facility for trypsinisation
and further downstream processing. For protein identification, each lane was cut into
eight horizontal slices with a scalpel. The slices were further cut into small pieces and
stored in one well of a 96-well plate with 100 μL water per slice. The 96-well plate
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was send to the LRI Protein Analysis and Proteomics facility for trypsinisation and
further downstream processing.
2.5.2. Quantification and identification of changes in
phosphorylation (IP: ASPP)
This part of the method refers to 4.2.4. Three dephosphorylation reactions were
carried out for FLAG-Baz: (1) with GFP alone, (2) with ASPP and PP1 and (3)
with ASPP, PP1 and RASSF8. For each reaction, one sample at 15 minutes and one
sample at 30 minutes reaction time were taken. The six samples were injected three
times each (technical replicates) by the LRI Protein Analysis and Proteomics facility.
MaxQuant software was used for label-free quantitation.
Changes in the amount of detected phospho-peptides were analysed in Perseus. Six
pairwise comparisons were carried out for each of the six samples. For each time point
(15 and 30 minutes) comparisons between the control (GFP only) and the two con-
ditions (PP1+ASPP and PP1+ASPP+RASSF8) were carried out. Additionally, the
conditions with and without RASSF8 were compared to each other. All Baz phospo-
peptides with statistically significant reduced intensities in the conditions where PP1
was present were selected. Phospho-peptides with a posterior error probability (PEP)
of larger than 1x10-5 were filtered out. The PEP indicates how likely it is that the
peptide is wrongly identified as being present in the experiment.
To calculate the fold change of peptide intensities, raw intensities were first nor-
malised for each technical replicate to the average of all peptide intensities. The fold
change was defined as the ratio between two average normalised intensities. Lastly,
the average of all fold change values of significant comparisons was reported.
2.5.3. Quantification and identification of changes in
phosphorylation (IP: PP1)
This part of the method refers to 4.2.6. Similar to the experiment described above,
three dephosphorylation reactions were carried out for FLAG-Baz: (1) with GFP
alone, (2) with PP1 alone or (3) with PP1, ASPP, RASSF8 and Ccdc85. Only one
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sample for each condition after 10 minutes of dephosphorylation was taken. The three
samples were each split into two aliquots. One half was used for label free quantitation
(LFQ) as before (three technical replicates for each sample). The second half was
dimethyl-labelled on primary amines using formaldehyde. The GFP treated sample
was labelled with deuterated formaldehyde, while the PP1 only and PP1, ASPP,
RASSF8 and Ccdc85 treated samples were labelled with normal formaldehyde. Two
mixtures were created from the labelled samples: (1) heavy labelled GFP treated
sample with PP1 only treated regular labelled sample and (2) heavy labelled GFP
treated sample with the PP1, ASPP, RASSF8 and Ccdc85 treated regular labelled
sample. Each mixture was injected three times (technical replicates). MaxQuant and
Mascot software were used for quantitation.
Changes in the amount of detected phospho-peptides were analysed in Skyline.
For label free quantitation (LFQ) two comparisons were made: (1) between GFP
treated and PP1 only treated and (2) between PP1 only treated and PP1, ASPP,
RASSF8 and Ccdc85 treated. The fold-change was calculated as a ratio of average
intensities. The localisation of the phosphorylation was determined using MaxQuant.
For each dimethyl-labelled mixture, a direct comparison for each identified peptide
could be made between the two different treatments, as they were labelled with either
deuterated or normal formaldehyde. Thus, similar to the LFQ, two comparisons could
be made. The fold-change was calculated analogously.
2.6. SEM
Adult male flies were collected and transferred to fresh vials for one day allowing the
flies to clean themselves. Samples were pre-dried with subsequent washes in 25 %,
50 %, 75 % and twice in 100 % ethanol for 30 minutes each. The last drying step
was carried out over night. After pre-drying, samples were fixed, dried using critical
point drying and coated with platinum by Nic Tapon. Images were recorded on a
Jeol JSM 7700F scanning electron microscope.
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2.7. Quantification
2.7.1. Wing size and roundness measurements
Adults fly wings were imaged with a LeicaDFC420C camera mounted on a Zeiss
Axioplan2 microscope. ImageJ was used to trace the outline of wing blades. The
wing roundness was defined as the ratio of the length divided by the width of the
wing blade. The length was measured as a straight line along the whole length of the
L4 vein. The width was measured as a straight line across the cross-vein from the
anterior to the posterior margin of the wing.
2.7.2. Interommatidial cell counting
The cell outlines of 40 h APF retinas were visualised using anti-E-cadherin antibodies
and imaged. Interommatidial cells (IOCs) were counted within a hexagonal region
of interest using ImageJ. Each vertex of the hexagon was placed in the centre of the
six ommatidia surrounding one central ommatidium. Cells that were bisected by the
lines of the hexagon were only counted as half a cell.
Bristle clusters were not counted as IOCs. Bristle misplacement was defined as any
hexagon containing either two bristle clusters directly next to each other or when two
bristle clusters were not separated by tertiary pigment cells. Missing bristle clusters
were not counted as bristle misplacement.
2.7.3. Cell-cell junction signal intensity (Baz)
A single confocal plane was imaged. ImageJ was used to draw a line along the cell-
cell contacts of two neighbouring primary pigment cells with their surrounding IOCs.
The average signal intensity of five such lines was measured for ASPP mutant tissue
and wild type tissue.
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The PP1/ASPP complex
The Affinity Purification and Mass-Spectrometry (AP-MS) results from Matthias
Gstaiger’s lab (Hauri et al. 2013) suggested that ASPP and N-terminal RASSF family
proteins were associated to PP1s. Before I started investigating Drosophila ASPP and
PP1, only one publication described the association of a fragment of human ASPP2
(called p53BP2) with PP1 (Helps et al. 1995). ASPP family proteins were primarily
known for their regulation of p53-mediated transcription (Trigiante and Lu 2006).
The link between ASPP family proteins and PP1 was revisited more recently (Liu
et al. 2011, Llanos et al. 2011, Skene-Arnold et al. 2013).
In this chapter I show that Drosophila ASPP also can also bind to PP1. Further-
more, I provide in vivo evidence for the functional importance of the ASPP/PP1
complex. Lastly, I describe two additional subunits (RASSF8 and Ccdc85) that can
associate with the core ASPP/PP1 complex.
3.1. The core ASPP/PP1 complex
3.1.1. ASPP interacts with PP1 via its RVXF motif
In Drosophila ASPP, the RVXF motif that precedes four ankyrin repeats and an SH3
domain is conserved (Fig. 3.1A, and see 1.3.1). Furthermore, the characteristic basic
and acidic residues that flank both sides of the RVXF motif (Hendrickx et al. 2009)
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Figure 3.1.: ASPP binds to PP1α96A and PP1β9C via its RVXF motif
(A) Domain structure of ASPP. ASPP is conserved at the both termini, where all
identifiable domains are located. Coiled coil region was predicted by jpred3 (Cole
et al. 2008). Four ankyrin repeats and SH3 domain annotation based on ASPP2 struc-
ture (Gorina and Pavletich 1996). Conserved regions between Drosophila ASPP, and
human ASPP1/2 are indicated by red dashed lines.
(B, C) Western blots of co-IP experiments using anti-FLAG antibody coupled beads
with S2 cell lysates. Cells were transfected with the indicated constructs. Western blots
were probed with indicated antibodies. (B) ASPP preferentially binds to PP1α96A and
PP1β9C. (C) Mutation of V812 and F814 to alanine within the RVXF motif of ASPP
(ASPP-FA) decreases the binding between PP1s and ASPP. A weak binding of ASPP
to PP1α87B is visible in this condition in contrast to (B).
100
Chapter 3. The PP1/ASPP complex
are present in Drosophila ASPP as well (Fig. 3.1A). The conservation suggests that
Drosophila ASPP, similar to human ASPP1 and ASPP2, might bind to PP1
Initially, I tested if Drosophila ASPP can bind to PP1 in co-immunoprecipitation
(co-IP) experiments. The four PP1 catalytic subunits bound to ASPP to different
degrees (Fig. 3.1B). ASPP bound to PP1α96A most strongly, followed by PP1β9C.
PP1α87B and PP1α13C could bind to ASPP only weakly (Fig. 3.1C, 3.2C). The
RVXF motif is required for binding, since mutating V812 and F814 of the motif
(ASPP-FA) reduced the binding between ASPP and the PP1 catalytic subunits
(Fig. 3.1C). Residual binding remains between ASPP-FA and PP1 under the con-
ditions of the co-IP experiment (Fig. 3.1C). This suggests that residues other than
the RVXF motif might participate in the ASPP/PP1 interaction.
3.1.2. The SH3 domain of ASPP contributes to PP1 binding
The strong preference of Drosophila ASPP for a subset of PP1 isoforms is not reflected
in human ASPP1 or ASPP2 (Skene-Arnold et al. 2013). Human ASPPs bind to all
three human PP1 isoforms. Only one of the isoforms, PP1α, shows a slightly stronger
binding of ASPP1/2 and iASPP (Skene-Arnold et al. 2013).
To understand what residues in PP1α96A and PP1β9C might be responsible for the
stronger binding of ASPP, I aligned the sequences of Drosophila and human PP1s.
From this alignment, it was evident that the two PP1s that bind to ASPP more weakly
lack a short C-terminal stretch, which is shared among all other PP1s, including the
three human isoforms (Fig. 3.2A). To show that this C-terminal stretch is essential
for ASPP binding, I generated C-terminally truncated PP1α96A (PP1α96A-ΔC) and
PP1β9C (PP1β9C-ΔC) that lack residues 304–327 and 304–330 respectively. The
truncated PP1s had C-terminal ends that resembled PP1α87B and PP1α13C. In co-IP
experiments, ASPP binding to the truncated PP1α96A and PP1β9C was reduced
compared to the full-length proteins (Fig. 3.2B). This suggests that the C-terminus
of PP1α96A and PP1β9C are important for ASPP binding.
Skene-Arnold et al. have pointed out that the C-terminus of human PP1s contain
a class II SH3 domain binding motif (Skene-Arnold et al. 2013). This motif is char-
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Figure 3.2.: ASPP binds to the C-terminus of PP1α96A and PP1β9C with its
SH3 domain
(A) Alignment of the C-terminus of Drosophila and human PP1s. PP1α13C and
PP1α87B have shorter C-termini that lack the class II SH3 domain binding motif.
All human PP1 isoforms possess the binding motif. PxxPxR motif highlighted in red.
(B-D) Western blots of co-IP experiments using anti-FLAG antibody coupled beads
with S2 cell lysates. Cells were transfected with the indicated constructs. Western
blots were probed with indicated antibodies.
(Continues on following page)
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acterized by a proline-rich stretch with the consensus sequence of PxxPxR. Human
ASPPs can bind to this motif via its SH3 domains (Skene-Arnold et al. 2013). The
class II SH3 domain binding motif that is present in all human PP1s is only found in
PP1α96A and PP1β9C (Fig. 3.2A), the PP1s that bind to ASPP more strongly.
To test if Drosophila ASPP binds to PP1α96A and PP1β9C via its SH3 domain,
I generated an ASPP mutant with an SH3 domain that is deficient in binding to
PxxPxR motifs (ASPP-WK). The tryptophan to lysine mutation in SH3 domains
has been used as binding mutant in unbiased pull-down assays (Bisson et al. 2011)
and is thought to maintain the overall structure of the domain (Yang et al. 1995).
As predicted, the WK-mutation reduced binding to PP1α96A and PP1β9C in co-IP
experiments (Fig. 3.2C). Also as expected, ASPP-WK did not show a decreased
binding to PP1α87B and PP1α13C, compared to wild type ASPP (Fig. 3.2C), since
these lack the SH3 domain binding motif. These results demonstrate that SH3 domain
engagement is important for PP1 binding.
In all above co-IP experiments, ASPP-WK still retained residual PP1 binding.
Neither mutating the RVXF motif alone (Fig. 3.1C), nor the SH3 domain alone
(Fig. 3.2C) was sufficient to abrogate ASPP/PP1 binding completely. Thus, I gen-
erated an RVXF, SH3 double mutant ASPP (ASPP-FA/WK) to test if combining
them would further reduce the binding strength to PP1. In co-IP experiments, ASPP-
FA/WK did not show further decrease of the binding between ASPP and PP1α96A,
or PP1β9C (Fig 3.2D). Together with the observation that PP1α87B was binding to
Fig. 3.2: (Continued from previous page)
(B) PP1α96A and PP1β9C need their C-terminus for efficient binding to ASPP.
PP1α96A-ΔC lacks residues 304–327 and PP1β9C-ΔC lacks residues 304–330. (C)
The SH3 domain of ASPP is required for binding to PP1α96A and PP1β9C. When
a key residue of the SH3 domain (W987) is mutated to lysine (ASPP-WK), binding
to PP1α96A and PP1β9C is reduced. PP1α13C and PP1α87B, which do not have the
class II SH3 domain binding motif, bind to ASPP and ASPP-WK with similar affini-
ties. (D) Mutation of the SH3 domain in addition to the RVXF motif (ASPP-FA/WK)
does not further decrease binding to PP1α87B, PP1α96A or PP1β9C, when compared
to ASPP-FA. Residual binding between PP1s and ASPP-FA/WK remains.
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ASPP-FA, this suggests that other binding surfaces between ASPP and PP1 might
exist, or the residual binding correspond to non-specific interaction between overex-
pressed proteins.
3.1.3. The PxxPxR motif of PP1 and the SH3 domain of ASPP
positioned favourably for binding to each other
The proposed binding between the PxxPxR motif of PP1 and the SH3 domain of
ASPP involves the C-terminal part of PP1. Despite being present in many of the
PP1s used for crystallization, the C-terminus (last 30 residues) is almost always
missing in the final structures (e.g., Egloff 1997, Goldberg et al. 1995, Hurley et al.
2007, Ragusa et al. 2010). This suggests that it is flexible in those complexes (Terrak
et al. 2004). In contrast, in an ASPP/PP1 complex, the C-terminus of PP1 is likely
to be stabilised by binding to the SH3 domain of ASPP. I wished to use an in silico
modelling approach to test if the proposed SH3/PxxPxR-interaction is topologically
possible.
To date, the only protein structure that resolves a part of the C-terminus of PP1
is a human MYPT1/PP1β complex structure (Terrak et al. 2004). In this structure,
residues 299–308 of PP1β associate with the ankyrin repeats that follow the RVXF
motif of MYPT1. However, the last residues of PP1β (309–327) that contain the
PxxPxR motif are also unresolved in this structure. Intriguingly, MYPT1 and ASPP
are very similar. The sequences of the RVXF motif and the following four ankyrin
repeats on these proteins perfectly align with each other. Thus, it would be feasible
to use the MYPT1/PP1β complex structure to construct a model for an ASPP/PP1
complex.
Skerne-Arnold et al. reasoned similarly and proposed a structural model for
ASPP2/PP1β using the MYPT1/PP1β complex structure (Skene-Arnold et al. 2013).
Their analysis did not include the SH3 domain of ASPP2. I wanted to go one step
further and include the SH3 domain of ASPP2 in order to model the SH3/PxxPxR-
interaction. This was achieved by including the structure of an SH3 domain contain-
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Figure 3.3.: The PxxPxR motif of PP1 could bind to the SH3 domain of ASPP,
based on in silico modeling
(A) Model of ASPP2/PP1β complex based on MYPT1/PP1β (PDB: 1S70),
ASPP2/p73 (PDB: 4A63) and Ponsin/Paxilin (PDB: 2O9V). ASPP2 was aligned to
MYPT1 using their ankyrin repeats and Ponsin was subsequently aligned to ASPP2
using their SH3 domains. ASPP2 is depicted in red (RVXF motif), purple (ankyrin
repeats) and pink (SH3 domain). PP1β is shown in orange, while the Paxilin peptide
that is analogous to the PP1β C-terminus is shown in light orange.
(B) Detailed view of the PxxPxR motif-containing peptide. The two prolines that char-
acterize the PxxPxR motif are shown in red. W1097 of ASPP2 that corresponds to
W987 in Drosophila ASPP (mutated in ASPP-WK) is depicted in light blue.
(C) Sequence of C-terminus of PP1β. The two glycines that are visible in the model
are highlighted in orange. The two prolines that characterize the PxxPxR motif are
highlighted in red. The distance that had to be bridged between G308 and P314 is
indicated in green.
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ing protein bound to a class II SH3 doman binding peptide. The modeling was done
in collaboration with Dr Stephane Mouilleron (LRI Protein Structure core facility).
Our model of ASPP2/PP1β (Fig. 3.3A) used the structure of MYPT1/PP1β
(1S70, Terrak et al. 2004), ASPP2/p73 (4A63, Canning et al. 2012) and Pon-
sin/paxilin (2O9V, Gehmlich et al. 2007). Based on the model, it is reasonable
to assume that the PxxPxR motif of PP1β can bind to the SH3 domain of ASPP2 in
the typical orientation of class II binding motifs. The distance between the carbon
atom of the carboxyl-group of G308 of PP1β and the nitrogen atom of the amino-
group of the first proline that is essential within the PxxPxR motif is only 6.8 Å
(Fig. 3.3B). This distance could easily be bridged by the five residues that separate
G308 from P314 of PP1β (Fig. 3.3C). Thus, this model supports the hypothesis that
in an ASPP/PP1 complex, the SH3 domain could bind to the PxxPxR motif of PP1.
3.2. The ASPP/PP1 complex in vivo
3.2.1. GFP-tagged ASPP localises to cell-cell junctions
In vitro, and in cell culture it has been shown that ASPP family proteins can bind
to PP1 (Llanos et al. 2011, Skene-Arnold et al. 2013) and at least ASPP2/PP1 can
dephosphorylate the transcriptional co-activator and YAP paralogue TAZ (Liu et al.
2011). In the previous subchapter, I have shown that Drosophila ASPP and PP1
can also bind to each other. In this subchapter I will explore the in vivo function of
the ASPP/PP1 complex at an organismal level and investigate which of the known
ASPP null mutant phenotypes (Langton et al. 2009) are PP1-dependent.
To test if the binding between ASPP and PP1 is required in vivo, I generated
N-terminally GFP-tagged wild type ASPP and ASPP-FA plasmids for constitutive
expression in Drosophila. The RVXF mutant instead of the RVXF, SH3 double
mutant was chosen, since additional mutation of the SH3 domain did not further
decrease PP1 binding (Fig 3.2C). Furthermore, an additional mutation could affect
ASPP binding to proteins other than PP1 that relied on the SH3 domain. Using
the PhiC31 integrase system, the DNA constructs were inserted into the genome on
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Figure 3.4.: GFP-tagged ASPP and ASPP-FA localise to cell-cell junctions
Confocal X-Y sections of pupal retinas at 26 h APF (A, A’) or third instar larval wing
discs (B–C”) stained with the indicated antibodies. Flp/FRT clones were generated
with eyFlp (A, A’) or hsFlp (B–C”).
(A), (A’) GFP-tagged ASPP and ASPP-FA behaves like endogenous ASPP in the
retina. In Flp/FRT clones that express ASPP (A) or ASPP-FA (A’) under the ubiquitin
promoter, ASPP localises to cell-cell junctions. The levels of exogenous protein in the
clones (left) are slightly higher than in wild type tissue (right). Clone boundaries are
marked with dashed yellow line. (B–C”) GFP-tagged ASPP and ASPP-FA behaves like
endogenous ASPP in larval wing imaginal discs. In Flp/FRT clones that express ASPP
(B–B”) or ASPP-FA (C–C”) under the ubiquitin promoter, ASPP localises to cell-cell
junctions. As in the retina, levels of endogenous ASPP are slightly lower (B’, C’).
Clone boundaries are marked with dashed yellow lines. Using β-galactosidase staining
intensity, tissues that only express endogenous ASPP (endo), a mixture (het) or only
exogenous, GFP-tagged ASPP (GFP) can be distinguished.
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chromosome 2R at 53B2 (ubi-ASPP and ubi-ASPP-FA). The two insertions were
recombined with the ASPPd null-allele.
Initially, I wanted to verify that the transgenes were expressing at close to en-
dogenous levels and that the GFP tag did not interfere with ASPP localisation. To
directly compare exogenous with endogenous ASPP, I generated mitotic clones with
the Flp/FRT system. Mitotic clones in pupal retinas (Fig. 3.4A, A’) and larval
wing imaginal discs (Fig. 3.4B’, C’) that only expressed exogenous ASPP showed
that ASPP-GFP localised to cell-cell junctions similarly to endogenous ASPP. In ad-
dition, the levels of exogenous ASPP were comparable to, only slightly higher than
endogenous ASPP. There was no discernible difference regarding localization and lev-
els between expression of ASPP compared to ASPP-FA. These results suggest that
ubi-ASPP should be able to rescue loss of endogenous ASPP. Also any difference
between ubi-ASPP and ubi-ASPP-FA should be due to PP1 binding, rather than to
differences in localization or expression level.
3.2.2. Eye patterning and wing size determination are dependent
on the ASPP/PP1 interaction
ASPP null mutant flies have four described phenotypes: (i) rough eyes and bristle
misplacements, (ii) increased wing size, (iii) wing notching when combined with het-
erozygous Csk loss-of-function (Langton et al. 2007) and (iv) anterior scutellar bristle
duplication (Langton 2008). In this section, as well the following two sections, I used
ASPPd/ASPP8 trans-heterozygous flies when I refer to ASPP null mutant flies in the
text. This was done to minimize the risk of artifacts due to the genetic background
in homozygous flies.
First, I investigated the eye development (see 1.1.2 for details on eye development).
In a perfectly patterned eye, 12 secondary and tertiary pigment cells that are also
referred to as interommatidial cells (IOCs) surround one ommatidium (see Materials
and methods for details on quantification). ASPP null mutant flies have an increased
number of IOCs (15.3±1.6, Fig. 3.5B, E). This is rescued by the expression of ASPP
(12.2±0.5, Fig. 3.5C, E), but not ASPP-FA (13.8±1.1, Fig. 3.5D, E). Additionally,
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Figure 3.5.: The ASPP-FA mutant fails to rescue eye mispatterning
(A–D) Confocal X-Y sections of pupal retinas at 40 h APF stained with anti-E-cadherin
antibody to mark cell outlines. The regular pattern of developing eyes (A) is disrupted
in ASPP null mutant flies (B). The pattern is restored when exogenous ASPP is ex-
pressed (C), but not when ASPP-FA is expressed (D). Bristle misplacements can also
be observed (arrowheads in B, D).
(E) ASPP but not ASPP-FA expression restores the number of IOCs in ASPP mutants.
Error bars represent the standard deviation of the observed distributions. A one-way
ANOVA test indicated that the differences among means were significant (p<0.001).
Three pairwise comparisons were carried out (ASPP-/- vs. wt, wt vs. FA and control
vs. wt) and p-values were adjusted using Bonferroni’s correction. Significant differences
are indicated. *** represents p<0.001. IOCs in 50 hexagons from at least 6 retinas
were counted per condition.
(F) ASPP but not ASPP-FA reduces the frequency of bristle misplacements in ASPP
mutants. Bristle clustering or placement of a bristle in a neighbouring position that
should be occupied by a tertiary pigment cell was counted as misplacement. Bristle
misplacements were counted in 50 hexagons from at least 6 retinas.
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Figure 3.6.: The ASPP-FA mutant partially rescues wing size
(A–C) ASPP null mutant flies have enlarged wings (A). The increase in wing size is
rescued by the expression of ASPP (B), but not ASPP-FA (C). Wings from female flies
shown.
(D) Overlay for direct comparison of rescue with ASPP and ASPP-FA.
(E) Quantification of wing sizes normalised to control wing size. The whiskers of the
box-plot indicate minimum and maximum values. A one-way ANOVA test indicated
that the differences among means were significant (p<0.001). Two pairwise compar-
isons were carried out (ASPP-/- vs. ubi-ASPP and ubi-ASPP vs. ubi-ASPP-FA) and
p-values were adjusted using Bonferroni’s correction. Significant differences are indi-
cated. *** represents p<0.001. At least 20 wings were counted per genotype.
(F–H) Expressing HA-tagged ASPP in the wing of male flies leads to small but signifi-
cant undergrowth. Compared to expressing ASPP-FA with the MS1096-GAL4 driver
(G), ASPP expressing wings (F) are smaller. Control wings without a UAS-transgene
(H) are of similar size to ASPP-FA wings.
(I) Overlay for direct comparison of expression of ASPP and ASPP-FA.
(J) Quantification of wing sizes normalised to control wing size. The whiskers of the
box-plot indicate minimum and maximum values. An unpaired t-test showed that
mean wing size in MS1096>ASPP and MS1096>ASPP-FA differ significantly from
each other. *** indicates p<0.001. At least 20 wings were counted per genotype.
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Figure 3.7.: The ASPP-FA mutant partially rescues wing notching
(A) Losing one copy of Csk in an ASPP null background leads to wing notching.
(B) Expressing exogenous ASPP-FA does not fully rescue the notching phenotype.
Notches are smaller than with ASPP null.
(C) Quantification of wing notching phenotype. Only the genotypes shown in (A) and
(B) showed any notching. 100 wings were analyzed per genotype and sex.
bristle clustering that is prevalent in ASPP null mutant flies (Fig. 3.5B) can be
rescued with exogenous ASPP, but not ASPP-FA (Fig. 3.5F). These results show
that ASPP/PP1 binding is required for eye patterning.
Next, I examined wing sizes. As described previously (Langton et al. 2007), ASPP
null mutant wings were about 10 % larger than wild type wings (Fig. 3.6A, E).
Expression of ASPP in the ASPP null background rescued the increase in wing size
(Fig. 3.6B, E). However, expression of ASPP-FA only partially rescued the increase
in wing size (Fig. 3.6C, E). When directly comparing the rescue with ASPP and
ASPP-FA, the median wing size of ASPP-FA-expressing flies was about 6 % larger
(Fig. 3.6D, E). Furthermore, expression of UAS-ASPP with theMS1096-GAL4 driver
in the wing of male flies leads to slight undergrowth that is not observed with UAS-
ASPP-FA (Fig 3.6F-J). In female flies, there was no significant difference (data not
shown), possible because the MS1096-GAL4 driver is on the X chromosome and
therefore more highly expressed in males due to dosage compensation. Together,
the loss-of-function and overexpression results show that ASPP/PP1 binding is also
required for wing size determination.
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Figure 3.8.: The ASPP-FA mutant does not rescue anterior scutellar bristle
duplication
(A) Anterior scutellar bristle duplication in ASPP null mutant female on the right side
(arrowhead).
(B) ASPP expression in ASPP null mutant flies partially rescues the bristle duplication
phenotype. ASPP-FA expression does not alter the ASPP null phenotype. 150 flies
per genotype and sex were analyzed. Anterior scutellar bristle duplication either on
the left side, right side or both sides was counted as duplication event.
3.2.3. Activation of Csk partially depends on the ASPP/PP1
interaction
ASPP positively regulates the Src-family kinase inhibitor Csk (Langton et al. 2007).
Strikingly, wings become notched when one copy of the hypomorphic allele Csk1jd8
was introduced in an ASPP null mutant background (Fig. 3.7A and Langton et al.
2007). The wing notching could be fully rescued when exogenous ASPP was expressed
in this background (Fig. 3.7C). With exogenous ASPP-FA, most wings were rescued
(Fig. 3.7C). In the small percentage of flies that had notches, the notches were not as
prominent as in the ASPP null mutant flies (Fig. 3.7B). Thus, although PP1 binding
seems to contribute to the regulation of Csk by ASPP, other ASPP functions are
likely to be required for Csk regulation.
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3.2.4. Specifying anterior scutellar sensory organs depends on the
ASPP/PP1 interaction
Another phenotype observed in ASPP null mutant flies is the duplication of anterior
scutellar bristles (aSCs, Langton 2008). Whole sensory organs, rather than just the
bristles, were duplicated in these instances (Fig. 3.8A). Two bristles emerged from
two separate sockets. The duplication occurred on both sides and no bias towards
any side was observed. The duplication events (either on the left, right, or on both
sides) were more common in females in ASPP null mutants (66 %), than in males
(30 %). The bristle duplication could be partially rescued by exogenous ASPP but not
by ASPP-FA (Fig. 3.8B). The partial rescue of exogenous wild type ASPP suggests
that either the slightly higher expression levels (see section 3.2.1) or the GFP tag
might interfere with endogenous function. However, PP1 binding to ASPP is clearly
required for correct aSC specification.
Taken together, these results demonstrate that the RVXF motif of ASPP is required
in vivo for its function. The degree to which a PP1-binding deficient ASPP is able
to rescue differs for the different phenotypes. While for eye patterning, wing size
determination and aSC specification PP1 binding is strictly required, activation of
Csk seems to be at least partially PP1-independent.
3.2.5. PP1α96A and PP1β9C localise to cell-cell junctions in the
developing retina
The importance of the RVXF motif of ASPP in vivo implies that the phenotypes seen
in ubi-ASPP-FA rescue flies are due to reduced PP1 function. If the binding between
ASPP and PP1 is essential, PP1 mutants should recapitulate some phenotypes of
ubi-ASPP-FA rescue flies. The focus of the following analyses was on PP1α87B,
PP1α96A and PP1β9C, since they bound to ASPP more strongly (see section 3.1.1)
and PP1α13C expression seems to be mostly restricted to testis (Celniker et al. 2009).
In order to be regulated by ASPP, PP1 would be expected to co-localise with
ASPP in vivo. To study the localization of PP1s, I generated two transgenic lines for
PP1α87B and PP1α96A (ubi-GFP-PP1α87B and ubi-GFP-PP1α96A) that expressed
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Figure 3.9.: PP1α96A and PP1β9C but not PP1α87B localise to cell-cell junc-
tions in the developing retina
Confocal X-Y sections of pupal retinas at 26 h APF stained with anti-E-cadherin anti-
body and GFP/YFP-fluorescence.
(A), (A’) GFP-PP1α87B localises to the cytoplasm of IOCs at 26 h APF.
(B), (B’) GFP-PP1α96A partially co-localises with E-cadherin at cell-cell junctions un-
der the same conditions as in (A).
(C), (C’) YFP-PP1β9C partially co-localises with ASPP at cell-cell junctions under the
same conditions as in (A).
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Figure 3.10.: PP1β9C;PP1α96A double mutants have an increased number of
IOCs in the ventral part of the developing eye
(A–D) Confocal X-Y sections of pupal retinas at 40 h APF stained with anti-E-cadherin
antibody to mark cell outlines. Losing PP1α96A does not influence eye development
(A), while PP1β9C hypomorphs (B) show occasional IOC and bristle mispatterning
(arrowheads). In PP1β9C1;;PP1α96A2 double mutants, the dorsal part of the eye de-
velops normally (C), while a small ventral patch shows severe mispatterning (D).
(E) Only the ventral part of the retina in PP1β9C1;;PP1α96A2 double mutants has a
significant increase in the number of IOCs. Error bars represent the standard deviation
of the observed distributions. A one-way ANOVA test indicated that the differences
among means were significant (p<0.001). Two pairwise comparisons were carried out
(PP1β9C1 vs. dorsal part of PP1β9C1;;PP1α96A2 and PP1β9C1 vs. ventral part of
PP1β9C1;;PP1α96A2) and P-values were adjusted using Bonferroni’s correction. Sig-
nificant and non-significant (n.s.) differences are indicated. *** represents P<0.001.
IOCs in 25 hexagons from at least 3 retinas were counted per condition. Dorsal and
ventral parts in PP1β9C1;;PP1α96A2 flies from the same retinas were analyzed.
(Continues on following page)
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N-terminally GFP-tagged proteins under the control of the ubiquitin promoter. The
constructs were injected into VIE217 flies and targeted to the landing site on 3L
using the PhiC31 integrase system. For PP1β9C, I used an existing YFP-trap line
(YFP-PP1β9C ) where a YFP reporter encoded by a P-element transposon vector is
spliced in between the first and second exon (Morin et al. 2001). While PP1α87B was
cytoplasmic in IOCs at 26 h APF (Fig. 3.9A, A’), a fraction of PP1α96A and PP1β9C
localised to cell-cell junctions with E-cadherin or ASPP (Fig. 3.9B-C’). These results
do not exclude the possibility that PP1α87B might form a complex with ASPP at
the junctions. However, overall, PP1α96A and PP1β9C seem to be better candidates
in vivo due to their more specific junctional localization.
3.2.6. Eye patterning is defective in PP1α96A;PP1β9C double
mutants
Next, I wanted to test if any PP1 mutants would phenocopy ASPP null mutants.
Out of all described PP1 mutants, only a viable PP1β9C hypomorph (PP1β9C2) was
annotated to have any phenotypes that resemble ASPP null mutants. PP1β9C2 flies
are described to have a roughened eye and missing aSCs (Deak 1977). Although
PP1β9C2 was not available, another hypomorphic PP1β9C allele, PP1β9C1, that
has a missense mutation (V284A) (Raghavan et al. 2000) showed a roughened eye
that is caused by bristle misplacements and IOC patterning defects (Fig. 3.10B, F).
Furthermore, this allele caused anterior scutellar bristle duplications (Fig. 3.12).
These two phenotypes of PP1β9C1 flies were reminiscent of ASPP null mutants,
albeit much weaker. Thus, I tested if the weaker phenotype was due to the fact that
PP1α96A could act redundantly with PP1β9C by generating a PP1β9C;;PP1α96A
double mutant. By itself, PP1α96A2 flies are viable null mutants that have no
Fig. 3.10: (Continued from previous page)
(F) PP1β9C1;;PP1α96A2 double mutants show bristle misplacements. Bristle clustering
or placement of a bristle in a neighbouring position that should be occupied by a tertiary
pigment cell was counted as misplacement. Bristle misplacements were counted in 25
hexagons from at least 3 retinas.
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Figure 3.11.: PP1β9C;PP1α96A double mutants have patterning defects in the
ventral part of eye
Scanning electron micrograph of adult fly eyes. The regular patterning in wild type
flies (A) is disrupted in PP1β9C;PP1α96A double mutant flies (B). The mispatterning
is increased on the ventral side of the eye, while the dorsal side is less severely affected.
The ventral side is at the top of the images, while the dorsal side is at the bottom.
Figure 3.12.: PP1β9C mutant flies have duplicated aSCs
While PP1β9C1 mutants have a bristle duplication phenotype, PP1α96A2 does not.
150 flies per genotype and sex were analyzed. PP1β9C1;;PP1α96A2 double mutants
showed fewer instances of duplicated bristles. aSC duplication either on the left side,
right side or both sides was counted as duplication event.
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discernible phenotype (Kirchner et al. 2007). In particular, the eye patterning of
PP1α96A null mutant flies had no visible defects (Fig. 3.10A).
Surprisingly, the eye defect of PP1β9C1;;PP1α96A2 flies was more pronounced in
the ventral part of the eye (Fig. 3.11B). This difference is reflected in the arrange-
ment of the IOCs and bristles (Fig. 3.10C, D). The number of IOCs in the ventral
part of the eye in PP1β9C1;;PP1α96A2 flies was significantly higher (16.1±2.1) than
in the dorsal part (13.0±1.1) or when compared with PP1β9C1 single mutant flies
(12.3±0.6). The reason for this difference between the dorsal and ventral part of
the eye in PP1β9C1;;PP1α96A2 flies is unclear. Nonetheless, the strong genetic in-
teraction between PP1α96A and PP1β9C but not PP1α87B suggests that they act
redundantly in eye patterning.
In contrast to eye patterning, removing PP1α96A did not enhance the scutellar bris-
tle phenotype of PP1β9C1 flies. On the contrary, PP1β9C1;;PP1α96A2 flies showed
fewer instances of aSC duplications (Fig. 3.12A). This suggests that PP1α96A does
not play a role in aSC specification. Taken together, the above results are consistent
with a model in which ASPP forms a complex with PP1α96A or PP1β9C to modulate
cell-cell rearrangements in the developing fly eye.
3.3. RASSF8 and Ccdc85—two additional subunits of
the ASPP/PP1 complex
3.3.1. Drosophila Ccdc85 binds to ASPP
In the previous subchapter, I have described that ASPP family proteins are at the
core of an ASPP/PP1 complex. They posses a conserved RVXF motif, directly bind
to PP1 and are found in PP1β pull-downs (Fig. 1.10 and Hauri et al. 2013). In the
network uncovered by the AP-MS experiments, two other proteins families seem to be
tightly connected to ASPP and PP1: Ccdc85 (coiled coil domain containing) family
proteins and N-terminal RASSF family proteins. In this subchapter, I will investigate
extensions to the core ASPP/PP1 complex by Drosophila RASSF8 and Ccdc85 and
characterize the ccdc85 gene.
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Figure 3.13.: Ccdc85 binds to ASPP and all four PP1 isoforms
(A) Domain structure of Ccdc85. The coiled coil region and the most C-terminal part
of Ccdc85 are conserved. Ccdc85 has a non-conserved GILK motif that could serve as
PP1 binding site. Coiled coil region predicted by jpred3 (Cole et al. 2008). Conserved
regions between Drosophila Ccdc85, and human CCDC85A/B/C indicated by dashed
red lines.
(B) Western blots of co-IP experiments using anti-FLAG antibody coupled beads with
S2 cell lysates. Cells were transfected with the indicated constructs. Western blots were
probed with indicated antibodies. Ccdc85 binds to ASPP and all four PP1 isoforms in
co-IP experiments.
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There are three Ccdc85 homologues in human (CCDC85A/B/C), while there is
only one Ccdc85 orthologue in Drosophila. Not much is known about this protein
family. For human CCDC85A, no information is available beyond annotation as a
protein. CCDC85B has been discovered as a nuclear hepatitis delta antigen inter-
acting protein (Brazas and Ganem 1996). More recently, several studies confirmed
that CCDC85B is nuclear and suggested that it can regulate transcription via tran-
scription factor TCF4 (Iwai et al. 2008), C/EBPβ (Bezy et al. 2005) or transcription
modulator MCRS1 (Du et al. 2006). Functionally, CCDC85C remains uncharacter-
ized, but it localises to tight junctions of radial glia (Mori et al. 2012). Additionally,
in AP-MS experiments, CCDC85C was found in pull-downs of YAP (Couzens et al.
2013, Wang et al. 2014).
Drosophila Ccdc85 consists of coiled coil regions but has no other detectable do-
mains or features. The coiled coil regions are conserved between Drosophila Ccdc85
and all human CCDC85s (Fig. 3.13A). Drosophila Ccdc85 is encoded by CG17265
and has not been studied previously. I will refer to CG17265 as ccdc85 hereafter,
following the mammalian nomenclature.
First, I wanted to confirm the AP-MS result for Drosophila Ccdc85 and test the
binding of Ccdc85 to PP1, ASPP and RASSF8. In co-IP experiments, Ccdc85 was as-
sociated to ASPP and all four PP1 isoforms (Fig. 3.13B). Neither Drosophila Ccdc85,
nor any of the human CCDC85s have an RVXF motif that could facilitate binding to
PP1s. However, Drosophila Ccdc85 could bind to PP1 via its SILK motif (Fig. 3.13A),
a motif of four amino acids that also contributes to PP1 binding (Hendrickx et al.
2009). These observations, together with the AP-MS data suggest that Ccdc85 could
be part of an ASPP/PP1 complex.
3.3.2. RASSF8/ASPP/PP1 and Ccdc85/ASPP/PP1 complexes
can form
If RASSF8 and Ccdc85 were additional subunits of an ASPP/PP1 complex, they
would have to be able to form trimeric RASSF8/ASPP/PP1 and Ccdc85/ASPP/PP1
complexes. In co-IP experiments performed by Jennifer Banerjee in our laboratory,
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Figure 3.14.: RASSF8 and Ccdc85 each form a trimeric complex with ASPP
and PP1
Western blots of co-IP experiments using anti-FLAG antibody coupled beads or GFP-
Trap beads with S2 cell lysates. Cells were transfected with the indicated constructs.
Western blots were probed with indicated antibodies.
(A) RASSF8 binds to PP1α96A only via ASPP. The experiment for this panel was
done by Jennifer Banerjee.
(B) Ccdc85 binds to PP1α96A more strongly when ASPP is present. In the FLAG-
Ccdc85 pulldown, PP1α96A can be detected. Levels of pulled-down PP1α96A increase
when ASPP is present. In the GFP-PP1α96A pulldowns, Ccdc85 can only be detected
when ASPP is present.
RASSF8 could form a trimeric complex with PP1α96A and ASPP (Fig. 3.14A).
Furthermore, the binding between RASSF8 and PP1α96A was only observed when
ASPP was present (Fig. 3.14A). This result suggests that in the trimeric complex of
RASSF8/ASPP/PP1, ASPP serves as the bridging component.
For Ccdc85, the situation is slightly more complex, since it could bind to all four
PP1 isoforms without co-expression of ASPP (Fig. 3.13B). Nonetheless, the bind-
ing between Ccdc85 and PP1α96A was strongly enhanced when ASPP was present
(Fig. 3.14B). This suggests that, analogous to the RASSF8/ASPP/PP1 complex,
ASPP can serve as a bridging component for Ccdc85 and PP1. However, additional
secondary interactions between Ccdc85 and PP1 might exist.
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3.3.3. RASSF8 and Ccdc85 bind to the coiled coil region of
ASPP and can form a trimeric complex
To better understand the topology of the trimeric complexes, I mapped the inter-
actions between RASSF8, Ccdc85 and ASPP. Firstly, I used three different ASPP
fragments to pull-down RASSF8 in co-IP experiments. The ASPP fragments were
covering the conserved N-terminal coiled coil region (1–234), the unconserved mid-
dle region (231–795) and the C-terminus containing the RVXF motif, the ankyrin
repeats and SH3 domain (796–1020). Consistent with Y2H-data generated in the lab
(Eunice Chan—unpublished observations), the coiled coil region of ASPP alone was
sufficient for binding to RASSF8 (Fig. 3.15A). Similar to RASSF8, Ccdc85 was able
to specifically bind to the coiled coil region of ASPP (Fig 3.15B). These results show
that RASSF8 and Ccdc85 bind to the same region of ASPP that is distinct from the
PP1 binding site.
To confirm that RASSF8 and Ccdc85 could bind to ASPP independently from PP1,
I tested the binding of both proteins to ASPP-FA. Neither RASSF8 binding to ASPP
(Fig. 3.15C), nor Ccdc85 binding to ASPP (Fig. 3.15D) was impaired by mutating
the RVXF motif. This also implies that the failure of ASPP-FA to rescue ASPP
null mutant defects (e.g., Fig. 3.5D–F) was not due to changed binding strength of
ASPP-FA to RASSF8 or Ccdc85.
As RASSF8 and Ccdc85 bind to the same region of ASPP, they could preclude
each other from binding simultaneously. To test this, I conducted co-IP experiments
between Ccdc85, RASSF8 and ASPP. Either pulling down RASSF8 or Ccdc85 could
only co-IP the other protein when ASPP was present (Fig. 3.16A). This demonstrates
that RASSF8, Ccdc85 and ASPP could form a trimeric complex and ASPP bridged
this interaction as well. This result also implies that a RASSF8/Ccdc85/ASPP/PP1
tetrameric complex could be possible (Fig. 3.16C). Although co-IP experiments from
cell lysates alone cannot conclusively demonstrate the formation of a tetrameric com-
plex, when all four proteins were co-expressed, they could be pulled-down by ASPP
(Fig. 3.16B).
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Figure 3.15.: RASSF8 and Ccdc85 bind to the coiled coil region of ASPP
Western blots of co-IP experiments using anti-FLAG antibody coupled beads with S2
cell lysates. Cells were transfected with the indicated constructs. Western blots were
probed with indicated antibodies.
(A) The N-terminus of ASPP that contains its coiled coil region is sufficient for RASSF8
binding. The conserved N-terminus (1–234), but neither the unconserved middle part
(231–795) nor the ankyrin repeat and SH3 domain containing region bind to RASSF8.
(B) The N-terminus of ASPP (1–234) that contains its coiled coil region is sufficient
for Ccdc85 binding. (C) RASSF8 binds to ASPP and ASPP-FA with equal strength.
RASSF, the classical RA-family protein, was used as negative control. (D) Ccdc85
binds to ASPP and ASPP-FA with equal strength.
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Figure 3.16.: RASSF8 and Ccdc85 form a trimeric complex with ASPP
Western blots of co-IP experiments using anti-FLAG antibody coupled beads or GFP-
trap beads with S2 cell lysates. Cells were transfected with the indicated constructs.
Western blots were probed with indicated antibodies.
(A) Ccdc85 binds to RASSF8 via ASPP. RASSF8 and Ccdc85 co-purify with each other
only when ASPP is present.
(B) PP1α96A, RASSF8 and Ccdc85 co-IP with GFP-ASPP. Note that ASPP levels in
the input were very low, but upon concentration by IP, ASPP could be detected.
(C) ASPP could act as a bridging subunit for the tetrameric complex. With its N-
terminal coiled coil region it can bind to RASSF8 and Ccdc85, while with its RVXF
motif and SH3 domain it can bind to PP1.
3.3.4. ccdc85 transposon insertions have a rough eye phenotype
The above in vitro co-IP experiments suggest that RASSF8 and Ccdc85 could be part
of an ASPP/PP1 complex. In vivo, RASSF8 shares common functionality (e.g., eye
patterning) and localization with ASPP (Langton et al. 2009). However, Ccdc85 has
not been studied at all in vivo.
For ccdc85 (Fig. 3.17A), a plethora of fly lines with transposon insertions are
available. Transposons will often disrupt the gene where it is inserted. I selected three
lines with transposon insertions for further investigation, hoping to obtain a line that
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Figure 3.17.: ccdc85 mutant deletes the 5’-UTR of the gene
(A) Gene structure of ccdc85. In the viable ccdc85C1.1 mutant, 2.4 kb are removed. The
deletion affects the 5’-UTR of ccdc85 and the 3’-UTR of CG3558. The two transposons
are inserted in or near the 5’UTR-region of ccdc85. Coding exons are marked in orange,
non-coding exons in grey.
(B) Agarose gel containing ethidium bromide to visualise the large deletion in ccdc85C1.1
mutant. A PCR across the 5’-UTR of ccdc85 in ccdc85C1.1/Df(2L)Exel7014 flies yields
a product that is 2.4 kb smaller than in wild type flies.
(C) Agarose gel containing ethidium bromide to visualise mRNA levels of
ccdc85, its neighbouring gene CG3558 and RpL32 as control. RT-PCR of
ccdc85C1.1/Df(2L)Exel7014 adult flies reveals that ccdc85 mRNA levels were unde-
tectable, while CG3558 levels were slightly affected.
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has a complete or partial loss-of-function of ccdc85. I decided to examine two lines
with P-elements within the first non-coding exon (P{GawB}NP4651, P{XP}d06579 )
and one containing a piggyBac transposon directly after the first non-coding exon
(PBac{RB}e02956 ). All three lines were homozygous viable. Two out of the three
lines, P{XP}d06579 and PBac{RB}e02956 (Fig. 3.17A), had rough eye phenotypes.
Furthermore, the eye phenotype was also observable when either of the two lines
were crossed to a ccdc85 deficiency line (Df(2L)Exel7014 ). This suggests that loss-
of-function of Ccdc85 can cause eye roughness.
3.3.5. ccdc85 null mutants have eye development defects, similar
to ASPP null mutants
As transposon insertions often only partially disrupt gene function, Nic Tapon mo-
bilised the P-element of P{XP}d06579 in order to create a null mutant by imprecise
excision. He screened 218 mobilizations of the P-element by putting those chromo-
somes in trans to the ccdc85 deficiency (Df(2L)Exel7014 ). None were lethal over
the deficiency and 12 showed a rough eye phenotype. Only two lines had a rough
eye phenotype that was detectably stronger than the original P-element line over the
deficiency.
I genotyped all lines that gave a rough eye phenotype by PCR. Only one line
(ccdc85C1.1) had a sizeable deletion, which removed the first non-coding exon com-
pletely (Fig. 3.17A, B). Subsequent sequencing showed that the lesion was from
chr2L:2,998,544 to chr2L:3,000,949 and an extra adenine was inserted. In ccdc85C1.1,
the region that codes for the 3’-UTR of the neighbouring CG3558 gene is also par-
tially affected. Unfortunately, this includes the polyadenylation signal for the CG3558
transcript. To test if ccdc85C1.1 is a null mutant for ccdc85, I performed RT-PCR ex-
periments. ccdc85 mRNA levels were undetectable for the ccdc85C1.1 mutants, while
CG3558 mRNA levels were slightly reduced (Fig. 3.17C). Thus ccdc85C1.1 seems to
be a null mutant for ccdc85, however, it is also likely to be a hypomorph for CG3558.
To compare the eye roughness seen in the ccdc85 loss-of-function flies to ASPP
loss-of-function, I examined developing retinas at 40 h APF. At this stage, ccdc85
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Figure 3.18.: ccdc85 mutants phenocopy ASPP mutant eye phenotypes
(A–D) Confocal X-Y sections of pupal retinas at 40 h APF stained with anti-E-cadherin
antibody to mark cell outlines. (A, A’) ccdc85 null mutant flies have defects in eye de-
velopment. Two examples are shown. The bristle duplication phenotype (arrowheads)
resembles the phenotype observed in ASPP null mutants (Fig. 3.5B and D). (B,C) Ex-
pression of Ccdc85 with a weak GMR-GAL4 driver (B) causes loss of IOCs and cone
cells are surrounded with more than two primary pigment cells.
(D) ccdc85 null mutants have an increased number of IOCs (14.2±1.2), comparable
to ASPP null mutants (15.3±1.6, see Fig. 3.5E). Expression of Ccdc85 leads to a sig-
nificant decrease in the number of IOCs, compared to GFP expression. An unpaired
t-test was carried out to determine if the means between GFP and Ccdc85 expression
were significantly different from one another. *** indicates p<0.001. Grey dashed line
indicates the theoretical number of IOCs in a perfectly organised tissue (12.0). IOCs
in 30 hexagons from at least 4 retinas were counted per condition.
(E) Loss of ccdc85, as well as higher levels of Ccdc85 cause bristle misplacements. Bristle
clustering or placement of a bristle in a neighbouring position that should be occupied
by a tertiary pigment cell was counted as misplacement. Bristle misplacements were
counted in 30 hexagons from at least 4 retinas.
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Figure 3.19.: RASSF8 and ccdc85 null mutant flies have no defect in anterior
scutellar bristles
Neither RASSF8 nor ccdc85 null mutant flies have any defects in their aSCs. aSC
duplication either on the left side, right side or both sides was counted as duplication
event.
null mutant flies show mispatterned IOCs in the eye (Fig. 18A, A’). Similar to ASPP
null mutants, bristles often cluster together (Fig. 3.18A’, F). The number of IOCs
(14.2±1.2) is higher than in controls (Fig. 3.18D). It is interesting to note that this
number is closer to ASPP null mutant eyes (15.3±1.6, see Fig. 3.5E) than to RASSF8
null mutant eyes (17.6±2.7, see Fig. 4.1F). Furthermore, despite the increase in IOC
numbers, only a single layer of IOCs separate primary pigment cells in ccdc85 and
ASPP mutants. In contrast, RASSF8 mutants frequently have multi-layered IOCs
(see Fig. 3.18A, A’ and Fig. 3.5B in comparison to Fig. 4.1A). These results suggest
that Ccdc85 could function together with ASPP in eye development.
In contrast to eye development, neither RASSF8 nor ccdc85 null mutant flies (both
trans-heterozygous over a genomic deficiency) had any defects in aSCs (Fig. 3.19).
This is surprising for ccdc85 null mutants, as aSC duplication was occasionally ob-
served in ccdc85C1.1 homozygous flies (data not shown). These results suggest that
although RASSF8 and Ccdc85 might function together in eye development, this might
not be true for bristle specification.
Despite the rough eye phenotypes seen in ASPP and RASSF8 mutant flies, ASPP
and RASSF8 overexpression does not lead to a rough eye (Paul Langton and Julien
Colombani—unpublished observations). However, when I expressed Ccdc85 using a
weak eye-specific GMR-GAL4 driver (see List of Genotypes for details), a very severe
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loss of IOCs (10.1±1.9) could be observed (Fig. 3.18C). Expressing GFP (12.8±1.0)
as a control did not reduce the number of IOCs (Fig. 3.18B). Together with the loss-
of-function phenotype, this suggests that Ccdc85 protein levels need to be tightly
controlled to ensure proper eye development.
3.4. Concluding remarks and future directions
In this chapter I have shown that the ASPP/PP1 complex is conserved in Drosophila.
Two additional proteins, RASSF8 and Ccdc85, can associate with the ASPP/PP1
core complex. Moreover, I have provided in vivo evidence that PP1 binding is es-
sential for the function of ASPP. Mutants of PP1, RASSF8 and ccdc85 share some
phenotypic similarity with ASPP mutants. A possible mechanism that could explain
the similarity of phenotypes is that the ASPP/PP1 holoenzyme acts as an active
phosphatase complex that uses ASPP, RASSF8 and Ccdc85 to restrict the enzymatic
activity towards certain substrates. In the next chapter I will explore this possibility
and investigate two potential substrates for the ASPP/PP1 complex.
3.4.1. Is the SH3 domain a general PP1-binding domain?
The PxxPxR motif of PP1s is conserved in other animals and even some fungi such as
Aspergillus (data not shown). Thus, it is possible that many more regulatory subunits
use SH3 domains to bind to PP1. Additionally, SH3 domains can be important
binding to PP1s, independent of the PxxPxR motif. This has been shown for Dis2 in
Schizosaccharomyces pombe and Glc7p in Saccharomyces cerevisiae, two orthologues
of the PP1 family (Hachet et al. 2011, Knaus et al. 2005). Dis2 binds to the regulatory
subunit Tea4 (Hachet et al. 2011) and Glc7p binds to Bud14p (Knaus et al. 2005). In
both cases, deleting the SH3 domain of the regulatory subunit abrogates the binding
to the PP1 catalytic subunit. Thus, the interaction between SH3 domains and PP1s
could characterise a distinct category of PP1 regulatory subunits.
Adding the SH3 domain as an additional parameter for PP1 regulatory protein
database searches can increase the specificity of the search, as the RVXF motif alone
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Figure 3.20.: Dlg has an RVXF motif C-terminally to its SH3-domain
Alignment of the RVXF motif of Drosophila and human Dlg. The sequences shown start
right after the predicted SH3 domains. Conserved residues are indicated by asterisks.
Basic residues are found N-terminally of the motif, while acidic residues can be found
C-terminally (not shown). While the basic residues are highly conserved, the primary
sequence surrounding the acidic residues is not.
is relatively unspecific due the shortness of the consensus sequence. Searching the
human and Drosophila proteome using Prosite for any protein that has an SH3 do-
main and fits to the [KR]-x(0,1)-[VI]-{FIMYDP}-[FW] definition of the RVXF motif,
revealed only five proteins with orthologues in both organisms. Excluding proteins
with RVXF motifs within known domains reduced the list to one protein, Dlg. Dro-
sophila Dlg and three of the four human DLG isoforms (DLG1, DLG2 and DLG3)
have the conserved RVXF motif C-terminally of their SH3 domain (Fig. 3.20). Fur-
thermore, DLG3 had already been shown to interact with PP1 and both DLG2 and
DLG3 inhibit phosphorylase phosphatase activity of PP1 (Hendrickx et al. 2009),
typical of regulatory subunits. Dlg is a baso-laterally localised polarity determinant
in epithelial cells that acts together with Scrib and Lgl (see 1.5.6). It is therefore pos-
sible that Dlg can specify PP1 activity at the baso-lateral membrane towards specific
substrates. Thus, while ASPP would regulate PP1 activity at adherens junctions,
Dlg could fulfil a similar function basally. Overall, this preliminary search supports
the idea that PP1/SH3 domain binding could be a general interaction mechanism
between a subclass of PP1 regulatory subunits and the catalytic subunit.
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3.4.2. Is PP1α96A the catalytic subunit of the ASPP/PP1
complex
PP1α96A probably acts as the primary PP1 isoform that binds to ASPP in vivo. It
was binding most strongly to ASPP in co-IP experiments (Fig. 3.1C) and was the only
PP1 isoform identified by mass spectrometry in a pull-down experiment using GFP-
tagged ASPP as a bait (see 5.4.1). Lastly, PP1α96A localises to cell-cell junctions in
the retina (Fig. 3.9 B, B’), where ASPP is also found (Langton et al. 2009).
However, it is likely that other PP1 isoforms can act redundantly with PP1α96A.
The lack of any detectable phenotype of PP1α96Amutants supports the idea of redun-
dancy. The likeliest alternative to PP1α96A is PP1β9C, due to its strong binding to
ASPP (Fig. 3.1C) and its junctional localisation (Fig. 3.9 C, C’). However, PP1α13C
and PP1α87B could also replace PP1α96A, as ASPP can bind to PP1s independent
of its RVXF motif and its SH3 domain (Fig. 3.2D). Another reason why PP1β9C is
unlikely to be the only possible replacement for PP1α96A is that even when PP1β9C
and PP1α96A are mutated, the phenotype of the double mutant is different to ASPP
null mutant or ASPP-FA rescue flies (Fig. 3.10 and Fig. 3.12). Thus, despite possibly
being the main PP1 isoform that interacts with ASPP, PP1α96A can be replaced by
other PP1 isoforms.
3.4.3. Which subunits constitute the ASPP/PP1 holoenzyme?
ASPP and PP1 form the core of the ASPP/PP1 holoenzyme, as ASPP has the RVXF
motif and SH3 domain that can directly interact with PP1. RASSF8 and Ccdc85
can attach to this core. It remains unclear if a hetero-tetrameric complex could
form. Analytical gel filtration could be used on purified proteins to determine the
composition of potential holoenzymes. Furthermore, sucrose gradient centrifugation
could be employed for cell or tissue lysates. It is possible that distinct types of
holoenzymes may form in vivo. Each type of holoenzyme might be differentially
regulated and the substrates may differ.
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The non-overlapping phenotypic spectrum of the null mutants suggests that differ-
ent holoenzymes may form in vivo. While ASPP and ccdc85 mutants have a very
similar rough eye phenotype (Fig. 3.5B and 3.18A, A’), ccdc85 mutants do not share
the aSC duplication phenotype seen in ASPP mutants (Fig. 5.8B and 5.19). Thus,
it is possible that Ccdc85 forms a complex with ASPP and PP1 in the developing
retina, but not in sensory organ precursors that give rise to the scutellar bristles.
Additionally, expression patterns of ASPP and its interactors could be analysed in
different tissues. If Ccdc85 were only important in the retina, it would not have to
be co-expressed with ASPP in sensory organ precursors. Together these experiments
could indicate which types of ASPP/PP1 holoenzymes are required in which tissue.
3.4.4. What is the function of Ccdc85?
The ccdc85 mutant that was generated might be hypomorphic for CG3558. To verify
that the rough eye phenotype was due to the lack of Ccdc85 instead of CG3558,
expressing Ccdc85 in ccdc85C1.1 flies should restore normal eye patterning, while
expressing CG3558 should not.
As Ccdc85 can bind to all four isoforms of PP1 (Fig. 3.13B) it is possible that
Ccdc85 and PP1 directly bind to each other, independent of ASPP. Furthermore,
overexpression of Ccdc85 in the eye reduces the number of IOCs (Fig. 3.18C) in
contrast to ASPP or RASSF8 overexpression (Paul Langton and Julien Colombani—
unpublished observations), suggesting an ASPP or RASSF8 independent function.
A careful analysis of further ccdc85 mutant phenotypes could reveal tissues or a
developmental context, where ASPP is not required. Ccdc85 could help to recruit
other proteins to PP1. With AP-MS experiments (similar to Fig. 5.10) using Ccdc85
as bait, further scaffolds, regulators and substrates that might not directly bind to
ASPP or PP1 could be identified.
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PP1 regulatory subunits can be substrate specifying subunits or inhibitors. ASPP
family proteins are likely to be substrate specifying PP1 subunits, since they inhibit
PP1 activity towards some substrates, but not others (Helps et al. 1995). Similar to
many other substrate specifying subunits (Hendrickx et al. 2009), a fragment of hu-
man ASPP2 can inhibit PP1 activity towards phosphorylase, the standard substrate
for in vitro PP1 assays (Helps et al. 1995). However, ASPP2 does not inhibit PP1
activity towards myosin light chain (Helps et al. 1995).
In this chapter I describe two potential substrates for the ASPP/PP1 complex:
The transcriptional co-activator Yki and the polarity determinant Baz. For Yki, I
have not found evidence that it is dephosphorylated by the ASPP/PP1 complex. In
the case of Baz, I show in vivo evidence that its localisation is affected by loss of
ASPP and present a list of residues that are dephosphorylated in vitro.
4.1. Yki is a potential substrate for ASPP/PP1
The transcriptional co-activator Yki was the first candidate substrate I have tested
for the ASPP/PP1 complex. Three pieces of evidence suggested that Yki might be as-
sociated with the ASPP and N-terminal RASSF protein families: (1) Several reports
in mammalian cells have shown that ASPP1/2 regulate core Hippo pathway compo-
nents. ASPP2/PP1 dephosphorylates TAZ in cell culture on S311, the LATS1/2
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Figure 4.1.: RASSF8 genetically interacts with kib, but not crb to regulate IOC
number
(A-E) Confocal X-Y sections of pupal retinas carrying eyFlp mitotic clones of the indi-
cated mutants at 40 h APF stained with anti-E-cadherin antibody to mark cell outlines.
(A) RASSF86 mutant retinas have extra IOCs. Multi-layering of IOCs is often observed,
where IOCs laterally contact other IOCs instead of primary pigment cells.
(B) kibΔ32 mutant retinas have extra IOCs. IOCs form a single layer of cells in contrast
to RASSF86 mutants.
(C) kibΔ32 , RASSF8 double mutant retinas have a substantially increased number of
IOCs. Primary pigment cells are mostly unaffected.
(D) crb82-04 mutant retinas resemble wild type retinas.
(E) crb82-04 , RASSF86 double mutant retinas are disordered, but have the same num-
ber of extra IOCs compared to RASSF86 single mutant retinas.
(Continues on following page)
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inhibitory phosphorylation site on TAZ (Liu et al. 2011). Additionally, nuclear
ASPP1 can drive the expression of pro-apoptotic genes together with LATS2 (Aylon
et al. 2010), while cytoplasmic ASPP1 inhibits LATS1/2 activity towards YAP and
TAZ (Vigneron et al. 2010). (2) Drosophila ASPP and RASSF8 mutants have over-
growth phenotypes, such as enlarged wings and rough eyes (including extra IOCs)
that are reminiscent of upstream members of Hippo signalling (Langton et al. 2007
2009). (3) In multiple AP-MS experiments, ASPP2 and RASSF8 have been found to
bind to YAP and TAZ (Couzens et al. 2013, Hauri et al. 2013, Wang et al. 2014).
4.1.1. RASSF8 does not regulate Ex, a Hippo pathway target
Based on current evidence, it is not entirely clear if ASPP and N-terminal RASSF
family proteins would be predicted to activate or inhibit Hippo signalling (if they are
involved in Hippo signalling at all). In Drosophila, ASPP and RASSF8 have growth
inhibitory functions, suggesting that they should inhibit Yki function. This is consis-
tent with the idea that human ASPP1/2 (Samuels-Lev et al. 2001) and RASSF8 (Lock
et al. 2010) might be tumour suppressors. However, this neither fits with cytoplasmic
ASPP1 activating YAP/TAZ by inhibiting LATS1/2 (Vigneron et al. 2010), nor with
ASPP2/PP1 dephosphorylating and activating TAZ (Liu et al. 2011).
Given the more ample evidence of ASPP and RASSF8 being tumour suppressors,
I first tested the hypothesis that they are positive regulators of Hippo signalling. I
focused on RASSF8, since it has been reported to bind Wts in a yeast two-hybrid
Figure 4.1: (Continued from previous page)
(F) kibΔ32,RASSF86 but not crb82-04,RASSF86 double mutant retinas have a signifi-
cant increase in the number of IOCs compared to RASSF86 mutant retinas. Error bars
represent the standard deviation of the observed distributions. A one-way ANOVA
test indicated that the differences among means were significant (p<0.001). All pair-
wise comparisons with RASSF86 single mutants were carried out and p-values were
adjusted using Bonferroni’s correction. Significant differences are indicated. *** repre-
sents p<0.001, n.s. means not significant. IOCs in 25 hexagons from at least 3 retinas
were counted per condition.
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Figure 4.2.: The Hippo pathway reporter ex-lacZ is unchanged in RASSF8
mutants
Confocal X-Y sections of larval eye imaginal discs stained with anti-β-galactosidase
antibody to measure transcriptional activity of the Hippo pathway. ex-lacZ reporter
levels remain unchanged in RASSF8 single (A, A’) and double mutants (D, D’, F, F’).
In contrast, a mutation in wts (B) strongly increases ex-lacZ reporter transcription.
Wild type areas are marked positively with GFP, mutant areas are GFP-negative.
Clones were induced using eyFlp. Arrowheads indicate wild type tissue with decreased
β-galactosidase staining compared to surrounding mutant tissue. Scale bar represents
50 μm.
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Figure 4.3.: Ex levels are unchanged in kib and RASSF8 clones
(A–C’) Confocal X-Y sections of larval imaginal eye discs stained with an anti-Ex
antibody. Apical Ex localisation in larval wing imaginal discs is not influenced by loss
of RASSF8 (A, A’), kib (B, B’) or both (C, C’). Scale bar represents 20 μm.
(D–F) Confocal transverse sections through larval imaginal wing discs stained with an
anti-Ex antibody. Wild type areas are marked positively with GFP, mutant areas are
GFP-negative. Mitotic clones were induced using hsFlp. Scale bar represents 10 μm.
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assay (Giot et al. 2003). As previously described, RASSF86 single mutant flies had
a mild eye roughness phenotype with some extra IOCs (17.6±2.7, Fig. 4.1A—as
compared with 12 IOCs in wild type). This is reminiscent of the apically localised
upstream activators of Hippo signalling, Kib, Mer, Ex and Crb that act redundantly
to regulate growth through Hippo signalling (Genevet and Tapon 2011). Consistent
with the literature, kibΔ32 (Genevet et al. 2010) and crb82-04 (Ling et al. 2010) single
mutants had 22.0±2.4 and 13.3±1.4 IOCs respectively (Fig. 4.1B, D).
If RASSF8 was similar to these upstream activators, a synergistic increase in the
number of extra IOCs in double mutant combinations would be expected, such as that
observed for themer;kib and kib;crb double mutant combinations (Ling et al. 2010, Yu
et al. 2010). Indeed, clones in kibΔ32,RASSF86 double mutant flies had 43.3±5.1 IOCs
per hexagon (Fig. 4.1C), which is more than an additive effect of the single mutants.
Despite the massive increase in the number of IOCs, primary pigment cells and cone
cells were largely unaffected. However, clones in crb82-04,RASSF86 double mutant
flies did not have significantly more IOCs (16.6±1.7) than in clones of RASSF86
single mutants (Fig. 4.1E). This was also observed with another crb allele, crb8F105
(16.9±1.7, Fig. 4.1F). Together, these results show that kib, but not crb synergises
with RASSF8 to control the number of IOCs.
The multi-layering and increase of IOCs in kibΔ32,RASSF86 double mutants are
comparable to hpo and wts null mutant eyes (Hamaratoglu et al. 2006). This sug-
gests that kib and RASSF8 might act redundantly to promote Hippo signalling. It has
been reported that double mutants of upstream members of Hippo signalling, but not
single mutants show a detectable upregulation of Yki target genes (Ling et al. 2010,
Yu et al. 2010). Thus, I tested if ex, a widely used transcriptional target of Hippo
signalling is affected in double mutants of RASSF86 with kibΔ32 and crb11A22. How-
ever, neither kibΔ32,RASSF86 double mutants, nor crb11A22,RASSF86 double mutants
showed elevated ex transcription in imaginal eye discs using the ex-lacZ enhancer
trap line, which carries a transposon-encoded lacZ reporter at the endogenous ex
locus (Fig. 4.2D, F). β-galactosidase staining in these combinations was comparable
to single mutants of RASSF86, kibΔ32 and crb11A22 (Fig. 4.2A, C, E). As expected,
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Figure 4.4.: No binding between Yki and ASPP, RASSF8 or Ccdc85
Western blots of co-IP experiments using anti-FLAG antibody-coupled beads and S2
cell lysates. Cells were transfected with the indicated constructs. Western blots were
probed with indicated antibodies.
(A) In a pull-down of Yki, neither ASPP, nor RASSF8 are detected when the two
protein are expressed separately or together.
(B) In a pull-down of Ccdc85, Yki does not co-IP. Co-expressed ASPP in contrast is
co-IPed by Ccdc85.
wtsM5.41 mutants showed strongly elevated β-galactosidase levels (Fig. 4.2B). Sim-
ilar to the transcriptional ex-lacZ reporter, Ex protein levels remained unchanged
in either RASSF86 and kibΔ32 single mutant or kibΔ32,RASSF86 double mutant wing
imaginal discs (Fig. 4.3). Thus, although RASSF8 and kib synergistically regulate
the number of IOCs, this does not seem to be via Hippo signalling.
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4.1.2. ASPP, RASSF8 and Ccdc85 do not bind to Yki in co-IP
experiments
Although the in vivo data suggested that RASSF8 might not function as a Hippo
signalling upstream element such as Kib, I still wanted to test whether RASSF8,
together with ASPP could dephosphorylate Yki. Analogous to ASPP2 in mammalian
cells (Liu et al. 2011), the dephosphorylation could remove the inhibitory phosphate
of Yki. Alternatively, more consistent with the idea that ASPP and RASSF8 are
tumour suppressors, the dephosphorylation could remove an activating rather than
an inhibitory phosphate. Either way, binding of Yki to an ASPP/PP1 complex would
be required for effective dephosphorylation. Indeed, both RASSF8 and ASPP2 have
been recovered in several AP-MS experiments, using YAP and TAZ as baits (Couzens
et al. 2013, Hauri et al. 2013, Kohli et al. 2014, Wang et al. 2014).
In co-IP experiments, Yki did not bind to ASPP or RASSF8, alone or in com-
bination (Fig. 4.4A). Similarly, Ccdc85 alone or a Ccdc85/ASPP complex did not
bind to Yki (Fig. 4.5B). These results do not rule out that Yki might bind to PP1
directly. However, the data does not provide evidence that an ASPP/PP1 complex
may dephosphorylate Yki.
4.1.3. ASPP, RASSF8 and PP1 do not regulate Yki S168
phosphorylation in S2 cells
The negative results from the co-IP experiments do not exclude the possibility that
weak binding between the ASPP/PP1 complex and Yki occurs. This might be suf-
ficient in vivo for efficient dephosphorylation. Thus, I decided to test in S2 cells,
if overexpressing or knocking down components of the ASPP/PP1 complex has an
influence on Yki S168 phosphorylation. Expressing either RASSF8, ASPP, ASPP-FA
or the negative regulator of Hippo signalling RASSF in S2 cells slightly decreased
Yki S168 phosphorylation (Fig. 4.5A). However, the reduction was very subtle and
variable between experiments, especially when compared to the substantial and re-
producible increase of Yki S168 phosphorylation elicited by Hpo expression.
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Figure 4.5.: Expression of ASPP or RASSF8 does not significantly influence
Yki S168 phosphorylation
Western blots of S2 cell lysates. Cells were transfected with the indicated constructs.
Western blots were probed with indicated antibodies. Yki S168 phosphorylation is
slightly reduced when ASPP is co-expressed. Reduction is variable between experi-
ments. In contrast, the Yki S168 phosphorylation is always increased when Hpo is
expressed.
When ASPP or individual PP1 catalytic subunits were knocked-down, no signif-
icant change in S168 phosphorylation of endogenous Yki was observed (Fig. 4.6C,
D). Efficient knockdown was confirmed using tagged proteins (Fig. 4.6A, B), since
no antibodies were available to detect endogenous ASPP or PP1s in S2 cells. These
results suggest that in S2 cells, Yki is not dephosphorylated by an ASPP/PP1 com-
plex. However, there are several caveats with the cell-based experiments as discussed
below (see 4.2.3).
In conclusion, I could not uncover any evidence that ASPP/PP1 dephosphorylates
Yki in Drosophila. This does not rule out that Yki is dephosphorylated by ASPP/PP1
in different cellular contexts. Weak binding between Yki and the ASPP/PP1 complex
might occur in vivo and could regulate transcriptional targets of Yki in other tissues
than the larval eye or wing imaginal discs.
141
Chapter 4. Substrates of the ASPP/PP1 complex
Figure 4.6.: Knock-down of ASPP, RASSF8 or PP1 have no effect on Yki S168
phosphorylation
Western blots of S2 cell lysates. Cells were transfected with the indicated con-
structs/treated with the indicated dsRNAs. Western blots were probed with indicated
antibodies.
(A) Exogenous ASPP is efficiently knocked-down with two different dsRNAs. (B) Ex-
ogenous PP1s are efficiently knocked-down with dsRNAs designed to be specific for
each PP1 subunit.
(C) Knock-down of ASPP has no effect on endogenous Yki S168 phosphorylation.
(D) Knock-down of PP1s has no effect on endogenous Yki S168 phosphorylation.
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4.2. Baz is a potential substrate for ASPP/PP1
In parallel to Yki, I considered the polarity protein Baz as a second candidate sub-
strate for the ASPP/PP1 complex. Three pieces of evidence suggest that Baz might
be associated with the ASPP/PP1 complex: (1) PAR3, the mammalian orthologue
of Baz, has been found to bind to ASPP2 and regulate tight junction formation to-
gether with ASPP2 (Cong et al. 2010, Sottocornola et al. 2010). Especially during
the de novo formation of tight junctions, ASPP2 is required to localise PAR3 (Cong
et al. 2010). (2) PP1 alone can directly dephosphorylate PAR3 on several serine
residues (Traweger et al. 2008). (3) Baz has been found to physically interact with
ASPP and RASSF8. In yeast two-hybrid data generated in our lab, Baz could bind
to Drosophila RASSF8 (Eunice Chan—unpublished observations), human RASSF8
has been found to co-purify with PAR3 (Brajenovic et al. 2004) and PAR3 could pull-
down RASSF7, 9 and 10 in the AP-MS experiments carried out by our collaborators
(Fig. 1.10).
4.2.1. ASPP regulates the junctional localisation of Baz in the
developing retina
As Baz localisation in many systems is regulated by phosphorylation (see 1.5.3),
dephosphorylation by the ASPP/PP1 complex could affect it. I decided to investi-
gate Baz localisation in the developing retina, since PP1 (Fig. 3.9B, C), ASPP and
RASSF8 (Langton et al. 2009) are all junctionally localised and their inactivation
leads to phenotypic consequences in this tissue (Langton et al. 2007 2009 and Chap-
ter 3).
In ASPPd mitotic mutant clones, the intensity of Baz at cell-cell junctions in IOCs
was reduced, in comparison to adjacent wild type tissue (Fig. 4.7 A, B). This result
shows that ASPP is required for proper Baz localisation in developing retinas. The
reduction of Baz localisation in ASPP mutant clones is incomplete, suggesting that
other localisation cues might stabilise Baz at cell-cell junctions. An example of re-
dundant localisation cues for polarity proteins is found in follicle cells. There, aPKC
143
Chapter 4. Substrates of the ASPP/PP1 complex
Figure 4.7.: Baz is mislocalised in ASPP mutant clones
(A, A’) Confocal X-Y sections of pupal retinas at 26 h APF. Baz-GFP fluorescence
is detected. Flp/FRT clones were generated with eyFlp and marked by absence of
mCherry (purple). In ASPP mutant retinas, Baz levels at cell-cell junctions are re-
duced. Clone boundary marked with dashed yellow line.
(B) Quantification of GFP intensity of cell-cell contacts between IOCs and primary
pigment cells in mutant and wild type tissue of retina shown in A. An unpaired t-test
showed that the mean intensities differ significantly from each other. *** indicates
p<0.001. Five traces of the contacts between the IOCs surrounding two primary pig-
ment cells were analyzed for each condition. GFP intensity was normalised to the mean
of fluorescent signal intensity in the wild type tissue.
localises correctly in baz and crb single mutant mitotic clones, but not in double mu-
tant clones (Fletcher et al. 2012). Similarly, Baz was localised correctly in crb mutant
retinas (Fig. 4.8A), but when ASPP was additionally knocked-down, Baz was barely
detectable at cell-cell junctions (Fig. 4.8C). This suggests that, additionally to known
polarity proteins, ASPP is also necessary for stabilising Baz at cell-cell junctions.
4.2.2. ASPP can bind to Baz via RASSF8
Baz needs to bind to PP1, in order to be dephosphorylated by an ASPP/PP1 complex.
It has been suggested that mouse PAR3 could directly bind to PP1 (Traweger et al.
2008). To test the binding between PP1 and Baz in Drosophila, I performed co-IP
experiments. Baz showed weak interaction with PP1s, but associated with RASSF8
more strongly (Fig. 4.9A). In contrast to human PAR3 and ASPP2 (Cong et al. 2010,
Sottocornola et al. 2010), no binding between Baz and ASPP was detectable.
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Figure 4.8.: ASPP and Crb are required to localise Baz to cell-cell junctions
Confocal X-Y sections of pupal retinas at 26 h APF stained with an anti-Baz antibody.
MARCM clones were generated with eyFlp and marked by GFP.
(A, A’) In crb82-04 mutant retinas, Baz localisation is largely unaffected. Clone bound-
aries marked with dashed yellow line.
(B, B’) In retinas where ASPP is knocked down, Baz localisation at cell-cell junctions
is reduced.
(C, C’) Depleting ASPP in a crb82-04 mutant retina completely removes Baz from cell-
cell junctions.
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Figure 4.9.: Baz binds to ASPP via RASSF8
(A, B) Western blots of co-IP experiments using anti-FLAG antibody-coupled beads
and S2 cell lysates. Cells were transfected with the indicated constructs. Western blots
were probed with indicated antibodies.
(A) Baz co-IPs with RASSF8, but not with ASPP. All four PP1 isoforms weakly bind
to Baz.
(Continues on following page)
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As only RASSF8 and Baz strongly interacted with each other, we hypothesized
that RASSF8 helps to bridge the interaction between Baz and ASPP/PP1. Indeed,
ASPP could interact with Baz only in the presence of RASSF8 in co-IP experiments
(Fig. 4.9B). Drosophila RASSF8 and isoform A of human RASSF8 have a putative
PDZ-domain binding motif (PBM) that is not present in the alternatively spliced
human RASSF8 isoform B (Fig. 4.9C). The last four residues fit to a group of PBMs
that have a glycine as their fourth to last residue (Tonikian et al. 2008). This group
does not belong to any of the four classes of PBMs. Baz and PAR3 have three PDZ-
domains that could bind to the PBM of RASSF8. The interaction networks that were
constructed by Matthias Gstaiger’s lab (Hauri et al. 2013) were based on isoform B of
RASSF8, the isoform without the PBM. Thus, to test if the PBM was important for
PAR3 binding, I cloned isoform A of human RASSF8 into a Flp-In vector for insertion
into HEK293 cells, followed by AP-MS experiments. Matthias Gstaiger confirmed
that the PBM of human RASSF8 is required for PAR3 binding (Fig. 4.9D). In contrast
to isoform B, isoform A of RASSF8 could pull-down substantial amounts of PAR3.
Known polarity determinants were detected as well. Members of the PAR complex
(see 1.5.2) such as PAR6β/γ (Par6 in Drosophila), PKCι (aPKC in Drosophila), a
member of the CRB complex (see 1.5.2) PATJ/MPDZ (both orthologous to Patj)
and different 14-3-3 isoforms were pulled-down (Fig. 4.9D). Additionally, CCDC85C
was also a specific binding partner of isoform A of RASSF8. Together these results
Figure 4.9: (Continued from previous page)
(B) Baz co-IPs with ASPP only when RASSF8 is present.
(C) Alignment between the C-terminus of human and Drosophila RASSF8. Drosophila
RASSF8 and isoform A of human RASSF8 have a putative PDZ-binding motif. Aster-
isks indicate conserved residues in human (isoform A) and Drosophila RASSF8.
(D) Table with number of identified peptides in AP-MS experiments, where human
RASSF8 were pulled-down. Isoform A of human RASSF8, but not isoform B is able
to pull-down PAR3. Number of peptides for isoform A is average of 2 experiments.
Ratios close to 1 indicates no difference between isoforms A and B, ratios close to 0 in-
dicates preferential binding to isoform A. This experiment was performed by Matthias
Gstaiger.
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suggest that RASSF8 bridges the interaction between Baz/PAR3 and the ASPP/PP1
core complex in Drosophila and mammalian systems.
4.2.3. ASPP, RASSF8 and PP1 do not influence Baz
phosphorylation in intact S2 cells
Next, I tested if the ASPP/PP1 complex could dephosphorylate Baz. Phospho-
specific antibodies for pS151, pS1085 (Krahn et al. 2009) and pS980 (Morais-de Sá
et al. 2010) are available. A complication for interpreting phosphorylation results in
S2 cells is that Baz is degraded into smaller fragments, during purification (Fig. 4.9A,
4.10B and Krahn et al. 2009). Each phospho-specific antibody seems to bind to frag-
ments of different molecular weight (Krahn et al. 2009). To prevent Baz degradation,
in all subsequent lysates of Baz expressing S2 cells that are not used for co-IP ex-
periments, I lysed with RIPA buffer (see 2.2.13) instead of the normal HEPES lysis
buffer unless otherwise stated. These more stringent lysis conditions were sufficient
to prevent all degradation and Baz appears as a single band on Western blots (e.g.,
Fig. 4.10A).
I successfully tested the anti-pS151 and anti-pS1085 antibodies using Baz S151A
and S1085A mutants, which showed a reduced signal (Fig. 4.10A). To test the anti-
pS980 antibody, I co-expressed aPKC with Baz and detected an increased signal
(Fig. 4.10B, lysis was not performed in RIPA buffer). Using these antibodies, I
could not detect a decrease of phosphorylation of Baz when overexpressing ASPP or
RASSF8 (Fig. 4.10C). Only the expression of PP1α96A and PP1β9C decreased S1085
phosphorylation (Fig. 4.10C). However, this was not always reproducible. Moreover,
when ASPP or RASSF8 were knocked-down, no changes in Baz phosphorylation were
observed (Fig. 4.10D). Only the knock-down of Microtubule star (Mts), the PP2A cat-
alytic subunit, resulted in an increase in S151 and S980 phosphorylation (Fig. 4.10D).
This is different to the observation of Krahn et al., who reported an increase in S1085,
but not in S151 and S980 phosphorylation upon Mts depletion (Krahn et al. 2009).
The reason for this discrepancy is not clear.
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Figure 4.10.: Baz phosphorylation is largely unaffected by expression or knock-
down of PP1, ASPP or RASSF8
Western blots of S2 cell lysates. Cells were transfected with the indicated constructs/or
treated with the indicated dsRNAs. Western blots were probed with indicated anti-
bodies.
(A) The anti-pS151 and anti-pS1085 antibodies primarily recognise wild type Baz that
have intact S151 and S1085 residues.
(B) The anti-pS980 antibody recognises phosphorylation of S980 induced by ectopic
expression of aPKC. Lysis with normal lysis buffer instead of RIPA buffer.
(C) PP1α96A or PP1β9C expression weakly decreases S1085 phosphorylation of Baz.
This effect was not robustly seen across multiple repeats.
(D) Knock-down of ASPP and RASSF8 does not influence Baz phosphorylation. In
contrast Mts knock-down increases S151 and S980 phosphorylation of Baz.
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Figure 4.11.: Sqh is dephosphorylated in vitro by the MYPT-75D/PP1β9C com-
plex
(A) Western blots of co-IP experiments using GFP-trap beads with S2 cell lysates.
Cells were transfected with the indicated constructs. Western blots were probed with
indicated antibodies. MYPT-75D/PP1β9C complex forms in S2 cells, when both pro-
teins are co-expressed. MYPT-75D binds more strongly to PP1β9C than to PP1α96A.
(B) Western blots of in vitro phosphatase assay. Sqh was purified from Calyculin A-
treated S2 cells and eluted from anti-FLAG antibody coupled beads. MYPT-75D and
PP1β9C were purified from S2 cells using GFP-trap beads. Sqh is dephosphorylated
by the MYPT-75D/PP1β9C complex. Under these conditions, Sqh remains stable over
30 minutes and dephosphorylation does not occur when no PP1β9C is present.
Overall, as for the experiments with Yki, cell-based assays have several caveats.
Importantly, overexpressing only one subunit of the ASPP/PP1 complex might not be
sufficient to increase PP1 activity. Furthermore, it is likely that S2 cells do not express
any ASPP (Cherbas et al. 2011). Thus, there might be no endogenous ASPP/PP1
complex that could be affected by RNAi. Due to these limitations, I decided to carry
out dephosphorylation assays in vitro, where I can control the components of the
phosphatase complex used in the assay.
4.2.4. In vitro dephosphorylation of Baz reveals ten putative
dephosphorylation sites
Most published in vitro dephosphorylation assays use phosphorylase as a generic
substrate to measure phosphatase activity of the PP1 catalytic subunit. Commer-
cial kits are available for this purpose. However, in my case, I wished to detect
the dephosphorylation of a specific substrate by PP1 that is associated with its reg-
ulatory subunits. A similar experiment with a non-generic substrate and a PP1
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Figure 4.12.: Ten serine/threonine residues of Baz were weakly dephosphory-
lated in vitro
(A) Western blots of in vitro phosphatase assay. Baz was purified from Calyculin A-
treated S2 cells and eluted from anti-FLAG antibody coupled beads. The ASPP/PP1
complex was purified from S2 cells using GFP-trap beads. Phospho-specific antibodies
did not detect any dephosphorylation of Baz on S151, S980 and S1085 after in vitro
dephosphorylation by the ASPP/PP1 complex.
(B) Coomassie stained gel for label-free mass spectrometric analysis by the LRI Protein
Analysis and Proteomics facility. Sample preparation as in (A). Two dephosphoryla-
tion time points (15 minutes and 30 minutes) with three conditions each (GFP only,
ASPP/PP1 without RASSF8 and ASPP/PP1 with RASSF8) were analysed. ASPP,
RASSF8 and Baz are detectable by Coomassie staining, while PP1α96A is not.
(C) Summary of serine/threonine residues that were statistically significantly dephos-
phorylated in vitro. 6 phospho-peptides containing a total of 10 serine/threonine
residues were weakly dephosphorylated when RASSF8 was present, or when ASPP/PP1
without RASSF8 was compared to GFP only. Only T712 of Baz is conserved in human
PAR3. For more details on data analysis, see Materials and Methods.
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complex had been done before (Vereshchagina et al. 2004). In this work, bacterially
expressed Sqh (Spaghetti squash), the Drosophila orthologue of Myosin regulatory
light chain—MRLC, was dephosphorylated by a PP1β9C/MYPT-75D complex and
dephosphorylation was detected using a phospho-specific antibody.
Instead of using bacterially expressed proteins, I decided to express all proteins in
Drosophila S2 cells. The reason is twofold. Firstly, PP1 purified from E. coli has a dif-
ferent substrate specificity spectrum and can even dephosphorylate phospho-tyrosine
residues (MacKintosh et al. 1996). This is reportedly caused by the incorporation of
different metal ions (Mn2+ rather than Zn2+ or Fe2+ for the native enzyme) in the
catalytic centre. Secondly, in S2 cells, the substrate can be hyperphosphorylated at
multiple residues by phosphatase inhibitor treatment. This allows hyperphosphoryla-
tion of substrates at most sites, even those for which the kinase is unknown, allowing
for an unbiased screen of all potential dephosphorylation sites. Subsequently, dephos-
phorylated residues can be identified by quantitative mass spectrometry.
As a proof of principle that proteins expressed in S2 cells can work in an in vitro
dephosphorylation assay, I first established the assay using the well-characterized
MYPT-75D/PP1β9C complex together with Sqh as a substrate. S21 of Sqh is known
to be dephosphorylated by MYPT-75D/PP1β9C (Vereshchagina et al. 2004). The
phosphorylation status of S21 can be monitored with a phospho-specific human anti-
MRLC antibody that cross-reacts with Drosophila Sqh (Lee and Treisman 2004).
I could confirm in co-IP experiments that a MYPT-75D/PP1β9C complex formed
and, as expected, MYPT-75D preferentially bound to PP1β9C in comparison to
PP1α96A (Fig. 4.11A). Furthermore, I could observe dephosphorylation of S21 of
Sqh in vitro within 10 minutes of adding MYPT-75D/PP1β9C, but not by adding
GFP (Fig. 4.11B). Thus purifying the components for the phosphatase assay from
S2 cells was a valid approach. The substrate remained stable over 30 minutes under
the conditions of the assay, and no unspecific dephosphorylation took place when
PP1β9C was absent.
Using the same set-up, I tested dephosphorylation of Baz by ASPP/PP1. Exoge-
nous Baz was hyperphosphorylated by Calyculin A treatment of the expressing S2
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cells, purified and added to ASPP/PP1 complexes that also contained RASSF8. The
ASPP/PP1 complexes were isolated by pull-down of GFP-tagged ASPP. Within 30
minutes, no dephosphorylation of S151, S980 or S1085 was observed (Fig. 4.12A).
Nonetheless, it was still possible that other serine or threonine residues had been
dephosphorylated. To detect dephosphorylation of other residues, I repeated the de-
phosphorylation assay for two time points (15 and 30 minutes) with GFP alone, with
ASPP/PP1 or ASPP/PP1/RASSF8 and sent gel purified Baz (Fig. 4.12B) for mass
spectrometric analysis at the LRI Protein Analysis and Proteomics facility. The
reason to differentiate between ASPP/PP1 with and without RASSF8 was that it
seemed plausible that RASSF8 would be required for ASPP/PP1 to bind to Baz for
effective dephosphorylation. MaxQuant software was used for label-free quantitation
in collaboration with Dr Karin Barnouin (LRI Protein Analysis and Proteomics facil-
ity). Out of all Baz phospho-peptides, six were significantly and consistently reduced
(Fig. 4.12C). The identification of the phosphorylated residue in an individual peptide
was sometimes ambiguous. In these cases all serine or threonine residues within the
peptide were considered as candidates. Some dephosphorylation events were seem-
ingly dependent on RASSF8, while others were not (i.e., ASPP and PP1 alone were
sufficient).
4.2.5. Only one of the putative dephosphorylation sites affects
Baz localisation in S2 cells
Baz was mislocalised in ASPP mutant mitotic clones (Fig. 4.7), which could have been
caused by hyperphosphorylation of Baz due to the lack of the ASPP/PP1 complex.
In order to test this hypothesis, I expressed GFP-tagged Baz in S2 cells. Wild type
Baz is membrane-associated in S2 cells (Matos Simões et al. 2010 and Fig. 4.13A).
Furthermore, Baz can become cytoplasmic (GFP-Baz-N, residues 1–1096, Fig. 4.13B),
when its C-terminal region, which contains the phosphoinositide binding domain, is
removed (Matos Simões et al. 2010). The cytoplasmic localisation suggests that this
S2 cell-based assay might be suitable to detect the dissociation of Baz from the
membrane upon phosphorylation.
153
Chapter 4. Substrates of the ASPP/PP1 complex
Figure 4.13.: Mutating S1176 of Baz leads to vesicular localisation in S2 cells
Confocal X-Y section of S2 cells transfected with GFP-Baz constructs. Scale bar rep-
resents 20 μm.
(A) Baz localises to the plasma membrane of S2 cells.
(B) The N-terminus of Baz (residues 1–1096) localises in aggregates in the cytoplasm.
(C) The C-terminus of Baz (residues 1097–1464) is sufficient for membrane localisation
in S2 cells. GFP-BazC harbours its phosphatidylinositol-phosphate binding site.
(D–P) Most phospho-mimicking Baz mutations at putative dephosphorylation sites do
not influence the binding of Baz to the plasma membrane. Mutating S1176 to aspartate
is sufficient to mislocalise Baz to vesicular structures (O).
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Figure 4.14.: Improved in vitro dephosphorylation assay reveals six weakly and
six strongly dephosphorylated serine/threonine residues of Baz, including
S980
(A) Western blots of in vitro phosphatase assay. Baz was purified from Calyculin
A-treated S2 cells and eluted from anti-FLAG antibody coupled beads. ASPP/PP1
complex was purified from S2 cells using anti-FLAG antibody coupled beads. S980 is
dephosphorylated within 15 minutes, while S151 and S1085 are not. Slightly increased
dephosphorylation was observed when ASPP, RASSF8 and Ccdc85 were present.
(B) Coomassie stained gel for label free and dimethyl-labelled mass spectrometric analy-
sis by the LRI Protein Analysis and Proteomics facility. Sample preparation as in (A).
One time point (10 minutes) with three conditions (GFP, PP1α96A, PP1α96A with
ASPP, RASSF8 and Ccdc85). GFP, PP1α96A and Baz show identifiable bands, while
ASPP, RASSF8 and Ccdc85 do not.
(C–E) Quantification results of peptides containing pS151, pS980 and pS1085 using
label-free quantification. While S980 phosphorylation is 31-fold and 16-fold lower when
PP1, or the ASPP/PP1 complex is present, S151 and S1085 phosphorylation are not
reduced. For a list of all phospho-peptides that were changed after dephosphorylation
and details of statistical analysis see Appendix A.
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Thus, I generated phospho-mimicking mutants for all 10 putative dephosphoryla-
tion sites and included three additional sites S1169, S1170 and S1176, since these were
closest to the PIP binding region (1173–1197) of Baz (Krahn et al. 2010). Each mutant
was expressed in S2 cells. However, no Baz mutant showed a cytoplasmic localisation
that was comparable to the N-terminal region of Baz (Fig. 4.13D–P). Surprisingly,
mutating S1176 to aspartate was sufficient to localise Baz to intracellular vesicular
structures (Fig. 4.13N, O). These results suggests that hyperphosphorylation of none
of tested residues was sufficient for removing Baz from the membrane in S2 cells.
4.2.6. Second in vitro dephosphorylation of Baz reveals seven
novel putative dephosphorylation sites
The first dephosphorylation assay was not optimal for two reasons. Firstly, there was
no positive control to verify that any dephosphorylation was taking place, proving
that the isolated complexes were active. Secondly, also possibly connected to the
first issue, PP1 concentration in the ASPP pull-downs was very low (Fig. 4.12A) and
could not be detected by Coomassie staining (Fig. 4.12B). Thus, I decided to repeat
the dephosphorylation assay but instead of pulling down ASPP, I pulled down PP1
directly to ensure that enough PP1 was present in the assay. With this approach, I
could observe a dephosphorylation of S980, but not of S151 or S1085 (Fig. 4.14A).
This showed that the isolated complexes were active, but that dephosphorylation
was nevertheless not promiscuous. The presence of ASPP, RASSF8 and Ccdc85 in
addition to PP1 alone slightly enhanced the dephosphorylation of S980.
I repeated this pull-down for mass spectrometric analysis by the LRI Protein Anal-
ysis and Proteomics facility. In contrast to the ASPP-pulldowns, PP1 was Coomassie
stainable (Fig. 4.14B). However, ASPP, RASSF8 and Ccdc85 were less abundant
(Fig. 4.14A) and not Coomassie stainable (Fig. 4.14B). The samples were split into
two aliquots. One half was used for label-free quantification (LFQ), while the other
half was dimethyl-labelled on primary amines using formaldehyde and quantified as
two mixtures (GFP mixed with PP1 and PP1 mixed with PP1 complex, for details
see Materials and Methods). Mascot was used for quantification. It was reassuring to
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see that the dephosphorylation of S151, S980 and S1085 detected by mass spectrom-
etry (Fig. 4.14C–E) corresponded well with the result obtained with phospho-specific
antibodies (Fig. 4.14A). From these quantifications I identified 10 dephosphorylated
peptides with LFQ and 6 dephosphorylated peptides with dimethyl-labelling on vi-
sual inspection (see Appendix A). The top candidate from this experiment was T720,
as it is conserved in human PAR3 and its phosphorylation was consistently reduced
in both approaches. In summary, the second run of the assay yielded seven novel
potential serine/threonine residues that might be dephosphorylated by ASPP/PP1
not found in the first run of the assay.
4.3. Concluding remarks and future directions
In this chapter I have addressed a core challenge within the PP1 field: Identifying
specific serine/threonine residues that are dephosphorylated by a PP1 holoenzyme.
For this purpose, I established a protocol for effective hyperphosphorylation of pu-
tative substrates and their subsequent dephosphorylation by the PP1 holoenzyme.
In collaboration with Dr Bram Snijders and Dr Karin Barnouin of the LRI Protein
Analysis and Proteomics facility we established label-free and post-labelling methods
for identification and quantification of putative dephosphorylation sites. Although
I could not find evidence that Yki is dephosphorylated by the ASPP/PP1 complex,
the identified serine/threonine residues that were dephosphorylated in Baz provide a
foundation for further cell-based and in vivo validation. In the next chapter I will
explore the regulation of ASPP and RASSF8 as well as a more unbiased approach to
identify novel substrates and regulators of the ASPP/PP1 complex.
4.3.1. Is YAP/TAZ dephosphorylation by ASPP/PP1 conserved
in Drosophila?
I could not uncover any evidence that Yki is dephosphorylated by an ASPP/PP1 com-
plex. In mammals, at least TAZ is directly dephosphorylated by ASPP2/PP1 (Liu
et al. 2011) and the inhibition of LATS1/2 by ASPP1 (Vigneron et al. 2010) would
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be coherent with ASPP1/PP1 dephosphorylating YAP. In line with this, ASPP2 or
PP1 expression strongly enhanced YAP transcriptional activity in a cell-based as-
say (Hauri et al. 2013). Given this data in mammalian systems, it is possible that the
regulation of YAP/TAZ by ASPP1/2 is not conserved in Drosophila. This would not
be the only regulatory mode of YAP/TAZ that is not present for Yki. For instance,
the phosphodegron that is responsible for YAP/TAZ ubiquitylation and proteasomal
degradation upon phosphorylation by LATS1/2 (Zhao et al. 2010 and see 1.4.2) is not
conserved in Drosophila, nor does loss of the fly orthologue of the mammalian ubiqui-
tin ligase complex (SCFβTRcP in mammals, SCFslimb in flies) affect Yki stability (Paulo
Ribeiro—unpublished observations). In addition, YAP and TAZ possess C-terminal
PDZ-binding motifs, which are not conserved in dipteran Yki proteins (Bossuyt et al.
2014, Hilman and Gat 2011).
It was suggested that the whole junctional regulatory machinery of YAP/TAZ
may have been rewired during the evolution of Neodiptera, which includes Droso-
phila (Bossuyt et al. 2014). Some elements of the regulatory machinery have been
lost such as AMOT and the Yki PDZ-binding motif while others were gained such
as the myosin Dachs (Bossuyt et al. 2014, Genevet and Tapon 2011). This shift in
Hippo pathway regulation is mirrored by a change of apico-basal polarity in insects,
exemplified by the emergence of the basal septate junction as a functional equivalent
to the apical tight junction (St Johnston and Ahringer 2010 and see 1.5.8). However,
the cause-effect relationship between these two events is unclear. Thus, it is tempting
to speculate that ASPP/PP1 regulation of YAP phosphorylation may have been lost
in Drosophila as part of this evolutionary shift.
However, with the successful dephosphorylation of Baz in vitro, it would be possible
to carry out an in vitro dephosphorylation assay of Yki. This might reveal that
Yki S168 could be dephosphorylated by ASPP/PP1 after all. Alternatively, other
serine/threonine residues might be dephosphorylated. For instance, it is possible
that, as yet uncharacterised activating rather than inhibitory phosphorylation sites
on Yki might be targets of the ASPP/PP1 complex. This would resolve the puzzling
observation that genetic evidence suggests that ASPP proteins function as growth
158
Chapter 4. Substrates of the ASPP/PP1 complex
suppressors both in flies and mice (Kampa et al. 2009, Langton et al. 2007, Vives
et al. 2006), while dephosphorylation of the inhibitory site on YAP/TAZ/Yki would
be expected to promote growth.
4.3.2. How can the phosphatase assay be improved?
The IP of the ASPP/PP1 holoenzyme for the phosphatase assays was not very ef-
ficient. In the GFP-ASPP pull-down, there was no Coomassie detectable PP1α96A
(Fig. 4.12B). In contrast, the FLAG-PP1α96A pull-down might have yielded many
PP1α96A catalytic subunits unbound to any regulatory subunits, or bound to other
endogenously expressed regulatory subunits, rather than bound to ASPP, RASSF8
and Ccdc85 (Fig. 4.14B). In the first case there was possibly no or only little de-
phosphorylation, in the second case there might have been ASPP, RASSF8 and
Ccdc85-independent dephosphorylation. A potential solution to this would be a
step-wise purification protocol with larger amounts of starting material. In the first
step, FLAG-PP1α96A would be purified as before. Instead of directly using this for
the dephosphorylation assay, FLAG-PP1α96A and its associated proteins could be
eluted and a second GFP-ASPP purification carried out. With sufficient starting
material, this would yield a much higher fraction of ASPP/PP1 complexes. As a
complementary approach, we are investigating the possibility of carrying out human
ASPP/PP1 complex purification from HEK293 cells. Preliminary data suggest that
a better stoichiometry of catalytic to regulatory subunits may be achievable using
ASPP2 pulldowns (Teresa Bertran—unpublished observations). In addition, a com-
parison of Baz and PAR3 in vitro dephosphorylation assay results should be helpful
in identifying functionally important sites.
An alternative to in vitro dephosphorylation assays to identify ASPP/PP1 target
sites would be an unbiased phospho-proteome analysis. In collaboration with Dr Bram
Snijders, Dr Helen Flynn and Dr Steven Howell, I have prepared whole fly lysates
of ASPPd mutant and wild type flies for post-labelling and subsequent phospho-
proteome analysis. This approach has not proceeded further than a technical proof-
of-principle phase. Although there are limitations, such as the difficulty of phospho-
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site identification on low-abundance proteins in a complex mixture, this might prove
to be a fruitful avenue for the discovery of novel substrates for any PP1 holoenzyme
subunit.
4.3.3. Is Baz dephosphorylated by ASPP/PP1 in vivo?
The second in vitro dephosphorylation assays revealed seven additional ser-
ine/threonine residues that might be dephosphorylated in Baz. To test if these play
a role in localising Baz to the membrane in vivo, the S2 cell based assay would be
one possible option. An alternative would be to generate transgenic flies express-
ing phospho-mimicking Baz and test their junctional localisation and whether their
expression in the eye phenocopies ASPP mutants. It might be necessary to per-
form these experiments in a baz null background, as Baz can oligomerise (Benton
and St Johnston 2003) and wild type Baz might rescue any functional defect of the
phospho-mimicking Baz. It is also probable that multiple phosphorylation sites might
need to be targeted to observe a robust effect.
To test whether the Baz mislocalisation in ASPP mutant mitotic clones is truly due
to loss of the ASPP/PP1 complex, rather than a PP1-independent function of ASPP
(Fig. 4.7), an alternative experiment could also be carried out. In the case of PP1
dependence, Baz should be mislocalised in ASPP-FA rescue tissue as it is in ASPP
mutant tissue. However, the anti-Baz antibody was not sensitive enough to detect any
difference in localisation (data not shown). Thus, the Baz-GFP line (Fig. 4.7) could
be used instead. The GFP fluorescence signal of Baz-GFP reports small differences in
Baz intensity better than the antibody due to superior signal-to-noise ratio (compare
Fig. 4.7 to Fig. 4.8.).
Additionally, phospho-specific antibodies could be generated to show that hyper-
phosphorylated Baz accumulates in ASPP null mutant tissue. Anti-pS980 antibody
can detect endogenous Baz in vivo (Morais-de Sá et al. 2010, Walther and Pichaud
2010). Thus, it would be possible to test if S980, or other hyperphosphorylation
(e.g., S1176) is observed in ASPP-FA mutant mitotic clones. I will discuss the po-
tential functional implications of Baz dephosphorylation by ASPP/PP1 in the main
discussion (see 6.3).
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Regulators and substrates of the
ASPP/PP1 complex
In Chapter 4, I applied a targeted approach and tested two potential substrates of
the ASPP/PP1 complex based on protein-protein interaction data from mammalian
systems. The discovery of Ccdc85 as a subunit of the PP1 holoenzyme showed that
unbiased approaches are valuable for identifying novel interactors of the ASPP/PP1
complex.
In this chapter, I explore potential leads from publicly available unbiased interac-
tion screens. I describe two potential regulators of RASSF8/ASPP (Wts and Seven
in Absentia—Sina) and an additional scaffold (Magi) that may anchor RASSF8 at
cell-cell junctions. Furthermore, in GFP-ASPP pull-downs from Drosophila heads, I
identified several potential novel ASPP interactors, which are specific to the central
nervous system. Lastly, I use a genetic modifier screen based on available protein-
protein interaction data to identify further potential targets and regulators of the
ASPP complex.
5.1. Wts phosphorylates RASSF8
In a genome-wide yeast two-hybrid screen, RASSF8 was shown to bind to Wts (Giot
et al. 2003). Based on this result, Julien Colombani, who worked on ASPP and
RASSF8 in our lab, tried to confirm this interaction in co-IP experiments, but never
succeeded (Julien Colombani—unpublished observations). More recently, a collab-
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Figure 5.1.: RASSF8 is phosphorylated by Wts on S209
(A) Domain structure of RASSF8. The RA domain was identified by SMART (Letunic
et al. 2012). The coiled coil regions were predicted by jpred3 (Cole et al. 2008). The
RASSF8 sequence surrounding S209 fit to the Wts consensus phosphorylation motif
and to a mode I 14-3-3 binding motif. (B, C) Western blots of S2 cell lysates. Cells
were transfected with the indicated constructs/dsRNAs. Western blots were probed
with the indicated antibodies. (B) RASSF8 shows mobility shift, when co-expressed
with Hpo. Mobility shift is abolished, when Wts is knocked-down. The RASSF8 S209A
mutant does not shift when co-expressed with Hpo. (C) The anti-pS209 antibody can
detect phosphorylation of RASSF8.
orator, Dr Cathie Pfleger (Mount Sinai Hospital, New York) found RASSF8 in a
biochemical screen for Wts kinase substrates. As a substrate, RASSF8 would not
have to associate with Wts at high affinity to be efficiently phosphorylated (Pinna
and Ruzzene 1996), potentially explaining the negative co-IP result. With this infor-
mation in hand, I decided to re-examine the relationship between Wts and RASSF8.
5.2. Wts phosphorylates RASSF8 at S209
To confirm the result from the Wts kinase substrate screen, I conducted gel mobility
shift assays using hand-cast SDS-PAGE gels. In these assays, phosphorylated proteins
can migrate differentially compared to the non-phosphorylated form. Co-transfection
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Figure 5.2.: RASSF8 S209 phosphorylation generates a 14-3-3 binding site
Western blots of co-IP experiments using anti-FLAG antibody-coupled beads from S2
cell lysates. Cells were transfected with the indicated constructs/dsRNAs. Western
blots were probed with the indicated antibodies. 14-3-3ε (A) and 14-3-3ζ (B) bind
to RASSF8 but not RASSF8 S209A, when co-transfected with Hpo. For 14-3-3ε and
14-3-3ζ binding to RASSF8, phosphorylation by Wts is required.
of RASSF8 with Hpo in S2 cells resulted in reduced mobility (upward shift) compared
with RASSF8 alone, suggesting that RASSF8 is phosphorylated upon Hpo expression
(Fig. 5.1B). The rationale for co-expressing Hpo instead of Wts is that exogenous Wts
is not highly active in S2 cells, while Hpo and MST kinases can homodimerize and
potently self-activate upon overexpression (Avruch et al. 2012). Expression of Hpo
then activates endogenous Wts (Wu et al. 2003). To test whether Wts is required for
the Hpo-induced RASSF8 mobility shift, I used RNAi to deplete Wts in cells over-
expressing Hpo. Upon Wts depletion, Hpo was no longer able to induce a RASSF8
mobility shift (Fig. 5.1B). This is consistent with the idea that Wts rather than Hpo
can phosphorylate RASSF8.
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Drosophila RASSF8 has only one serine, S209, that fits the Wts consensus motif
(H-x-x-[HKR]-x-[ST], Hao et al. 2008). I mutated this serine and tested the resultant
mutant (RASSF8 S209A) for the Hpo-induced mobility shift. Interestingly, the S209A
mutant was no longer able to shift upon Hpo co-expression (Fig. 5.1B). Lastly, I raised
a phospho-specific antibody using a pS209 peptide (see Materials and Methods). This
antibody only recognized RASSF8 when it was co-transfected with Hpo, but not the
RASSF8 S209A mutant, even when co-expressed with Hpo (Fig. 5.1C). Together,
these results suggest that Wts can phosphorylate RASSF8 at S209.
5.3. Wts phosphorylation generates a 14-3-3 binding
site
Wts phosphorylation of Yki at S168 creates a 14-3-3 binding site (Dong et al. 2007,
Oh and Irvine 2008 and 1.4.2). RASSF8 phosphorylation by Wts might also promote
14-3-3 binding, analogously to Yki. This hypothesis is supported by the observa-
tion that the S209 phosphorylation site (Fig. 5.1A) fits to a mode I 14-3-3 binding
site (Johnson et al. 2010).
Indeed, RASSF8 could bind to both Drosophila 14-3-3 isoforms (ε and ζ) when
co-expressed with Hpo (Fig. 5.2A, B). Under the same conditions, RASSF8 S209A
did not bind to 14-3-3 (Fig. 5.2A, B). Binding between RASSF8 and 14-3-3 ε and ζ
is dependent on S209 phosphorylation, as co-transfection with Hpo while knocking-
down Wts abrogates binding (Fig. 5.3C). In summary, these experiments suggest that
phosphorylation of RASSF8 S209 by Wts creates a 14-3-3 binding site.
5.4. Wts phosphorylation does not change binding to
known interaction partners
14-3-3 protein binding is thought to have three potential consequences for the tar-
get protein (Bridges and Moorhead 2005): (1) Binding to 14-3-3 can cause confor-
mational changes, (2) 14-3-3 can displace other binding partners by occupying the
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Figure 5.3.: RASSF8 phosphorylation by Wts does not inhibit binding to ASPP,
Baz, Magi, WAVE or Sec15
Western blots of co-IP experiments using anti-FLAG antibody coupled beads from S2
cell lysates. Cells were transfected with the indicated constructs. Western blots were
probed with indicated antibodies.
(A) All known interactors co-IP with RASSF8 and RASSF8 S209A equally well. Co-
transfection with Hpo ensures that S209 of RASSF8 is phosphorylated.
(B, C) Deletions of RASSF8 where residues 135–213 (RASSF8-Δ1) and 180–220
(RASSF8-Δ2) were replaced with the two residues GS show no difference in binding
to known RASSF8 interactors.
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same binding surface or (3) the 14-3-3 dimer brings together two interaction part-
ners with each 14-3-3 monomer binding to one partner. Given the numerous ver-
ified interactors of RASSF8, I decided the test if 14-3-3 binding would affect their
association with RASSF8. Additional to ASPP and Baz (as mentioned in previous
chapters), RASSF8 binds to the junctional scaffold Magi (see 5.3), the exocyst compo-
nent Sec15 (Eunice Chan—unpublished observations) and the Arp2/3 (Actin-related
protein)-activating protein WAVE (WASP family Verprolin-homologous protein) (Eu-
nice Chan—unpublished observations). When Hpo was co-expressed with RASSF8
to phosphorylate S209, none of the interactors were displaced (Fig. 5.3A). All bound
to RASSF8 to a similar extend as to RASSF8 S209A. This result shows that phos-
phorylation of S209 is insufficient to affect binding between RASSF8 and its known
interactors.
Using an overexpression approach as in Fig. 5.3A, it is difficult to obtain a stoi-
chiometric RASSF8/14-3-3 complex where all RASSF8 proteins are phosphorylated
and bound to 14-3-3. Indeed, a relatively small proportion of overexpressed RASSF8
is associated with 14-3-3 in Fig. 5.2A, B. This is a confounding factor that may
mask an effect of 14-3-3 binding of RASSF8 to its partners. Clearly, phosphorylation
of RASSF8 alone was not sufficient to affect binding to its interactors, as most of
RASSF8 is phosphorylated, indicated by the complete shift of RASSF8 upon Hpo
expression (Fig. 4.1B). Thus, to test the importance of the 14-3-3 binding surface of
RASSF8 in interacting with its known partners, I generated two RASSF8 deletion
mutants that lacked the 14-3-3 binding site. In the two mutants, residues 135–213
(RASSF8-Δ1) and 180–220 (RASSF8-Δ2) were replaced with two residues, GS. How-
ever, both mutants could bind to ASPP, Baz, Magi (Fig. 5.3B), Sec15 and WAVE
(Fig. 5.3C) to a similar degree as wild type RASSF8. These results shows that the
know interactors do not rely on the region surrounding the 14-3-3 binding site to bind
to RASSF8. Thus, it suggests that 14-3-3 binding to RASSF8 may not affect their
ability to interact with RASSF8.
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5.5. The in vivo function of RASSF8 phosphorylation
remains unclear
Since RASSF8 phosphorylation and 14-3-3 binding did not seem to have an effect
on association with its known interaction partners, I decided to test in vivo whether
RASSF8 function is dependent on phosphorylation. Thus, I generated C-terminally
GFP-tagged RASSF8 and RASSF8-SA for targeted insertion using the PhiC31 in-
tegrase system. The constructs were inserted into the genome on chromosome 3L.
The two insertion lines (ubi-RASSF8 and ubi-RASSF8-SA) were recombined with
the RASSF86 null-allele.
Initially, I verified that both GFP-tagged forms of RASSF8 were expressed and lo-
calised to adherens junctions. In larval wing imaginal discs, RASSF8 and RASSF8-SA
co-localised with E-cadherin at adherens junctions (Fig. 4A, B). The S209A muta-
tion did not interfere with correct localisation. To test if S209 phosphorylation could
mislocalise RASSF8, I expressed Wts in the posterior compartment of the wing using
the en-GAL4 driver. Wts expression caused a notable reduction in the size of the
posterior compartment (Fig. 5.5A, A’), but had no influence on RASSF8 localisation
(Fig. 5.5A, B).
Furthermore, both transgenes were able to rescue the rough eye phenotype (data
not shown) of RASSF86 adult flies and restored wing roundness (Fig. 5.6A-E).
Wing size was not significantly different between RASSF86 flies and the rescued flies
(Fig. 5.6F). There was a small difference in wing roundness between ubi-RASSF8
and ubi-RASSF8-SA, though given the modest size of this effect, its biological rel-
evance is questionable (Fig. 5.6E). In summary, these results suggest that RASSF8
phosphorylation by Wts does not influence its junctional localisation and that S209
phosphorylation is dispensable for wing and eye morphogenesis. Although 14-3-3 can
bind to RASSF8 upon phosphorylation in S2 cells, the biological significance of this
interaction remains unclear.
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Figure 5.4.: GFP-tagged RASSF8 and RASSF8-SA are localised at adherens
junctions
Confocal X-Y sections (A–A”, C–C”) and transverse sections (B–B”, D–D”) of third
instar imaginal wing discs stained with anti-E-cadherin antibody. Scale bar represents
50 μm (A–A”, C–C”) and 10 μm (B–B”, D–D”). GFP-tagged RASSF8 and RASSF8-SA
co-localise with E-cadherin at adherens junctions.
Figure 5.5.: RASSF8 localisation is unaffected by Wts expression
Confocal X-Y section (A, A’) and transverse section (B, B’) of a third instar wing
imaginal disc stained with anti-RASSF8 antibody. Scale bar represents 20 μm (A, A’)
and 10 μm (B, B’). Expression of Wts with en-GAL4 does not influence the localisation
of RASSF8.
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Figure 5.6.: RASSF8 and RASSF8-SA expression rescue the wing shape defect
of RASSF8 mutant
(A–D) Adult wings of the indicated genotypes. RASSF8 null mutant wings (B) are
rounder than wild type wings (A). RASSF8 (C) and RASSF8-SA (D) expression in
RASSF8 null backgrounds rescues the wing shape defect.
(E) Quantification of wing roundness (ratio of proximal-distal axis and ante-
rior/posterior). An unpaired t-test showed that mean wing size in ubi-RASSF8 and
ubi-RASSF8-SA differ significantly from each other. * indicates p<0.05. At least 20
wings were counted per genotype.
(F) Quantification of wing sizes normalised to RASSF8 rescue wings. A one-way
ANOVA test indicated that the differences among means were not significant (p>0.05).
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5.5.1. Degradation of ASPP by the proteasome
With the identification of RASSF8 and Ccdc85 as bona fide components of the
ASPP/PP1 complex, it is possible to search for common interactors identified in
public datasets with all proteins of the holoenzyme. Genome-wide interactor screens
are often plagued with high false positive rates. However, proteins that interact with
more than one subunit of the ASPP/PP1 holoenzyme are more likely to be true posi-
tives. One such interactor is the RING domain containing E3 ubiquitin ligase Sina (Li
et al. 1997). Three interactions discovered in yeast two-hybrid screens pointed at
Sina as a regulator of ASPP/PP1: (1) The human Sina orthologue SIAH1 binds to
ASPP2 (Wang et al. 2011a), (2) Drosophila Sina binds to RASSF8 (Giot et al. 2003)
and the closely related Drosophila Sina homologue (SinaH) binds to Ccdc85 (Giot
et al. 2003).
Human ASPP2 is ubiquitylated and degraded by the proteasome (Zhu et al.
2005). However the responsible E3 ligase was not known when I started examining
ASPP/PP1 regulation. Thus, I decided to test if Sina can ubiquitylate and degrade
the ASPP/PP1 complex. Jennifer Banerjee from our lab performed the in vivo Sina
experiments shown below. During our work, another group confirmed that human
ASPP2 could be ubiquitylated by SIAH2 and degraded by the proteasome (Kim et al.
2014).
5.5.2. Sina binds to ASPP and mediates its degradation
First, I tested if Sina could bind to ASPP. Co-transfecting ASPP with Sina in S2
cells lead to the degradation of ASPP (Fig. 5.7A). However, there was a detectable
amount of ASPP binding to a Sina C87A (Fig. 5.7A), a mutant that is catalytically
inactive (Hu and Fearon 1999) due to its impaired binding to one of the catalytic
Zn2+-cations. Furthermore, ASPP levels were comparable between co-expressing
ASPP with GFP or Sina C87A, suggesting that Sina C87A was indeed inactive.
Additionally, when the proteasomal inhibitors MG132 and LLnL were added to
S2 cells, ASPP degradation upon Sina co-expression was reduced (Fig. 5.7B). A
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Figure 5.7.: Sina binds to ASPP and induces ASPP degradation
Western blots of co-IP experiments using anti-FLAG antibody coupled beads from S2
cell lysates (A), or just S2 cell lysates (B). Cells were transfected with the indicated
constructs. Western blots were probed with indicated antibodies. (A) ASPP binds to
the catalytically inactive Sina C87A mutant. Co-transfection of Sina and ASPP lead
to the degradation of ASPP.
(B) Treatment of S2 cells with the proteasome inhibitors MG132 and LLnL stabilises
ASPP and Sina. A smear indicates possible ubiquitylation of ASPP.
smear was observed above the ASPP band on Western blots, potentially indicating
ubiquitylation. MG132/LLnL also stabilised ASPP but not GFP, without Sina co-
transfection, suggesting that endogenous Sina (or another E3 ligase) may control
ASPP levels in S2 cells. Together, the above results provide in vitro evidence that
Sina can bind to ASPP to ubiquitylate and degrade ASPP via the proteasome.
5.5.3. Sina reduces ASPP and RASSF8 levels in vivo
To show that Sina can regulate ASPP levels in vivo, Jennifer Banerjee expressed Sina
using the ptc-GAL4 driver in larval wing imaginal discs. Using antibodies to detect
endogenous ASPP and RASSF8, she could observe a reduction of ASPP (Fig. 5.8A–
A’) and RASSF8 levels (Fig. 5.8C–C’). The adherens junctions were not obviously af-
fected. Levels of Arm, the Drosophila orthologue of the transcription factor β-catenin
that is a core component of adherens junctions, were unchanged (Fig. 5.8A”, C”). The
reduction of ASPP and RASSF8 levels was dependent on the enzymatic function of
Sina, since a Sina mutant that lacked the catalytic RING domain (Sina-ΔRING) had
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Figure 5.8.: Sina expression in vivo leads to the degradation of ASPP and
RASSF8
Confocal X-Y sections of larval wing imaginal discs stained with indicated antibodies.
Scale bar represents 50 μm.
Expression of Sina using ptc-GAL4 driver causes the degradation of ASPP (A’) but not
arm (A”). Similarly, RASSF8 is degraded when Sina is expressed (D’), but E-cadherin
is not (D”). Sina that lacks its catalytic RING domain can neither degrade ASPP (B’)
nor RASSF8 (D’).
These experiments were performed by Jennifer Banerjee.
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no effect (Fig. 5.8B, D). These results show that in vivo, Sina can regulate ASPP and
RASSF8 levels.
5.6. Magi, a junctional scaffold protein binds to
RASSF8
Another potential interactor of the ASPP/PP1 complex is Magi, a PDZ and WW
domain containing junctional protein: (1) In a yeast two-hybrid screen for Droso-
phila RASSF8 interactors performed in the lab (Eunice Chan—unpublished obser-
vations), RASSF8 specifically bound to the two WW domains of Magi and (2) a
human ASPP2 peptide containing its PPXY motif, a common WW domain bind-
ing motif, could bind to MAGI1 (Pirozzi et al. 1997). Although Drosophila Magi is
largely uncharacterised (Beller et al. 2002), the human orthologues of Magi are known
to associate with multiple junctional proteins through their PDZ and WW domains
and are thought to be a junctional scaffolds (Shin et al. 2006). Through Magi, the
ASPP/PP1 complex could be connected to other junctional proteins.
5.6.1. RASSF8 binds to Magi via its PPXY motif
First, I tested in co-IP experiments if Drosophila Magi could bind to RASSF8 or
ASPP. Under these conditions only RASSF8, but not ASPP could co-IP with Magi
(Fig. 5.9B). However, ASPP was able to bind to Magi via RASSF8, thereby forming
a trimeric complex.
The yeast two-hybrid data suggested that RASSF8 could directly bind to the WW
domain of Magi (Fig. 5.9A). Indeed, RASSF8 has a PPXY motif (Fig. 5.9A) that
is conserved in orthologues of RASSF8 in other insects, but not in human RASSF7
or RASSF8. Using co-IP experiments, I showed that RASSF8 does indeed associate
with Magi in S2 cells (Fig. 5.9B). When Y297 of the PPXY motif of RASSF8 was
mutated to alanine, Magi could no longer bind to RASSF8 (Fig. 5.9C). Conversely,
when both WW domains were deleted in Magi, RASSF8 could no longer bind to Magi
(Fig. 5.9D). Mutating either of the conserved prolines of the WW domains of Magi
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Figure 5.9.: Magi binds to the PPXY motif of RASSF8 via its WW domains
(A) Domain structure of RASSF8 showing its PPXY motif and domain structure of
Magi. Magi has two WW domains and four PDZ domains. Domain annotation taken
from Uniprot. Red line indicates minimal fragment that was able to bind to RASSF8
in a yeast two-hybrid assay.
(B–D) Western blots of co-IP experiments using anti-FLAG antibody coupled beads
from S2 cell lysates. Cells were transfected with the indicated constructs. Western
blots were probed with indicated antibodies.
(B) RASSF8 co-IPs with Magi and can bridge the interaction between ASPP and Magi.
(C) Magi co-IPs with RASSF8 but not with RASSF8 Y297A, mutant for the PPXY
motif.
(D) Both WW domains of Magi are required for binding to RASSF8. When both WW
domains are deleted (ΔWW) or a key proline of either WW domain is mutated, RASSF8
can no longer bind to Magi.
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was also sufficient to abolish binding to RASSF8, suggesting that RASSF8 could bind
to either WW domain. Together, these results show that Magi and RASSF8 can bind
to each other via a PPXY motif/WW domain interaction.
Dr Alexandre Djiane, a collaborator, is investigating the in vivo relevance of the
Magi-RASSF8 interaction. The result of this study will be presented elsewhere. It
does appear that Magi mutants present many phenotypic similarities with RASSF8
and ASPP mutants.
5.7. Identification of novel binding partners of ASPP
ASPP is at the centre of the ASPP/PP1 complex. Through its RVXF motif, it can
directly bind to PP1. At the same time it might serve as a platform to extend the
reach of PP1, or for the complex to be tethered to scaffolds and regulators (such as
RASSF8 and Ccdc85). Unbiased AP-MS approaches in human HEK293 cells have
proven successful in identifying novel interactors of the ASPP/PP1 complex. Ccdc85,
a protein that had not been associated to ASPP or PP1 function before, was found to
be associated (see Chapter 3). To identify novel and tissue-specific binding partners
of ASPP in Drosophila, I pulled down HA-tagged ASPP from Drosophila adult heads
and embryos and sent all bound protein to the LRI Protein Analysis and Proteomics
facility for identification of the binding partners.
5.7.1. Several CNS specific potential interactors of ASPP were
identified
The obtained data was analysed using ProHits. For the identified proteins from adult
heads (Fig. 5.10A), proteins that were found in previous experiments using the same
tissue but unrelated baits were excluded. For embryos, no similar experiments had
been performed in the lab, thus all results are shown (Fig. 5.10B). Overall, data
quality of the adult fly head experiment was higher. More peptides were identified
for ASPP (the bait) and two known interactors, PP1α96A and RASSF8, were found.
Furthermore, PP1α96A only co-purified with ASPP but not ASPP-FA. In the pull-
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Figure 5.10.: AP-MS experiment with ASPP as bait recovers PP1α96A and
RASSF8
Table of potential ASPP interactors recovered in AP-MS experiments from tub-
GAL4>UAS-ASPP-HA, tub-GAL4>UAS-ASPP-FA-HA or tub-GAL4> (ctrl.) adult
head tissue (A) and embryos (B). HA-antibody-coupled beads were used for pull-down
of ASPP. Identified proteins were filtered to exclude metabolic enzymes, heat-shock
proteins, mitochondrial proteins, and extracellular proteins. All proteins with more
than 3 identified peptides in ASPP or ASPP-FA pulldowns are shown.
(A) ProHits was used to filter out any proteins that were identified in previous experi-
ments done in the lab with other, unrelated baits (other). Known interactors marked
with bold letters. RASSF8 was not identified using ProHits but only using a different
search engine (Scaffold). * RASSF8 was found with ASPP and ASPP-FA as bait. All
other proteins were identified by ProHits and Scaffold.
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down from embryos, only RNA binding proteins (Fne, Ssx, Yps, PUf68 and CG13900)
and a lipid droplet associated protein, Jabba, were identified. All these proteins are
likely to be very abundant in embryos, suggesting they might constitute artefacts.
Analysis of further pull-downs from embryos using unrelated baits would reveal if
they were specifically binding to ASPP.
In contrast, for adult heads, I could filter out all proteins that are highly abundant
in eye and brain tissue by comparing the ASPP pull-downs with pull-downs of un-
related proteins, performed in the lab. While some of the remaining interactors are
head or CNS-specific such as CG43367, PIP82, Liprin-α, CG10362 and Boss, other
interactors are ubiquitously expressed (Celniker et al. 2009). In summary, I used
AP-MS experiments in specific Drosophila tissues to identify potential novel inter-
actors of ASPP. Identifying known binding partners such as PP1α96A and RASSF8
among novel interactors gave confidence in the quality of the data. Together, this
suggests that it is possible to use the AP-MS approach to identify tissue specific
scaffolds, regulators and substrates of the ASPP/PP1 complex.
5.8. A genetic modifier screen identified modulators
of the ASPP rough eye phenotype
Additionally to the publicly available interactor databases, we have carried out in-
teractome screens for ASPP and N-terminal RASSF family proteins ourselves (see
above) and together with collaborators (Hauri et al. 2013). To test if any of these
potential interactors could be regulators or substrates of the ASPP/PP1 complex,
I decided to screen for modifiers of the ASPP/PP1-dependent rough eye phenotype
using genomic deficiency lines (see Appendix B for full list of interactors screened).
For non-Drosophila interactors, the closest orthologues were determined by BLAST
searches. The fly crosses and subsequent screening were done by Nic Tapon.
All genomic deficiency lines were crossed to flies expressing GMR-GAL4 -driven
ASPP RNAi (Fig. 5.11B). The screened flies were heterozygous for the deficiency.
Thus, any observed modification of the ASPP RNAi phenotype was caused by reduc-
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Figure 5.11.: A modifier screen identified potential regulators and targets of
ASPP/PP1 in the eye
Scanning electron micrograph of adult fly eyes and close-up view of ommatidia. The
regular patterning in wild type flies (A, A’) is disrupted when ASPP is knocked down
(B, B’). Heterozygous genomic deficiencies were screened for modification of the ASPP
RNAi phenotype. Examples of suppressors (C–D’) and enhancers (E–E’) shown. All
flies were kept at 29 ◦C for stronger expression of ASPP RNAi. Scale bar for (A–F)
represents 100 μm, for (A’-F’) 30 μm.
178
Chapter 5. Regulators and substrates of the ASPP/PP1 complex
ing gene dosage by half. Out of 58 deficiency lines we recovered 16 enhancers and 2
suppressors (examples in Fig. 5.11C-F). The strongest suppressor was I-2, an inhibitor
of PP1 (Fig. 5C, C’). This validated the rationale of the screen, as it suggested that
the lack of ASPP/PP1 activity in ASPP RNAi flies could be rescued when general
PP1 activity was increased. This result confirms that ASPP is a regulatory subunit of
a PP1 complex and activates the catalytic function of PP1. In summary, the modifier
screen was able to identify a subset of genes that might be regulators or effectors of
the ASPP/PP1 complex, additional to being physical interactors.
As most deficiencies deleted more than one gene, it is possible that the observed
effects were caused by the heterozygosity of neighbouring genes. Thus, further exper-
iments with single gene mutants are required to confirm that the potential interactors
were modifying the ASPP RNAi phenotype and not neighbouring genes. If any of
these genetic interactions are confirmed, the corresponding candidates could be tested
as potential modulators or targets of the ASPP/PP1 complex in further work.
5.9. Concluding remarks and future directions
In this chapter I have explored three interactors and potential regulators of RASSF8
and ASPP. The in vivo function of these interactors remains unclear and it is
possible that they could only affect RASSF8 and ASPP independently from their
PP1-function. Additionally, I complemented the AP-MS experiments from Matthias
Gstaiger’s lab in human HEK 293 cells with comparable experiments using Droso-
phila tissues. This allowed me to identify several potential novel ASPP interactors.
Lastly, we tested if missing one genomic copy of all identified interactors could mod-
ify the ASPP dependent rough eye phenotype. Further experiments will be required
to validate if the hits from the screen could modify ASPP/PP1 function or serve as
substrates. In the next chapter I will summarise the findings of this thesis and discuss
the function of the ASPP/PP1 in the context of previous work.
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Figure 5.12.: Model of RASSF8 as an effector of Hippo signalling
Wts might activate the inhibitory function of RASSF8 in proliferation and cell survival
by phosphorylation.
5.9.1. What is the role of RASSF8 S209 phosphorylation?
Although known RASSF8 interactors were not affected by RASSF8 S209 phosphory-
lation and the deletion of the region surrounding the 14-3-3 binding site (Fig. 5.3),
it is possible that other as yet unidentified interactors might associate with RASSF8
differentially when 14-3-3 is bound. Since RASSF8 is a scaffold protein, two scenarios
can be considered. 14-3-3 might increase or decrease the binding affinity of RASSF8
to its partners. Pull-down experiments with either RASSF8 or a RASSF8/14-3-3
complex as baits coupled to mass spectrometry for the identification of differential
binding partners could be carried out. The main technical difficulty of such an ap-
proach is to generate a sufficient amount of a stoichiometric complex of RASSF8 with
14-3-3 to serve as bait. Alternatively, RASSF8 or a RASSF8 deletion mutant, lacking
the 14-3-3 binding region could be used as baits. One potential confounding factor of
this approach is that 14-3-3 might not act by directly competing with a RASSF8 part-
ner for the same binding surface, but might instead induce a conformational change
in RASSF8 that could alter its interaction profile. The former experiment has the
benefit of being able to identify interactors that increase or decrease binding affinity
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when 14-3-3 is bound to RASSF8, while the latter can only detect interactors that
have a decreased affinity to the RASSF8/14-3-3 complex.
It is also possible that 14-3-3 might be bridging RASSF8 and Baz (Benton and
St Johnston 2003), which is known to bind to 14-3-3, although this was not apparent
using overexpressed proteins (Fig. 5.3A). Lastly, it is possible that phosphorylation
can cause RASSF8 to localise to other regions within the cell. However, this might
be context dependent and for example only happen when oncogenic Ras is present
(for more detailed discussion, see 6.7).
Additional in vivo experiments could be carried out to determine the func-
tion of RASSF8/14-3-3 complexes. It is possible that Hippo signalling relies on
RASSF8/14-3-3 as downstream effectors (Fig. 5.12). Based on RASSF8 null mu-
tant phenotypes, RASSF8 seems to inhibit proliferation or promote apoptosis (Lang-
ton et al. 2009). Additionally, the strong genetic interaction between RASSF8 and
kib in regulating IOC numbers (Fig. 4.1) suggests that Wts might act on Yki and
RASSF8/14-3-3 in parallel to inhibit proliferation and promote apoptosis. This model
predicts that RASSF8, but not RASSF8-SA can rescue the synergistic increase of
IOCs of kib and RASSF8 null mutants. In this or similar sensitised backgrounds for
activated or inhibited hippo signalling, the role of RASSF8 phosphorylation could
be uncovered. Lastly, the rescue observed with ubi-RASSF8-SA (Fig. 5.6) might be
due to the use of the ubiquitin promoter rather than the endogenous RASSF8 pro-
moter. Therefore, generating a knock-in allele of RASSF8-SA using genome editing
techniques might reveal a phenotype for this mutation.
5.9.2. Where is the ASPP/PP1 complex regulated by Sina?
Expressing Sina in larval wing imaginal discs reduced the levels of ASPP and RASSF8
(Fig. 5.8). However, it is not known in which physiological contexts Sina could be
required for ASPP and RASSF8 regulation. Sina has a well established role in speci-
fying the neuronal cell fate in photoreceptors (Carthew and Rubin 1990) and sensory
organ precursors (Pi et al. 2001) through the degradation of the transcriptional re-
pressor Ttk (Li et al. 1997, Tang et al. 1997). However, Sina might have a much
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broader role, as it seems to be ubiquitously expressed in most tissues and develop-
mental stages (Celniker et al. 2009).
To address the question of tissue specificity, double mutants of sina and ASPP
could be analysed and compared to sina mutants. In sina mutants, some phenotypes
might be caused by an excess of ASPP. This would be rescued by removing ASPP.
Furthermore, the regulation of ASPP levels by Sina might explain why ASPP overex-
pression does not give any strong phenotypes (Paul Langton and Julien Colombani—
unpublished observations). To show that this is the case, ASPP could be expressed
in a sina mutant, or mutant ASPP that cannot bind to Sina could be expressed. To-
gether these experiments would shed light on the regulation of ASPP by proteasomal
degradation in physiological contexts.
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Discussion
In my thesis I have investigated constituents, substrates and regulators of the
ASPP/PP1 complex. In the concluding discussion I will briefly summarise my main
findings. To put my results into a broader perspective I will discuss the importance
of junctional localisation of ASPP/PP1, its role in modulating junction formation,
particularly through the dephosphorylation of Baz, and a potential evolutionary link
between ASPP family proteins and RASSF8.
6.1. Summary of results
Although the interaction between ASPP2 (then known as p53BP2) and PP1 was dis-
covered almost twenty years ago, (Helps et al. 1995), this connection has only received
more attention relatively recently (Liu et al. 2011, Llanos et al. 2011, Skene-Arnold
et al. 2013). Published research (see 1.3.5 and 1.4.3) established ASPP family proteins
as PP1 interactors (Egloff 1997, Helps et al. 1995, Llanos et al. 2011, Skene-Arnold
et al. 2013) and defined TAZ as a potential substrate of the ASPP/PP1 complex (Liu
et al. 2011). However, many questions remained unanswered. In my thesis I addressed
some of these questions, which can be grouped into three broad categories correspond-
ing to my three result chapters: (1) Constituents of the ASPP/PP1 holoenzyme, (2)
substrates and (3) regulation of ASPP/PP1.
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Figure 6.1.: Summary of findings
Drosophila ASPP interacts with PP1 via its RVXF motif and its SH3 domain. Addi-
tionally, the adaptor proteins RASSF8 and Ccdc85 can bind to the ASPP/PP1 core
complex. RASSF8 is associated to two junctional components, Baz and Magi, via its
PBM and PPXY motif respectively. Wts and Sina are potential regulatory inputs for
the ASPP/PP1 complex that could phosphorylate RASSF8 and ubiquitylate ASPP.
In summary (Fig. 6.1), I have shown that, similar to human ASPP family pro-
teins, Drosophila ASPP interacts with PP1 via its RVXF motif (see 3.1.1) and its
SH3 domain (see 3.1.2). This interaction is important in vivo for ASPP function (see
3.2). I also showed that the adaptor proteins RASSF8 and Ccdc85 could bind to the
ASPP/PP1 core complex (see 3.3). Out of two tested substrates for the ASPP/PP1
complex, I found evidence that Baz might be dephosphorylated by ASPP/PP1. Bind-
ing is not direct, but mediated by the PBM of RASSF8 (see 4.2). Another junctional
protein, Magi, can also bind to RASSF8 (see 5.3.1). Lastly, I have identified Wts and
Sina as potential regulatory inputs into the ASPP/PP1 complex that could phospho-
rylate RASSF8 (5.1) and ubiquitylate ASPP (see 5.2) respectively. The function of
RASSF8 phosphorylation remains unknown, but ubiquitylation of ASPP leads to its
degradation (see 5.2).
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6.2. How is the ASPP/PP1 complex localised to
junctions?
As discussed in 1.2, a key role for PP1 regulatory subunits is to localise the catalytic
subunit to the correct subcellular localisation, in proximity to the substrate. The
localisation of ASPP and RASSF8 at adherens junctions in Drosophila (Langton et al.
2009) and of ASPP2 at tight junctions in mice and various mammalian cells (Cong
et al. 2010, Sottocornola et al. 2010) has been described before. However, it was
unclear how these proteins are localised to junctions. In this thesis, I described the
interactions of RASSF8 with two known junctional proteins, Baz (see 4.2) and Magi
(see 5.3) that might explain the anchoring of the ASPP/PP1 complex at the apical
junctions (adherens junctions in Drosophila and tight junctions in mammals).
The binding of human RASSF8 to PAR3 was mediated by its conserved PBM,
since only isoform A, which contains the PBM could pull-down PAR3 (see 4.2.2). It
is likely that this binding is conserved in Drosophila, as Drosophila RASSF8 has a
PBM as well (see 4.2.2). As Baz/PAR3 directly associates with the plasma mem-
brane by binding to phosphoinositide lipids (Horikoshi et al. 2011, Krahn et al. 2010,
Wu et al. 2007a), RASSF8 could be anchored via Baz/PAR3. It is possible that
RASSF8 becomes restricted to the apical junction together with Baz/PAR3, which
is specifically localised by multiple phosphorylation reactions (see 1.5.3). ASPP, PP1
and Ccdc85 could be subsequently localised to the apical junction via RASSF8. This
would predict that not only ASPP (Langton et al. 2009), but also PP1 (or at least
a pool of PP1 that is part of the ASPP/PP1 complex) and Ccdc85 should be mislo-
calised when RASSF8 is lost. An attractive model is that Baz/PAR3 not only recruits
the ASPP/PP1 complex to the apical junction, but ASPP/PP1 in turn could stabilise
Baz.
Whether the binding of RASSF8 to Magi could provide a membrane anchor for
RASSF8 and the ASPP/PP1 complex in Drosophila is less clear. Although the mam-
malian MAGI1 isoform is associated with the plasma membrane at tight junctions
via the adhesion molecule JAM4 (Hirabayashi et al. 2003), this is unlikely to be the
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case in Drosophila, as JAM family adhesion molecules are not conserved. Conversely,
RASSF8 is unlikely to be the only membrane anchor for Magi (via Baz) in Drosophila,
as loss of RASSF8 has no effect on Magi localisation (Alexandre Djiane—unpublished
observations). Further work on Drosophila Magi might reveal interactors that can
directly bind to the plasma membrane. The situation in mammals is probably dif-
ferent from Drosophila, as the PPXY motif of RASSF8, which is necessary for the
interaction with Magi, is not conserved. It is possible that the ASPP/PP1 complex
associates with mammalian MAGI isoforms via ASPP1 or ASPP2 instead of RASSF8
(see below).
By binding to other junctional scaffolds via their WW and PDZ domains, Baz and
Magi could incorporate RASSF8 and possibly the ASPP/PP1 complex in a bigger
junctional scaffold protein network. The resulting spatial proximity of PP1 with
other junctional proteins is equivalent to an increased junctional concentration. The
proximity could be sufficient to promote the dephosphorylation of the junctional
proteins nearby. This hypothesis could be tested. For instance, ASPP-FA rescue
mutants would then be expected to have hyperphosphorylated junctional proteins,
which could be revealed in whole fly phospho-proteome analyses (as mentioned in
4.3.2). In the next section I will discuss the potential influence of ASPP/PP1 on one
particular junctional protein, Baz.
6.3. What is the role of Baz dephosphorylation?
It is not yet clear, if the Baz mislocalisation in ASPP null mutant mitotic clones is
entirely due to reduced Baz dephosphorylation by PP1 function. This could be tested
in several ways (see 4.3.3). However, even if the mislocalisation in this specific experi-
ment was independent of dephosphorylation, it is still very likely that the ASPP/PP1
complex can dephosphorylate and regulate Baz/PAR3 in vivo, given that the ASPP
can bind to Baz via RASSF8 (see 4.2.2) and PP1 can dephosphorylate Baz/PAR3 in
vitro (see 4.2.6 and Traweger et al. 2008).
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Which sites could be dephosphorylated and what function would the dephosphory-
lation have? I will discuss four sets of possible dephosphorylation sites: (1) the aPKC
S980 site, (2) the Par1 S151 and S1085 sites, (3) potential Rho-kinase phosphorylation
sites and (4) T720, which was uncovered in the second in vitro kinase assay. These
sites are all conserved between Baz and PAR3. The focus on conserved phosphoryla-
tion sites is sensible since the Baz mislocalisation in ASPP mutant mitotic clones (see
4.2.1) is reminiscent of the reduction of PAR3 levels at tight junctions, when ASPP2
is lost (Cong et al. 2010, Sottocornola et al. 2010). If Baz/PAR3 mislocalisation was
dependent on PP1 function in both cases, the dephosphorylation sites involved are
likely to be conserved.
Dephospohrylation of S980
The most obvious residue that could be dephosphorylated by ASPP/PP1 is S980,
as S980 phosphorylation was strongly reduced by PP1 in vitro (see 4.2.6). However,
dephosphorylation of S980 by ASPP/PP1 does not fit with the observation that Baz
is mislocalised in ASPP mutant tissue. Instead of being mislocalised, S980 hyper-
phosphorylated Baz should rather be even more concentrated at adherens junctions,
as S980 phosphorylation promotes the dissociation of Baz from aPKC, thus removing
Baz from the sub-apical region (see 1.5.3). In follicle cells (Morais-de Sá et al. 2010)
and in photoreceptor cells (Walther and Pichaud 2010), S980E phospho-mimicking
mutant Baz localisation is indistinguishable from that of wild type Baz. Furthermore,
the only tissue, where expressing the phospho-mimicking mutant causes a phenotype
is in the oocyte, where Gurken protein, that is normally found in the anterior dorsal
corner, is mislocalised (Morais-de Sá et al. 2010). This subsequently leads to em-
bryos where the dorsal appendages are defective. If loss of ASPP caused Baz S980
hyperphosphorylation, this should lead to similar defects of the dorsal appendages
of ASPP null mutant embryos. However, during the collection of embryos for ASPP
AP-MS experiments (see 5.4), I did not detect any such defects (data not shown).
Thus, although ASPP/PP1 might dephosphorylate S980 in some situations, other
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residues would have to be dephosphorylated as well to explain the Baz mislocalisa-
tion phenotype.
Dephosphorylation of S151 and S1085
The second category of candidate residues for dephosphorylation by ASPP/PP1 are
the Par1 phosphorylation sites, S151 and S1085. In vitro PP1 was unable to de-
phosphorylate either S151 and S1085 (see 4.2.6) in contrast to similar experiments
using mammalian PP1 and PAR3 (Traweger et al. 2008). However, if ASPP/PP1
dephosphorylated S151 or S1085, this could explain the Baz mislocalisation, as phos-
phorylation of as S151 and S1085 phosphorylation leads to the removal of Baz from
membrane (see 1.5.3). Thus, the ASPP/PP1 complex could stabilise Baz at the
adherens junctions by dephosphorylating S151 or S1085. Since PP1 could not de-
phosphorylate S151 and S1085 in vitro, this hypothesis could be tested in vivo. Baz
junctional localisation could for instance be analysed in ASPP,par1 double mutants,
to test if loss of par1 compensates for ASPP loss-of-function.
Dephosphorylation of Rho-kinase phosphorylation sites
The third set of potential phosphorylation sites that could be targeted by ASPP/PP1
is the set of Rho-kinase phosphorylation sites at the C-terminus of Baz (Matos Simões
et al. 2010). Although the exact site or sites were not identified, truncation analyses
revealed that Rho-kinase is likely to phosphorylate residues close to the basic residues
that are required to bind to negatively charged phosphatidylinositides. The accumula-
tion of negative charges upon phosphorylation could counterbalance the basic residues
in the phosphoinositide binding patch, thereby causing loss of membrane association.
Since membrane attachment of Baz is observed in S2 cells (see 4.2.5) and can be
influenced by Rho-kinase expression (Matos Simões et al. 2010), it should be possible
to identify potential ASPP/PP1 dephosphorylation sites that are Rho-kinase tar-
get sites by expressing phospho-mimicking Baz mutants in S2 cells. The key residues
that are important for the association of PAR3 with phosphatidylinositides are K1013
and K1014 (Horikoshi et al. 2011), which are conserved in Drosophila (K1173 and
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K1174). The closest phosphorylatable serine/threonine residues of Baz are S1169,
S1170 and S1176. Interestingly, Baz S1176D was not localised to the plasma mem-
brane, but rather in intracellular vesicular structures in S2 cells (see 4.2.5). Whether
this mislocalisation has anything to do with phosphatidylinositol binding remains to
be determined. A complication is that none of these three residues is conserved in
PAR3. However, this may not be completely surprising, as Rho-kinase phosphory-
lation of T833 of PAR3, which is not close to its phosphatidylinositol binding site,
disrupts aPKC binding instead (Nakayama et al. 2008). Thus, if S1176 dephosphory-
lation were important for the attachment of Baz to the plasma membrane, this would
not explain why ASPP2 is important for the localisation of PAR3 at tight junctions.
Dephosphorylation of other phosphorylation sites
Lastly, of the sites that were uncovered in the dephosphorylation assays (see 4.2.6),
the best candidate residue is T720. The dephosphorylation of T720 was consistent be-
tween the label-free quantification and the dimethyl-labelled MS experiments. T720
seemed to be more efficiently dephosphorylated when ASPP, RASSF8 and Ccdc85
were present. T720 is conserved in PAR3 (T668). To test if this site is hyperphos-
phorylated when ASPP is lost, a phospho-specific antibody could be generated and
tested in ASPP mutant mitotic clones. In addition, T720E phospho-mimicking Baz
would be expected to be mislocalised in S2 cells and in vivo. Equivalent experiments
could be performed in mammalian cells using a T668E mutant form of PAR3. If none
of the above-mentioned sites turned out to be dephosphorylated by ASPP/PP1 in
vivo, the other sites that were dephosphorylated in vitro could be tested.
6.4. How does the activation of Csk by ASPP fit with
its role as PP1 regulatory subunit?
Our lab has reported that ASPP and RASSF8 can stabilise adherens junctions
through activating Csk, which restricts Src activity at the adherens junctions (Lang-
ton et al. 2007 2009). Supernumerary IOCs in ASPP and RASSF8 mutants, as well
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Figure 6.2.: Baz could recruit Csk to adherens junctions
(A) ASPP/PP1 could act independently on Baz and Csk. This could explain the genetic
interaction between ASPP and Csk (Langton et al. 2007), as well as the mislocalisation
of Baz in ASPP mutant tissue. Downstream, Baz and Csk are both involved in the
formation and maintenance of adherens junctions.
(B) Alternatively, ASPP/PP1 could only act on Baz, which in turn could recruit Csk,
similar to PAR3 (Wang et al. 2006). The binding site of Csk requires a phosphorylation
by Src in the case of PAR3 (Wang et al. 2006). This model is simpler as the first one,
as it involves Baz as a single ASPP/PP1 substrate for junctional remodelling.
as the defects in inter-IOC contacts during retinal morphogenesis had been attributed
to the ability of ASPP to activate Csk (Langton et al. 2007 2009). Indeed, in mam-
malian cells, Src has been reported to induce cadherin internalisation, both by direct
phosphorylatio, as in the case of VE-Cadherin (Gong et al. 2014), and via ubiquity-
lation by the Src-activated ligase Hakai in the case of E-cadherin (Fujita et al. 2002).
However, in my thesis I suggested that ASPP and RASSF8 were required for retinal
morphogenesis as part of an ASPP/PP1 complex that might dephosphorylate Baz.
Are these two models compatible with each other?
The simplest way to encompass both models is to hypothesise that ASPP/PP1
can act on Csk and Baz in parallel (Fig. 6.2A). ASPP/PP1 could activate Csk and
stabilise Baz by phosphorylation. Csk and Baz both then contribute to proper junc-
tion formation. In this model, ASPP/PP1 could activate Csk by dephosphorylation,
as loss of PP1 binding in ASPP leads to Csk dependent wing notching (see 3.2.3).
ASPP/PP1 is unlikely to dephosphorylate the only known serine/threonine phospho-
190
Chapter 6. Discussion
rylation site (S364 in human CSK), as its phosphorylation activates CSK (Vang et al.
2001). Thus other phosphorylation sites may be involved that could be identified by
in vitro dephosphorylation assays with Csk as substrate.
Alternatively, Csk activation could be dependent on Baz stabilisation (Fig. 6.2B).
For PAR3 it had been shown that EGF stimulation leads to the phosphorylation
of Y1127 of PAR3 via Src and another Src family kinase, Yes (Wang et al. 2006).
The phosphorylation creates a binding site for the SH2 domain of CSK (Songyang
et al. 1994). Thus, PAR3 might recruit CSK to tight junctions, where it inhibits Src
activity (Wang et al. 2006). A similar mechanism could act in Drosophila. ASPP
would stabilise Baz at adherens junctions by dephosphorylation and Src would phos-
phorylate Baz to create a Csk binding site. Csk would then bind to Baz and in turn
inhibit Src, thus stabilising adherens junctions. In this model, the Csk-dependent
wing notching in PP1 binding deficient ASPP rescue flies (see 3.2.3) could be due
to impaired Baz localisation, rather than Csk hyperphosphorylation, elegantly re-
ducing the number of dephosphorylation events required to explain the experimental
observations. However, Y1127 of PAR3 is not directly conserved in Baz, although
Y1284 of Baz fits an SH2 domain-binding consensus sequence (Songyang et al. 1994)
reasonably well. A few key experiments could be carried out to provide evidence for
this model. Most importantly, a Src phosphorylation site that promotes the binding
of Csk would need to be identified in Baz. Furthermore, Csk should co-localise with
ASPP and Baz and this localisation should be lost in the absence of Baz.
6.5. Does Drosophila ASPP have a nuclear function?
Although our lab has never observed Drosophila ASPP or RASSF8 localised any-
where else than at adherens junctions, it is possible that they could have a nuclear
role similar to human ASPP family proteins (see 1.3.2) and RASSF7 (see 1.3.8). Junc-
tional tethering may be conditional on cell type or proliferation status. The Ran-GDP
dependent nuclear localisation signal of ASPP1/2 (Lu et al. 2014) is conserved in Dro-
sophila ASPP. Thus, ASPP should be able to translocate into the nucleus. Whether
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Drosophila ASPP is able to promote p53 dependent transcription is doubtful, as key
residues that mediate binding of human ASPP1/2 to p53 are not conserved in Dro-
sophila ASPP (Langton et al. 2007). However, ASPP could have p53-independent
nuclear functions. It remains unclear, if ASPP, once in the nucleus, could bind to
PP1. It is possible that the nuclear function of ASPP is completely distinct from
its junctional role as PP1 regulatory subunit and it might for example serve as a
transcriptional co-factor (Aylon et al. 2010, Samuels-Lev et al. 2001). To check if
ASPP or RASSF8 can translocate to the nuclear in vivo, the transgenic ubi-ASPP
and ubi-RASSF8 flies that I generated could be used to screen for nuclear localisation
in different tissues.
6.6. How is ASPP/PP1 function regulated?
Two modes of regulation could prevent ASPP from binding to PP1. Firstly, the
C-terminal PxxPxR motif of PP1 can be phosphorylated by Cdk2 in a cell-cycle de-
pendent manner during early and mid-mitosis (Dohadwala et al. 1994, Kwon et al.
1997). Although this phosphorylation has been described to auto-inhibit PP1 (Do-
hadwala et al. 1994), it could also prevent ASPP from binding to PP1, as a phospho-
mimicking mutation of the PxxPxR motif inhibits PP1 from binding to ASPP family
proteins (Skene-Arnold et al. 2013). Thus, during mitosis, the phosphorylation could
prevent ASPP from binding to PP1. Secondly, Drosophila ASPP has a serine residue
within its RVXF motif that could be phosphorylated (see Fig. 3.1). Introduction of
a negative charge within the RVXF motif can disrupt binding to PP1 (Egloff 1997).
6.7. What are the overlapping and non-overlapping
roles of ASPP, RASSF8 and Ccdc85?
Even though ASPP, RASSF8, ccdc85 and kib mutants all cause rough eye phenotypes
(see 3.2.2, 3.3.5 and 4.1.1), there are subtle differences. The number of IOCs is highest
in kib mutant retinal mitotic clones with 22.0±2.4 (Fig. 4.1D). However, despite this
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large number of IOCs, all extra IOCs are neatly arranged in single layers (Fig. 4.1B
and Genevet et al. 2010, Yu et al. 2010). This suggests that during remodelling (see
1.1.3), only apoptosis is impaired, while cell-cell adhesion is not affected. This is in
stark contrast to RASSF8 mutant retinas, where the total number of IOCs (17.6±2.7)
is lower than in kib mutant mitotic clones. Despite fewer extra IOCs, multi-layering
can often be observed (Fig. 4.1A and Langton et al. 2009). The multi-layering is
consistent with the idea that loss of RASSF8 influences inter-IOC contacts. Thus,
despite the strong genetic interaction between RASSF8 and kib (see 4.1.1), they
might act on distinct processes.
Qualitatively and quantitatively, the ASPP and ccdc85 mutant retinas also differ
from RASSF8 mutant retinas (also see 3.3.5 for additional discussion). The number
of extra IOCs in ASPP and ccdc85 mutant retinas is lower than in RASSF8 mutant
retinas (15.3±1.6 and 14.2±1.2 respectively). Together with the observation that
RASSF8 null mutant flies have a round wing phenotype (Langton et al. 2009) that
is not observed in ASPP (Langton et al. 2007) or ccdc85 null mutant flies (data not
shown), this suggests that Ccdc85 might closely functions together with ASPP, while
RASSF8 might have additional, ASPP-independent functions. Analysing expression
patterns of ASPP, RASSF8 and Ccdc85 in different tissues and developmental stages
might be helpful in determining in which contexts they are all required and where
they carry out independent functions.
6.8. Have ASPP family proteins and RASSF8
undergone convergent evolution?
The phosphorylation of Drosophila RASSF8 by Wts (see 5.1.1) and the binding to
Magi (see 5.3.1) are probably not conserved in human RASSF8 (or any other hu-
man N-terminal RASSF family proteins), as the required sequence motifs are ab-
sent. However, human ASPP1 can be phosphorylated by LATS1/2 (Aylon et al.
2010) and an ASPP2 peptide that contains its PPXY motif can bind to human
MAGI1 (Pirozzi et al. 1997), suggesting that in humans, ASPP1/2 might carry out
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Figure 6.3.: The RA-like domain of ASPP1/2 is more closely related to the
RASSF8 RA domain than to other RA domains
A distance tree based on a multiple alignment between the RA and RA-like domains of
human ASPP1/2 and classical as well as N-terminal RASSF family proteins suggests
that the RA-like domain of ASPP1/2 are closely related to the RASSF7/8 group of
proteins.
some of the functions of Drosophila RASSF8. Given the conserved binding between
ASPP and RASSF8, it is possible that Magi association and phosphorylation by an
activated Hippo pathway kinase cascade evolved separately in Drosophila RASSF8
and human ASPP1/2. A direct evolutionary link between the motifs in Drosophila
RASSF8 and human ASPP1/2 is not obvious, as the sequences surrounding the motifs
do not bear any resemblance to each other.
A third feature that human ASPP1/2 shares with N-terminal RASSF8 family pro-
teins is its RA-like domain. Distance-based methods suggest that the RA-like do-
mains of human ASPP1/2 (see 1.3.1) are very closely related to the RA domains
of N-terminal RASSF family (Fig. 6.3). Furthermore, using the RA-like domain of
ASPP1/2 in a BLAST search for all Drosophila proteins returns the RA domain of
RASSF8 as the closest match (data not shown). Similarly, searching for human pro-
teins with the RA-like domain of ASPP1/2 returns the RA domain of human RASSF8
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as the closest match following ASPP1/2 (data not shown). The similarly between
the RA-like domain of ASPP1/2 and RASSF8 suggests that their function might
be conserved. Thus, similar to ASPP1/2 /(Wang et al. 2013a, Wang et al. 2013b),
Drosophila RASSF8 could also bind to oncogenic Ras and phosphorylation of Dro-
sophila RASSF8 could be required for its nuclear translocation when oncogenic Ras
is present—comparable to ASPP1 (Aylon et al. 2010). Taken together, since ASPP
family proteins and RASSF8 share these three motifs/domains with each other, it is
possible that convergent evolution equipped them with a similar set of functionality.
Analysing ASPP and N-terminal RASSF family proteins in other organisms could
test the hypothesis of convergent evolution.
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Baz dephosphorylation sites
Peptide abundances were quantified with Skyline. The localisation of the phospho-
rylation was determined in Perseus. All phospho-peptides with reduced abundance
when dephosphorylated either with PP1 alone, or when ASPP, RASSF8 and Ccdc85
were also present (see 4.2.6) were filtered using a PEP-Score criterion (see Material
and Methods for details).
The ratio of the abundance of phospho-peptide between GFP treatment and de-
phosphorylation with PP1 only, as well as the ratio between PP1 dephosphorylation
only and the dephosphorylation with the whole complex were calculated. A value
above 1 suggests that the indicated residue was dephosphorylated by PP1 alone or
that addition of ASPP, RASSF8 and Ccdc85 further increased dephosphorylation. All
measurements were done in three technical replicates. Unpaired t-tests were carried
out for all ratios. The given p-values have no correction for multiple testing.
The top hit, T720 is highlighted in bold. It was consistently dephosphorylated
by PP1 alone and more strongly when ASPP, RASSF8 and Ccdc85 were present.
Furthermore, T720 is conserved in PAR3.
S151 and S1085 were also listed in the tables below in italics as examples for
phosphorylated residues that were unchanged when detected by antibody staining on
Western blots (Fig. 3.14A).
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Figure A.1.: Identified residues that were dephosphorylated in vitro—LFQ
Figure A.2.: Identified residues that were dephosphorylated in vitro—dimethyl-
labelled quantification
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Appendix B.
Modifier screen
All genomic deficiency lines that were screened (see 5.5 for details) are listed below.
The gene names of human orthologues are given if orthologues are existent. The
source of the protein-protein interaction data is indicated, as well as the binding
partner. Enhancers of the ASPP RNAi phenotype (Fig. 5.11B, B’) have a positive
number in the result column, while suppressors have a negative number. The value
of this number represents the strength of enhancement/suppression observed. E.g.,
removing one copy of zir (3) strongly enhanced the phenotype (see Fig. 5.11E, E’),
while removing one copy of gdi (2) moderately enhanced the phenotype (see Fig.
5.11F, F’).
Figure B.1.: Results of modifier screen
(Continues on following page)
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